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OBJECTIVES 
 
Candida species are opportunistic fungal pathogens which cause severe infections in 
immunocompromised patients. Due to the profound developments in medical care, the number 
of immunocompromised patients has increased, and so has the number of life-threatening 
Candida infections1. At present, Candida is the 4th most common bloodstream pathogen in 
North America and ranks 8th in Europe13,19. High-risk groups include: neutropenic cancer 
patients, bone marrow and organ transplant recipients, patients suffering from AIDS, diabetics, 
and patients receiving broad-spectrum antibiotics or parenteral nutrition. Attributable mortality 
of Candida infections is as high as 38%, and crude mortality rates exceed 50%15,29,44,45.  
The most commonly used detection method for Candida infections, automated blood 
culture, is inadequate. Many yeast infections remain undetected or are diagnosed only after 
several days25. Furthermore, since different Candida species show differences in resistance 
against antimycotic agents13,28, identification up to the species level is essential for adequate 
treatment. In many clinical microbiological laboratories the identification methods are based 
on phenotypic characteristics. However, some species show a high degree of phenotypic 
similarity which complicates identification. Commercial tests usually show high sensitivities 
and specificities for Candida albicans, but are less reliable or require further testing for the 
identification of other species3,6,12,17.  
In addition to the inadequate detection, relatively little is known about the epidemiology of 
Candida infections. Typing of different strains of the same Candida species and linking these 
strain types to data on the presence of virulence factors or resistance to antimycotic agents may 
improve our understanding of the epidemiology of this yeast, and may help to identify genetic 
markers for these traits. Several typing methods have been used for Candida species, but none 
of them is considered the golden standard4,11,30,32,33,38.  
The first objective of this thesis was to improve the diagnosis and identification of Candida 
infections. The second objective was to study the epidemiology of C. albicans. In particular, 
we investigated whether a relatively new typing method, Amplified Fragment Length 
Polymorphism analysis (AFLP), is suitable for typing C. albicans. Furthermore, the 
relationship between the type of infection, geographic origin, and the expression of virulence 
factors by clinical C. albicans isolates was examined. 
 
 
DETECTION OF CANDIDA INFECTIONS 
 
Automated blood culture. Automated blood culture systems are routinely used as 
diagnostic tool. Since our hospital makes use of the BacT/Alert monitoring system of 
bioMérieux (formerly Organon Teknika, Boxtel, the Netherlands) we focus here on this 
device. However, although the contents of the culture media as well as the exact method of 
detection differs between the different systems, the basic protocol is the same. Blood is 
inoculated directly into the culture bottles containing proprietary media based on enriched 
trypticase soy broth. Different media are developed for the growth of aerobic and anaerobic 
organisms. Furthermore, the development of 'FAN' bottles (fastidious antibiotic neutralization) 
in some cases increased the detection rate43. Special media for detection of fungal growth are 
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also available14. However, because it is labour intensive and expensive to use several systems 
at the same time, most laboratories only use the standard blood culture bottles. In our hospital, 
regular anaerobic bottles and FAN aerobic bottles are used.  
The bottles are incubated under continuous agitation. A differentially permeable membrane 
in the bottom of the bottle separates the medium from a pH sensor. This green colored sensor 
turns yellow when carbon dioxide produced by growing microorganisms diffuses across the 
membrane and reacts with water generating hydrogen ions. This lowering of the pH is 
monitored by the instrument every ten minutes during incubation. When the instrument renders 
a positive signal, further testing is needed to identify the organism grown in the bottle. Usually, 
a Gram staining is performed, and the blood culture is subcultured on blood agar and, if 
necessary, other media.  
It is known that automated blood culture systems may fail to detect yeasts in up to 65% of 
the cases25. Many blood culture media are not optimal for fungal growth. Also, growth of fungi 
may be inhibited by the presence of antimycotic agents in the blood of the patient. The 
question whether terminal subculture of negative blood culture bottles will lead to enhanced 
detection rates is under debate23,31,36,39,46. In the study described in Chapter 1 of this thesis, we 
examined whether terminal subculture of negative blood culture bottles improves the detection 
rate for patients who are at high risk for candidaemia.  
NASBA. Since automated blood culture systems often need several days before fungal 
infections are detected, or even miss these infections entirely, improved detection methods are 
needed. Nucleic acid amplification technologies provide promising tools for the rapid 
detection of Candida species in clinical materials. Polymerase Chain Reaction (PCR) is the 
most generally used amplification technique. However, in 1991 Compton described a new 
amplification method, Nucleic Acid Sequence-Based Amplification (NASBA™), which has 
several advantages over PCR7. A schematic representation of this technique is depicted in 
Figure 1. The technique is based on the incorporation of a T7 RNA polymerase promotor 
sequence in one of the primers. This primer anneals to the single stranded RNA target. After 
primer extension by Avian Myeloblastosis Virus Reverse Transcriptase (AMV-RT), the RNA 
strand of the resulting RNA/DNA hybrid is degraded by RNase H. The second primer anneals 
to the single stranded cDNA, and a double stranded cDNA molecule is generated by AMV-RT. 
This cDNA now contains a double stranded T7 promotor which enables T7 RNA polymerase 
to generate multiple anti-sense RNA copies. These amplicons serve as templates for the cyclic 
phase of the amplification, as shown on the right-hand side in Figure 1.  
 In contrast with PCR, NASBA is an isothermal process which eliminates the need for 
(expensive) thermal cyclers. By using RNA as target, which is far less stable than DNA, the 
risk of obtaining false-positive results due to amplification of nucleic acids from dead or 
degrading cells is reduced. Also, no separate RT step is required for RNA amplification, and 
RNA can be amplified in a background of DNA molecules. Furthermore, unlike PCR where 
the initial primer level limits the maximum yield, the T7 RNA polymerase reuses the cDNA, 
resulting in an exponential increase in RNA amplicons. In addition, these single stranded 
amplicons are ideal targets for detection with specific probes, without the need for 
denaturation. The NASBA assay developed in this thesis uses ribosomal RNA as target, which 
can be present in as many as 10,000 copies per cell. This results in a very sensitive assay. The 
characteristics and applications of NASBA have recently been reviewed by Deiman et al.10. 
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Figure 1 
Schematic representation of nucleic acid sequence-based amplification (NASBA) 
 
 
In Chapter 2 of this thesis we describe the development of a NASBA assay for the 
detection of Candida species. The primers are based on the conserved regions of the 18S 
rRNA sequence of medically important fungi. Furthermore, specific probes were designed and 
tested for the identification of the different medically important species, including C. glabrata 
and C. krusei. Sample preparation remains a crucial step in all amplification methods. In case 
of disseminated infections, it is favorable to use whole blood instead of plasma or serum. The 
use of whole blood prevents the loss of target due to phagocytosed fungal cells or cells 
attached to leukocytes or other blood cells. According to Jordan, the use of plasma resulted in 
a loss of more than 50% of the initial input of C. albicans21. Rapid whole blood sample 
preparation methods generally cannot process more than 200 µl blood21,40. In Chapter 2 an 
improved rapid sample preparation for whole blood samples up to 1 ml is described.  
 Amplification technologies can also be used to reduce the time needed for species 
identification after growth is detected in blood culture bottles. Besides detection of Candida 
species directly in blood samples of patients, we wanted to know whether we could use our 
NASBA assay to quicken and maybe even improve the detection rate of Candida species in 
blood cultures. Therefore, culture-positive as well as negative blood cultures from patients 
with a proven candidaemia were analyzed, and the results of the NASBA assay were compared 
with the results of BacT/Alert monitoring. The results of this study are described in Chapter 3. 
  After the encouraging results of the previous studies, a clinical trial was initiated in order to 
evaluate the use of the NASBA assay for the improved detection of Candida species in 
patients suspected of having candidaemia. Since candidaemia is characterized by a low number 
of yeast cells in the blood stream, testing of  blood culture samples after a short (2 day) culture 
step was also included. The results of this clinical trial are presented in Chapter 4.  
 Contamination control. Implementation of the NASBA assay in a routine clinical 
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laboratory requires considerable standardization of the different procedures. In Chapters 3 and 
4, our amplicon detection assay was successfully replaced by the NucliSens Basic Kit 
detection module in combination with the NucliSens reader (bioMérieux (formerly Organon 
Teknika), Boxtel, the Netherlands). Chapter 5 describes our efforts to replace our in-house 
NASBA amplification protocol by the NucliSens Basic Kit amplification module. 
Unfortunately, impracticable difficulties with false-positive results were encountered due to 
contaminated components of the kit, and it was decided to continue working with our in-house 
assay. Over the years, working with sensitive amplification technologies like NASBA has 
inevitably experienced us in contamination control. The current problems lead us to review the 
implications of contaminations in diagnosis and research on infectious diseases (Chapter 6). 
In the same review we also discuss the functionality and draw-backs of different methods for 
prevention and destruction of contaminating DNA and give recommendations on how to 
improve laboratory practice. 
 
 
 
 
 
 
 
Figure 2 
Schematic representation of amplified fragment length polymorphism analysis (AFLP) 
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AFLP. While Candida albicans used to be the main cause of invasive fungal infections, 
non-albicans Candida species like C. glabrata, C. krusei and C. parapsilosis are increasingly 
isolated. These non-albicans Candida species now account for approximately 50% of all 
Candida infections22. The different Candida species show differences in resistance to 
antimycotic agents. C. krusei is innately resistant to fluconazole, and C. glabrata is able to 
acquire resistance to this drug very rapidly13,28. Furthermore, C. glabrata infections have been 
associated with an extremely high mortality16. Therefore, to start an adequate treatment as 
early as possible, it is essential to rapidly detect the causative organism up to the species level. 
With the NASBA assay developed in this thesis, it is possible to identify most medically 
important Candida species. Other probes can be designed and implemented in the assay when 
more species need to be identified. However, Amplified Fragment Length Polymorphism 
analysis (AFLP41), may also prove to be an excellent identification tool.  
A schematic representation of AFLP is shown in Figure 2. Chromosomal DNA is digested 
with two restriction enzymes, e.g. EcoRI and MseI, and adapters are ligated to the fragments. 
These adapters are known sequences which are designed in such a way that after ligation the 
recognition sites for the restriction enzymes are lost. Hence, restriction and ligation can take 
place in the same reaction tube. Two types of fragments are formed: fragments with the same 
adapter at both ends and fragments with the two different adapters at each end. The adapters 
are used as targets for the primers during PCR amplification. However, fragments with the 
same adapter at both ends will generally form 'stem-loop' structures after denaturation, which 
makes it impossible for the primers to anneal. Therefore, the amplification products will 
contain mainly fragments with a different adapter at each end. If necessary, by using one or 
more selective nucleotides on the 3'-end of the primers, the number of amplified fragments can 
be reduced to obtain a more distinctive pattern. One of the primers is labeled with a fluorescent 
dye. The fragments are separated in an automated sequence apparatus, and analyzed using 
software packages like BioNumerics (Applied Maths, Sint-Martens-Latem, Belgium). 
 The advantages and disadvantages of AFLP and the NASBA assay are summarized in Table 
1. Both methods only need small amounts of starting material and can be obtained in a kit 
format. The advantage of the NASBA assay over AFLP is that the former can be applied 
directly on clinical material, which speeds up the whole process. AFLP on the other hand is 
universally applicable and by storing the patterns, including those of reference strains, in a 
general accessible database a screening library for identification of species is obtained. 
Furthermore, for numerous organisms AFLP patterns can also be used for strain typing35. In 
conclusion: the NASBA assay is preferable for rapid diagnosis, whereas AFLP may be helpful 
to identify unknown isolates from cultures. Chapter 7 of this thesis describes the use of AFLP 
as an identification method for medically important Candida species.  
 
 
EPIDEMIOLOGY OF CANDIDA INFECTIONS 
 
 Virulence. Several putative virulence factors of C. albicans have been described5. One 
remarkable virulence factor is the capacity of C. albicans to 'switch' between different 
phenotypes at a relatively high frequency. This switching is characterized by differences in 
colony morphology, e.g. 'white', 'opaque', 'star', 'stippled', 'hat', 'irregular', 'wrinkle', and 'fuzzy'.  
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Table 1 
Advantages and disadvantages for the NASBA assay and AFLP as identification methods 
 Advantages Disadvantages 
NASBA assay - directly on clinical material 
- small amounts of material are sufficient 
- rapid 
- standardization with kit 
- several species-specific probes needed 
- not every species identifiable in current 
assay  
AFLP - universally applicable 
- database screening of results 
- possibilities for strain typing 
- small amounts of material are sufficient 
- standardization with kit 
- pure sample necessary 
- less rapid 
 
 
Phenotypic switching is reversible and is accompanied by changes in antigen expression and 
tissue affinities. Furthermore, transition between unicellular yeast cells and filamentous growth 
forms occurs. The formation of (pseudo)hyphae is probably associated with an enhanced 
capability to invade host tissues. C. albicans also produces adhesins, biomolecules that 
promote the adherence of the yeast to host cells. In addition, the organism secretes hydrolytic 
enzymes such as phospholipases and secreted aspartyl proteinases. Phospholipases most likely 
contribute to the pathogenicity of C. albicans by damaging host cell membranes, aiding the 
fungus by invasion of host tissues24. Secreted aspartyl proteinases are capable of degrading 
epithelial and mucosal barrier proteins like collagen, keratin and mucin, as well as antibodies, 
complement and cytokines9.  
The importance of these enzymes in C. albicans virulence has been ascertained by cloning 
and disrupting the genes involved, and studying the effect of these mutations on the virulence 
in animal models. Disruption of the phospholipase B gene significantly attenuated virulence in 
mice and dramatically reduced the ability of the yeast to penetrate host cells24. Disruption of 
the genes involved in secreted aspartyl proteinase production resulted in altered adherence of 
yeast cells and attenuation of virulence in different animal models8,18,34,42.  
The expression of certain virulence factors may be associated with specific characteristics 
such as geographic origin of the isolates or the type of infection. Knowledge of such 
correlations may help to understand the epidemiology of these infections. This may result in 
improved therapeutic regimens. In Chapter 8, the differences in phospholipase and secreted 
aspartyl proteinase production of a large panel of clinical C. albicans isolates obtained from 12 
different European countries were studied, and the results were linked to data on the 
geographic origin of the isolates and the site of infection. 
Strain typing. Strain typing is important in various situations37. When an outbreak of 
disease occurs in a hospital (ward), strain typing can be used to investigate whether this 
outbreak is caused by a single strain, or whether several strains are involved. Furthermore, by 
testing isolates from patients, health care workers and the hospital environment the origin of 
the outbreak can be identified and adequate measures to stop the outbreak and prevent future 
recurrences can be undertaken. Strain typing can also be of use to unravel the relationship 
between commensal and pathogenic strains. It is generally acknowledged that most infecting 
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Candida strains originate from the host's commensal flora. However, are all commensals 
capable of becoming pathogens? Strain typing methods have proven to be valuable tools in 
research on strain persistence or replacement during different stages of infections. Besides the 
dynamics of yeast strains within in human being, it is also essential to understand the dynamics 
of the organism in a human population. Are certain strains or clusters of strains associated with 
a geographic locale? Are there endemic strains in particular hospital wards?  
Besides being a tool for the identification of different species, AFLP may also be suitable 
for typing C. albicans. In fact, AFLP was developed as a typing method, and has been used 
successfully for many organisms including Saccharomyces cerevisiae, a close relative of C. 
albicans2,35,41. Several other typing methods have been described for C. albicans. However, no 
method has been accepted as the golden standard. Randomly Amplified Polymorphic DNA 
analysis (RAPD) has the disadvantage of being less reproducible than AFLP20,35. Other 
fingerprinting techniques which are often used are based on selective parts of the genome. For 
example, the PCR fingerprinting method described by Meyer et al. uses mini- and 
microsatellite sequences as targets for the primers27, reference strand-mediated conformational 
analysis (RSCA) is based on 18S rRNA sequences26, and the Ca3 probe used in Southern blot 
hybridizations of EcoRI digested genomic DNA hybridizes with genomic sequences 
containing repetitive elements33. AFLP patterns are a representation of the whole genome. 
Furthermore, these patterns can easily be stored in (general accessible) databases, which 
greatly facilitates the exchange of results between laboratories. In Chapter 9 of this thesis we 
investigated whether AFLP is suitable for typing C. albicans. AFLP was used to type the 
collection of European clinical C. albicans isolates, and the correlation between AFLP type 
and geographical origin, site of infection and the production of hydrolytic enzymes was 
studied. 
 
The results of all studies described in this thesis will provide tools for the improvement of 
diagnosis and identification of Candida infections, and contribute to our understanding of  the 
epidemiology of this yeast.  
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BRIEF REPORT 
 
 Yeasts have become increasingly important causes of invasive infections in 
immunocompromised patients. Candida albicans is the predominant causative agent in these 
infections. However, non-albicans Candida spp. are increasingly isolated. Automated blood 
culture systems are routinely used as diagnostic tool. Although the contents of the culture 
media of these systems as well as the exact method of detection differs between the different 
systems, the basic protocol is the same: blood is inoculated directly into the culture bottles and 
the bottles are cultured for 5-7 days, or until a positive growth-signal is obtained.  
 There has been an ongoing debate about the need of subculturing automated blood culture 
bottles that have remained negative. Some authors reported that yeasts often are detected only 
after terminal subculturing3,4. However, in recent years several authors claimed that all 
important pathogens (including yeasts) are detected by the automated blood culture system 
within the standard incubation time. For example, Reisner and Woods2, stated that when using 
the Bactec 9240 system, 4 days of culturing is sufficient to detect all bacteria, and no more 
than 6 days are required to detect all important yeasts. Longer incubation times would only 
result in detection of contaminants. Ziegler et al.5 compared different culture media in the 
Bactec 9240 and the BacT/Alert blood culture systems, and concluded that for both systems a 
5-day incubation period is sufficient, and no terminal subculture is required. The same 
incubation time was recommended by Kennedy et al.1 These authors declare that clinically 
relevant pathogens show a quick growth, and slow growing organisms are mainly 
contaminants.  
 The objective of our study was to evaluate whether these recent findings also hold true for 
patients who are at high risk for candidaemia. Therefore, positive as well as negative blood 
cultures obtained from patients with a culture-proven candidaemia were investigated. The 
results of BacT/Alert monitoring alone were compared with BacT/Alert monitoring in 
combination with blind subculturing of the negative blood cultures. 
 Ten patients were included. Nine patients were hospitalized in a university hospital, one 
patient was hospitalized in a children's hospital. Only the child was treated with antimycotic 
agents at the moment of inclusion. All blood cultures were taken on clinical indication and 
handled in the same microbiology lab. Blood samples were divided over two blood culture 
bottles: one FAN aerobic and one regular anaerobic BacT/Alert bottle. For the patient from the 
children's hospital, Pedi-BacT bottles were used (all bottles: Organon Teknika, the 
Netherlands). The blood culture bottles were incubated in the BacT/Alert monitoring system 
for 7 days, or until a positive signal was obtained. All bottles were subcultured on blood-agar 
and mold-agar. 
 For three patients, subculturing of the negative blood culture bottles resulted in extra 
information. Table 1 depicts the patient characteristics and the risk factors for invasive 
candidiasis present at the time of detection for these patients. For patients 2 and 3 (Table 1), 
the extra blood cultures found positive confirmed the diagnosis but did not change the 
treatment regimens. From the third patient however, positive subcultures were obtained when 
BacT/Alert monitoring alone would suggest that the infection was adequately treated (patient 
no. 1; Table 1). Nineteen blood cultures were drawn over a period of 19 days. Three of the six 
blood cultures found positive only after subculturing were drawn from the patient when 
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treatment with antimycotics (Amphotericin B) had already been started. Yeast was detected up 
to 7 days after the last BacT/Alert-positive blood culture. Treatment with Amphotericin B was 
continued until the patient died.  
 Our findings show, that subculturing of negative blood culture bottles can lead to 
additional information which may be clinically relevant. Therefore, we would like to comment 
that further evaluation of routine terminal subculturing of negative blood cultures from patients 
with suspected candidaemia and patients under treatment for candidaemia might be valuable. 
 
 
Table 1  
Clinical data and results of BacT/Alert monitoring and subculturing of the blood cultures 
Patient 
no. 
Underlying condition Risk factorsa BCB 
(total) 
BacT/Alert 
+ 
Subculture 
(add. +)  
Candida 
spp. isolated 
    AE AN AE AN  
1 infected echinococcal cyst a, c, d, e, f, g 19b 0 2 5 1 C. glabrata 
2 colostomy a, b, c, d, e, g 12 3 1 0 2 C. albicans 
3 Candida endocarditis around 
prosthetic valve 
a, b, g 8 1 0 0 1 C. albicans 
 BCB: blood culture bottles; AE: aerobic blood cultures; AN: anaerobic blood cultures 
a a: broad-spectrum antibiotics; b: dialysis; c: intratracheal tube; d: laparotomy; e: septic shock;  
f: colonization with Candida spp.; g: arterial or central venous catheter 
b data of one bottle not available 
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ABSTRACT 
 
Nucleic Acid Sequence Based Amplification (NASBA), an isothermal amplification 
technique for nucleic acids, was evaluated for the identification of medically important 
Candida species using primers selected from 18S rRNA sequences conserved in fungi. An 
RNA fragment of 257 nucleotides was amplified for Candida albicans. Nineteen different 
fungi were tested for rRNA amplification with the NASBA. All were positive when analyzed 
on agarose gel, whereas human RNA was negative. For the identification of Candida species, 
NASBA amplification products were analyzed in an enzyme bead-based detection format, 
using species specific biotinylated probes and a generic Candida HRPO probe or a membrane-
based system using biotinylated probes and avidin-HPRO. Discrimination of the major human 
pathogenic Candida spp. was based on a panel of biotinylated probes for Candida krusei, 
Candida tropicalis, Candida albicans, Candida glabrata, and Candida lusitaniae. Using 
rRNA dilutions obtained from pure cultures of C. albicans, the combination of NASBA and 
the enzymatic bead-based detection yielded a sensitivity equivalent to 0.01 cfu. In a model 
system using 1 ml of artificially contaminated blood as few as 1-10 cfu of C. albicans could be 
detected. Testing of 68 clinical blood samples from patients suspected of candidemia showed 
that eight samples were positive for C. albicans and one for C. glabrata. Testing of 13 clinical 
plasma samples from patients suspected of fungemia identified the presence of C. albicans in 
two specimens. The whole procedure of sample preparation, amplification and identification 
by hybridization can be performed in one day. This speed and the observed sensitivity of the 
assay make the NASBA a good alternative to PCR for the detection of candidemia. 
 
 
INTRODUCTION 
 
Opportunistic fungal infections are most often seen in immunocompromised patients. 
Candidiasis accounts for the majority of fungal infections in these patients. The diagnosis of 
systemic candidiasis has proved to be difficult. Blood cultures remain the major tool for the 
diagnosis of candidiasis, but fail to detect 50-70% of the cases. Detection of antibodies, 
antigens and metabolites have been investigated extensively, but none is satisfactory1,3,13,18. It 
is essential to have a rapid, reliable detection method which enables therapy to start as early as 
possible. 
Fungemia is characterized by low numbers of yeast cells in the bloodstream. As few as 1-10 
colony forming units (cfu) per ml of blood may be present. Therefore, amplification 
technologies provide promising methods for the rapid detection of fungemia. Several groups 
have shown the feasibility of PCR for the detection of candidemia6,7,10-12,14,17,20,22,23,25,26,28,32. 
However, sample volumes were either to small or the PCR amplification had good sensitivity 
but required a cumbersome sample preparation. More rapid sample preparation methods have 
been described, but these methods cannot process more than 200 µl blood19,31. 
An alternative approach to PCR is RNA amplification by NASBA (Nucleic Acid Sequence 
Based Amplification)9,21. NASBA is an isothermal nucleic acid amplification system of RNA 
that utilizes the simultaneous action of three enzymes: avian myeloblastosis virus reverse 
transcriptase (AMV-RT), RNase H and T7 RNA polymerase. Initially, a primer containing a 
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T7 RNA promotor sequence anneals to the single stranded RNA. After primer extension by 
AMV-RT, the RNA strand of the resulting RNA/DNA hybrid is degraded by RNase H. Then, 
the second primer anneals to the single stranded cDNA and AMV-RT generates a double 
stranded cDNA molecule containing a double stranded T7 promotor. Subsequently, T7 RNA 
polymerase initiates transcription and generates multiple anti-sense RNA copies, which now 
serve as template for the cyclic phase of the amplification. A major advantage of NASBA over 
PCR is that it is performed isothermally at 41°C and no separate RT step is required for RNA 
amplification. An additional advantage when using rRNA as target is that as many as 10,000 
copies of rRNA can be present per cell. When HIV-1 RNA is used as input, the detection level 
with NASBA was as low as 10 molecules21. 
This is the first study using NASBA for the detection of fungi in clinical samples. This 
study investigated the use of the NASBA technique in combination with an improved rapid 
sample preparation method for the detection of Candida species spiked in blood specimens 
and specimen from patients suspected of candidemia. Whereas in most studies either plasma or 
serum was used for sample preparation, we studied the recovery from whole blood, which had 
the advantage that phagocytosed fungal cells or cells attached to leukocytes or other blood 
cells were also detected. Primers for NASBA were based on the conserved regions of the 18S 
rRNA sequence of medically important fungi15. For the identification of medically important 
Candida species, specific biotinylated probes were developed for C. albicans, C. glabrata, C. 
krusei, C. tropicalis, and C. lusitaniae. These probes were used in a microtiter format 
hybridization assay to identify amplified RNA.  
 
 
MATERIALS AND METHODS 
 
Fungal species. C. albicans (CBS 562), C. tropicalis (CBS 2310), C. krusei (Issatchenkia 
orientalis) (CBS 573), C. (Torulopsis) glabrata (CBS 138), C. guilliermondii (CBS 2024), C. 
viswanathii (CBS 4024), C. lusitaniae (CBS 4413), C. parapsilosis (CBS 2195), 
Kluyveromyces marxianus (CBS 607), Kluyveromyces lactis (CBS 739), Torulasporula 
delbrueckii (CBS 133), Saccharomyces cerevisiae (CBS 375), Aspergillus niger (CBS102.12), 
A. nidulans (CBS 100.20), A. terreus (CBS 106.25), Penicillium chrysogenum (CBS195.46), 
P. marneffei (CBS 549.77), Paecilomyces variotii (CBS 339.51) were obtained from the 
Centraal Bureau voor Schimmelcultures (CBS, Baarn, The Netherlands). Cryptococcus 
neoformans NIH3413. Clinical isolates were collected from the University Hospital Utrecht or 
as part of the SENTRY Antimicrobial Surveillance Program, in which 24 European university 
hospitals participate. Clinical isolates were identified either by VITEK or API (bioMérieux, 
France). Yeasts were grown on Sabouraud Dextrose Agar at 25°C for 1-2 days. Patient blood 
samples were obtained from the Antoni van Leeuwenhoek Ziekenhuis, Amsterdam and the 
University Hospital Utrecht. Plasma samples were obtained from the Daniel den Hoed Kliniek, 
Rotterdam. 
Purification of target RNA. Blood was collected in EDTA tubes. To determine the 
sensitivity of the assay, blood samples were spiked with C. albicans. The collected blood 
samples were stored at -70°C until further use. Blood cells were lysed according to a modified 
protocol from Van Deventer32. Briefly, 0.9 ml of lysis buffer (0.32 M sucrose, 10 mM Tris-
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HCl (pH 7.5), 5 mM MgCl2, 1% Triton X-100) was added to 1.0 ml of thawed blood. After 
lysis, cell debris and Candida cells were pelleted by centrifugation at 16,000 x g for 5 min. The 
pellet was resuspended in 1.8 ml of lysis buffer with 15-75 U/ml DNase I (RNase-free, 
Boehringer Mannheim, Mannheim, Germany) and incubated for 30 min. at 37°C. After 
centrifugation at 16,000 x g for 5 min., the pellet was resuspended in 350 µl Qiagen RNeasy 
RLT solution (Qiagen, Hilden, Germany). Before loading the mixture onto a Qiagen RNeasy 
total RNA isolation column the suspension was sonicated for 5 min. in a Branson 221 
sonication bath (Lameris, Breukelen, the Netherlands) and 250 µl ethanol (96%) was added. 
The isolation was performed according to the instructions of the manufacturer with a minor 
modification: RNA was eluted from the column with 75 µl water for 10 min. at 56°C. 
Columns were heated in a multiblock heater (Lab-line, Beun de Ronde, Abcoude, the 
Netherlands). 
Primers and probes. The oligonucleotides used in this study are summarized in Table 1. 
Conserved primers were chosen from the 18S rRNA sequence alignment to amplify yeast and 
fungal specific sequences. Biotinylated primers were used for the identification of Candida 
species. 
 NASBA. Five µl target RNA in water was added to a  pre-reaction mixture. The final 
volume of 15 µl contained 53 mM Tris-HCl (pH 8.5), 16 mM MgCl2, 93 mM KCl, 6.7 mM 
DTT, 1.3 mM of each dNTP, 2.7 mM of each rNTP, 20% (v/v) dimethyl sulfoxide, and 0.27 
µM of each primer. This mixture was first incubated at 65°C for 5 min. followed by 5 min. at 
41°C. Then 5 µl of an enzyme mixture containing 2.1 µg BSA (Boehringer Mannheim), 6.4 U 
AMV-RT (Seigaku, Rockville, MD), 0.08 U RNase H (Pharmacia, Uppsala, Sweden), and 32 
U T7 RNA polymerase (Pharmacia) in 1.5 M sorbitol was added. The reaction mixture, a 20 µl 
total volume, was incubated for 90 min. at 41°C. After amplification 2.5-5 µl was analyzed on 
a 2% agarose gel (Pronarose, Hispanagar, Burgos, Spain). 
 
 
Table 1 
Oligonucleotides used for NASBA and hybridization analysis. 
Positiona 5'-label sequence (5' to 3') name description 
55-76 - ATGTCTAAGTATAAGCAATTTA p2.1 forward NASBA primer 
271-253 - AATTCTAATACGACTCACTATAGGGAG- p1.1 reverse NASBA primer with 
  AGACATGCGATTCGAAAAGTTAb  T7 promotor site 
157-174 HRPO TCTAGAGCTAATACATGC 1727 yeast/fungi probe 
180-203 biotin ATCCCGACTGTTTGGAAGGGATGT 1913 C. albicans, C. tropicalis, 
    C. parapsilosis probe 
227-244 biotin CCCTCGGGCCTTTTGATG 95.66 C. krusei probe 
180-203 biotin ATCTCGACCTCTTGGAAGAGATGT 1912 C. glabrata probe 
180-203 biotin AGCCCGACCTCTGGAAGGGCTGTA 1914 C. lusitaniae probe 
222-238 biotin CAATGTCTTCGGACTCTT 2176 C. tropicalis probe 
87-110 biotin CTGCGAATGGCTCATTAAATCAGT UNI2 universal yeast/fungi probe 
a position numbering of C. albicans 
b  italics: T7 promotor sequence 
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Enzymatic bead-based detection of NASBA products. Streptavidin-coated magnetic 
beads (Dynabeads M280-Streptavidin, Dynal, Oslo, Norway), washed once with 1% BSA in 
phosphate buffered saline were coated with 1 nmol biotinylated capture probe (Table 1) per 
300 µl magnetic beads and incubated for 1 h at room temperature with continuous shaking. 
After incubation, the beads were recovered by magnetic force and washed once in 5 x SSPE 
(0.75 M NaCl, 50 mM sodium phosphate buffer (pH 7.4), 5 mM EDTA) plus 0.1% SDS, and 
once in phosphate buffered saline (PBS) containing 0.1% BSA. The beads were resuspended in 
the original volume of PBS with 0.1% BSA and stored at 4°C until used. One and a half µl of 
the NASBA product was incubated with 5 µl of the capture probe-coated magnetic beads in 50 
µl hybridization mixture (5 x SSPE, 0.1% SDS, 0.1% blocking reagent (Boehringer 
Mannheim), and 10 µg/ml salmon sperm DNA) for 30 min. at 45°C in a flexible microtiter 
plate with shaking (Titertek, Flow Laboratories, Irvine, Ayrshire, Scotland). After recovery of 
the magnetic beads, they were incubated with 50 µl hybridization mix with the HRPO 
detection probe (1727) for 30 min. at 45°C with shaking. The beads were washed with 100 µl 
2 x SSC (2 x SSC equals 0.3 M NaCl, 30 mM sodium citrate (pH 7.2), 0.1% BSA), TBS (0.1 
M Tris-HCl (pH 8.0), 0.15 M NaCl) plus 0.2% Tween 20, and TBS, respectively. Then, 50 µl 
substrate was added (0.1 mg/ml 3,3',5',5-tetramethylbenzidine, 0.15 mg/ml urea peroxide in 
0.1 M sodium acetate (pH 6.0)). After 10 min. incubation at room temperature the reaction was 
stopped with 50 µl 2 M H2SO4. The A450 was measured in a Bio-Rad model 3550 microplate 
reader (Bio Rad, Hercules, CA). Samples were regarded as positive when the optical density 
was 3 times higher than the average of the negative controls. 
 Membrane-based identification. Two µl NASBA product was spotted onto Z-probe 
membrane strips (Bio-Rad) which were rinsed with MilliQ water and dried. The filter with the 
spots was dried and baked for 30 min. at 80°C. The strips were covered with approximately 5 
ml preheated hybridization mix containing 7% SDS, 5 x SSC, 20 mM sodium phosphate and 
10 x Denhardt's solution. Twelve and a half µl biotin-probe (5 µM) was added and 
hybridization was allowed for 2 h at 50°C. The strips were washed twice for 5 min. with 
preheated 1% SDS in 3 x SSC at 50°C. Then the strips were washed once with 0.1% SDS in 2 
x SSPE (1 x SSPE equals 100 mM di-sodium phosphate (pH 7.4), 175 mM NaCl, 1 mM 
EDTA) for 10 min. at room temperature. The strips were blocked with 0.5% SDS and 5% 
skimmed milk in 5 x SSPE for 15 min. at room temperature. The strips were washed once for 
2 min. with 0.1% SDS in 2 x SSPE at room temperature. Two µl streptavidin-HRPO conjugate 
in 5 ml 0.1% SDS, 5 x SSPE was added to each strip and incubated for 30 min. at room 
temperature. Strips were washed twice for 1 min. and once for 10 min. with 0.1% SDS in 2 x 
SSPE and twice for 2 min. with 2 x SSPE at room temperature. Excess fluid was removed on 
filter paper and 5 ml substrate  (2.5 mg diamino-benzidine, 1.25 mg CoCl2, 0.02% nickel 
sulphate, 0.011% H2O2 in phosphate buffered saline) was added. Color development was 
stopped by rinsing with tap water.  
 Controls. To monitor the testing of samples several positive and negative controls were 
developed. A positive control for the whole procedure including RNA isolation was generated 
by adding 100 µl containing 1 x 108 cfu C. albicans to 0.9 ml lysis buffer, as a negative control 
1 ml lysis buffer was used. The controls were centrifuged for 5 min. at 16,000 x g and the 
pellet was resuspended in 1.8 ml lysis buffer with 15-75 U/ml DNase I. Controls were treated 
further as described above. In addition to the controls described above, which also include 
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sample preparation, separate controls for the amplification were used. One positive control and 
two negative controls were used for each NASBA run. In the negative controls no template 
was added. The positive control consisted of the addition of 70 pg C. albicans RNA to the 
NASBA pre-reaction mixture. C. albicans control RNA was obtained by the transcription of 
the PCR product with primer p1.1 and p2.1 (Table 1) from the 18S rRNA genes, which was 
cloned into pGEM-T (Promega, Madison, WI). The negative controls were positioned at the 
beginning and the end of the series of samples which were tested. Finally for each species a 
bead-assay control was added. The target for hybridization was generated by amplifying the 
rRNA isolated from 1 x 107 cfu of the respective species with primers p1.1 and p2.1 as 
described above. 
 
 
RESULTS 
 
NASBA. Positive NASBA results were obtained for all fungi examined, including C. 
albicans, C. tropicalis, C. krusei, C. glabrata, C. guilliermondii, C. viswanathii, C. lusitaniae, 
C. parapsilosis, K. marxianus, K. lactis, T. delbrueckii, S. cerevisiae, A. fumigatus, A. flavus, 
A. niger, A. nidulans, A. terreus, P. chrysogenum, P. marneffei, Paecilomyces variotii, and C. 
neoformans. No amplification products were obtained with RNA isolated from Escherichia 
coli, Staphylococcus aureus and RNA isolated from human blood (data not shown). 
Identification of Candida spp. Biotinylated probes developed for the discrimination of the 
medically important Candida species were tested with amplification products obtained from 
yeasts, fungi, and human RNA (Table 2). The probes for C. glabrata, C. krusei, and C. 
lusitaniae were specific for these species. The C. albicans probe 1913 reacted not only with C. 
albicans but also with C. tropicalis, C. viswanathii, C. parapsilosis, and C. guilliermondii. 
The C. tropicalis probe 2176 could be used to discriminate C. tropicalis from C. albicans, 
although it was not specific for C. tropicalis since it also hybridizes with K. marxianus, K. 
lactis, S. cerevisiae, and T. delbrueckii. All other fungi tested reacted only with the universal 
fungal probe UNI2, and were negative with the other Candida probes. 
Thirty-two clinical isolates of Candida spp. were tested by NASBA amplification and 
enzyme bead-based identification. Twenty-five strains of C. albicans, 4 strains of C. glabrata, 
and 2 strains of C. tropicalis were identified correctly. One strain was identified as C. 
tropicalis, whereas conventional methods identified it as C. albicans. 
Another 31 clinical isolates including 9 C. glabrata, 10 C. parapsilosis, 9 C. tropicalis, and 
3 C. guilliermondii isolates yielded the expected results in the membrane-based identification 
system, except for 1 C. glabrata isolate which was identified as C. parapsilosis with 
conventional methods. 
Sensitivity of detection of C. albicans by NASBA. Nucleic acids isolated from 2 x 104 cfu 
C. albicans were eluted in 100 µl water. A 10-fold dilution series was prepared from this stock 
solution and 5 µl of the dilution series was tested by NASBA. A 104-fold dilution, equivalent 
to 1 cfu was still positive on agarose gel (Fig. 1), whereas a 106-fold dilution, equivalent to 
0.01 cfu was still positive when analyzed with enzymatic bead-based detection. Assuming that 
a Candida cell contains approximately 104 rRNA molecules34, a sensitivity of 0.01 cfu is 
equivalent to 10 molecules of rRNA. When a tenfold dilution range was prepared from whole 
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C. albicans cells, followed by RNA isolation, NASBA amplification and enzymatic bead-
based detection, reproducibly a sensitivity of 1-10 cfu was obtained. 
Preparation of clinical samples. Blood samples were stored at -70°C until further 
processing. Short term storage of the blood samples had no negative effect on the sensitivity of 
the NASBA amplification. On the contrary, lysis of blood cells was more complete, and less 
dependent on blood composition than without storage at -70°C. 
Several rapid methods have been described for blood sample preparation for PCR of 
Candida spp. Removal of erythrocytes by centrifugation and the use of the supernatant 
(plasma)19 resulted in a loss of more than 50% of the initial input of C. albicans. A rapid 
method described by Fujita12 which included lysis of erythrocytes and leukocytes in TE buffer 
with proteinase K and Tween 20 detergent followed by pelleting the yeast cells was not 
suitable for the reproducible processing of 1 ml blood, because of the low numbers of yeast 
cells present in our samples. The first steps of the method described by Buchmann6 included 
lysis of blood cells by detergents, breakdown of human DNA by DNase, pelleting of the yeast 
cells, followed by a labour intensive DNA extraction from spheroplasts. The method described 
by Van Deventer32, which was based on the Buchmann method, but included glass beads for 
the isolation of Candida DNA, was not directly suitable for processing more than 200 µl 
blood. We optimized this method by preceding the sample preparation with freeze/thawing the 
sample, optimizing the lysis of blood and yeast cells, and the use of a RNeasy column to bind 
fungal nucleic acids in the presence of guanidine thiocyanate4. This resulted in a rapid sample 
preparation method. Using this method, we were able to process 1 ml of blood with a 
sensitivity of 1 cfu per ml of whole blood in a reproducible manner (Fig. 2). The data obtained 
by agarose gel electrophoresis were confirmed by an enzymatic bead assay with C. albicans 
and universal probe (Table 3). The whole procedure of blood lysis, RNA isolation, NASBA 
and enzymatic bead-based identification could be performed in one day. 
 
 
Table 2 
Specificities of the species specific biotinylated probes in the enzyme bead-based detection assay with NASBA 
products obtained from the amplification of rRNA (derived from 103 cfu) from different yeasts. 
RNA isolated from UNI2 1912 95.66 1914 1913 2176 
 fungi glabrata krusei lusitaniae albicans tropicalis 
C. glabrata + + - - - - 
C. krusei + - + - - - 
C. lusitaniae + - - + - - 
C. albicans + - - - + - 
C. tropicalis + - - - + + 
C. viswanathii + - - - + - 
C. guilliermondii + - - - + - 
C. parapsilosis + - - - + - 
K. marxianus + - - - - + 
K. lactis  + - - - - + 
S. cerevisiae + - - - - + 
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Contamination. Contamination is a major problem for amplification techniques, especially 
when 'universal' primers are used. Amplicon contamination has to be controlled by careful 
separation of amplification products from target or buffer, enzyme or nucleotide mixtures. 
Contamination of reagents and samples by environmental fungal RNA is more difficult to 
avoid, because of the ubiquitous nature of yeasts and fungi. A number of our negative controls 
showed amplification products on agarose gel. However, analysis in a bead assay showed that 
the amplification products were not obtained from Candida spp. present in the same assay, but 
appeared to be from other genera, e.g. Saccharomyces, Kluyveromyces, or other related yeasts. 
This problem infrequently occurred when no target rRNA from a sample was present. In 
addition we observed differences in the frequency when using different batches of reagents or 
water. 
 Clinical samples. Sixty-eight blood samples from patients suspected of candidemia were 
evaluated in the NASBA  and bead assay in series of ten samples. In addition to the samples a 
number of controls were included. A negative control and positive control for the whole 
procedure including RNA isolation were included. A positive control for the NASBA only and 
two negative controls for the amplification, one at the beginning and one at the end of the 
amplification series, were added. Finally, for each probe an enzymatic bead-based detection 
control was added. Blood samples were considered positive when the A450 reading in the 
enzymatic bead-based detection assay was three times the average of the negative control of 
the NASBA amplification. Using these criteria, nine of the blood samples were positive. Eight 
samples reacted with the C. albicans probe and one sample with the C. glabrata probe. In 
addition, thirteen plasma samples were tested. Two of the samples were positive and contained 
C. albicans. 
 
 
Figure 1 
Detection levels of NASBA using agarose gel electrophoresis analysis on a 10-fold dilution range of rRNA 
isolated from 2 x 104 cfu C. albicans. Lane 1: rRNA dilution equivalent to 1000 cfu;  lane 2: rRNA dilution 
equivalent to 100 cfu; lane 3: rRNA dilution equivalent to 10 cfu; lane 4: rRNA dilution equivalent to 1 cfu; lane 
5: rRNA dilution equivalent to 0.1 cfu; lane 6: rRNA dilution equivalent to 0.01 cfu; lane 7: rRNA dilution 
equivalent to 0.001 cfu and  lanes M: lambda PstI digest as marker. Lane 1-5: The amplification product consists 
of a DNA/RNA hybrid (upper band) and RNA (lower band). 
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Figure 2 
Agarose gel electrophoretic analysis of NASBA products 
after amplification of rRNA isolated from 1 ml blood 
samples spiked with increasing numbers of C. albicans. 
Lane 1: negative control for the NASBA; lane 2: blood 
sample without C. albicans; lane 3: 1 cfu/ml blood; lane 4: 
10 cfu/ml blood; lane 5: 100 cfu/ml blood; lane 6: 1000 
cfu/ml blood; lane M: lambda PstI digest as marker. The 
samples were also analyzed in the enzymatic bead-based 
detection system (Table 3). 
 
 
 
 
 
 
 
 
DISCUSSION 
 
We have developed a nucleic acid sequence-based amplification assay for the detection of 
Candida species. Amplification of nucleic acids by NASBA has a major advantage over PCR: 
the use of multicopy rRNA targets results in high sensitivities21,33. The primers chosen in the 
18S rRNA can be used for NASBA of rRNA from all yeast and fungal species tested, 
including Candida spp., Aspergillus spp., and C. neoformans. The probes which were chosen 
in the amplified region could be used for the identification of medically important Candida 
spp. The detection limit obtained in terms of rRNA molecules (analytical sensitivity) was 
approximately 10-100 copies, equivalent to less than 1 cfu C. albicans. PCR is known to be 
sensitive to inhibitory compounds from blood, such as hemoglobin16. NASBA is relatively 
insensitive to inhibitors from blood.  Due to the presence of thousands of copies of 18S rRNA 
the sample can be diluted. 
A side effect of this extremely high sensitivity is the increased danger of contamination2. In 
fact a low level contamination with fungal rRNA was present in some batches of enzyme 
preparations and/or reagents (data not shown). A similar phenomenon has been observed for 
bacterial and yeast DNA in the PCR when either universal 16S or 18S rRNA primers were 
used5,28. The problems caused by low levels of RNA could be alleviated by the use of specific 
probes.  
Identification of Candida spp. was based on its usefulness for therapy in clinical specimens. 
C. albicans is medically the most frequently encountered pathogenic yeast, but C. glabrata, C. 
krusei, C. parapsilosis, C. lusitaniae, and C. tropicalis are important emerging pathogens24,30. 
Especially, it is mandatory to identify C. glabrata, C. krusei, and C. tropicalis, because these 
species show a high prevalence of resistance against fluconazole, whereas C. lusitaniae 
isolates increasingly are reported to be Amphotericin resistant8,27,29. Consequently, specific  
biotinylated probes were developed for C. albicans, C. glabrata, C. krusei, C. tropicalis, and  
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Table 3 
A450-values obtained in the enzymatic bead-based detection assay with the C. albicans probe 1913 and the 
universal Candida probe UNI2 after NASBA of rRNA isolated from blood samples spiked with increasing 
numbers of C. albicans.  
Sample Lane no.a C. albicans probe UNI2 probe 
negative control NASBA 1 0.071 0.124 
negative blood 2 0.096 0.104 
1 cfu/ml 3 0.091 0.099 
10 cfu/ml 4 0.321 0.461 
100 cfu/ml 5 0.931 0.790 
1000 cfu/ml 6 0.751 0.806 
a The lane no. corresponds to the lane number in Fig. 2. 
 
 
C. lusitaniae. Identification of the NASBA products used a microtiter format, bead-based 
detection assay using biotin-labeled specific probes coupled to streptavidin-coated magnetic 
beads and detection with a generic probe which was labeled with HRPO. The use of 
streptavidin-coated magnetic beads as solid support for the biotinylated probes results in 
shorter diffusion distances and greater surface areas compared to standard hybridization 
assays. In turn, this led to shorter incubation times. An additional advantage of NASBA is that 
the resulting ssRNA product directly can be used in a hybridization assay, whereas PCR 
products have to be denatured19 with the inevitable chance of renaturing. The hybridization 
assay was approximately 10 times more sensitive than agarose gel electrophoresis. 
A number of papers described the use of PCR for the diagnosis of 
candidemia17,20,22,23,25,26,28,32, but sample preparation was either laborious or could not cope 
with larger volumes of blood, which are required to detect the low number of microorganisms 
encountered in blood. Therefore, we focused on a rapid sample preparation method which 
could accommodate volumes up to 1 ml. Most studies used the method described by 
Buchmann6.  Although this method was highly efficient6,28, it was labour intensive. Our 
method is a simplified version of the method described by Buchmann. Blood cells were 
selectively lysed, fungal cells pelleted and RNA was isolated using guanidine thiocyanate and 
silica spin columns. This method resulted in a clinical sensitivity of 1-10 cfu per ml of whole 
blood. The procedure of blood lysis and RNA isolation took less than 3 hours and NASBA 
with enzymatic bead-based identification takes approximately 5 hours. Taken together, the 
complete procedure could be performed in one day. The lysis method developed was not only 
suitable for obtaining RNA from Candida, but also Aspergillus spp. The lysis of cryptococci 
requires a minor modification because the sample had to be incubated with lyticase from 
Trichoderma harzianum before the addition of guanidine thiocyanate (data not shown). 
Evaluation of this NASBA protocol on 68 blood specimens obtained from patients 
suspected of candidemia suggested the presence of C. albicans in 8 specimens and in one 
specimen C. glabrata. Evaluation of 13 serum samples from patients suspected of candidemia 
identified two specimens with C. albicans. These data clearly show that NASBA in 
combination with the enzymatic bead-based identification can be used for the detection of 
Candida spp. in blood without prior need for culture. In fact the number of positive samples 
may increase when long term storage of the samples (which was more than 3 to 6 months for 
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many of our samples) can be avoided, because RNA appears to degrade during long term 
storage at -70°C. 
More research has to be performed on a clinical specimen, but the prospect for NASBA 
detection and identification of yeasts in blood seems good. The speed and accuracy of this 
nucleic acid amplification technology can result in a more rapid diagnosis of candidemia and 
thereby reducing morbidity and mortality. 
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ABSTRACT 
 
Candida spp. are the main causes of fungal infections in immunocompromised patients. It is 
known, that the routinely used automated blood culture systems may fail to detect yeasts. We 
therefore investigated, whether Nucleic Acid Sequence-Based Amplification (NASBA) can be 
used to improve the detection rate of Candida spp. in blood cultures. Culture-positive as well 
as negative blood cultures from patients with a proven candidaemia were analyzed, and the 
results of BacT/Alert monitoring were compared with the results of NASBA-based detection 
of yeast RNA. With the NASBA-assay, the number of positive blood cultures increased from 
21% to 34%. The NASBA-assay may confirm the diagnosis and demonstrate the need for 
prolonged treatment. In addition it may shorten the time to detection. In summary, using 
NASBA for the detection of yeast RNA in blood cultures, we have shown for the first time that 
it is possible to improve the detection rate of yeasts in blood cultures by using amplification 
technology.  
 
 
INTRODUCTION 
 
Most fungal species involved in human disease are opportunistic pathogens and only cause 
problems in debilitated individuals. However, due to the profound developments in medical 
care, the number of immunocompromised patients has increased, and yeasts and fungi are 
found more often as causes of systemic infections. High-risk groups include: neutropenic 
cancer patients, transplant recipients and patients receiving broad-spectrum antibiotics or 
parenteral nutrition20. Candidiasis accounts for the majority of fungal infections in these 
patients. In North America, Candida is the 4th most common bloodstream pathogen, and in 
Europe Candida spp. rank 8th5,8. The main species is Candida albicans, but in recent years 
other species such as C. tropicalis, C. parapsilosis, C. glabrata, C. lusitaniae and C. krusei 
were isolated more often1,15,16,21,24. These different Candida spp. show differences in resistance 
against antimycotic drugs. For example, C. krusei and many strains of C. glabrata show 
resistance against fluconazole16. Therefore, a rapid detection and identification to the species-
level is essential to start an adequate treatment as soon as possible. 
Automated blood culture systems are routinely used as diagnostic tool. However, in many 
cases these blood cultures fail to detect yeasts (up to 65%) or need prolonged incubation times 
or terminal subculturing of negative blood culture bottles before yeast growth can be 
detected11,18,19. This may be caused by the fact that many blood culture media are not optimal 
for fungal growth, by the presence of antimycotics in the blood and/or by a low number of 
organisms present in the blood. Special media for detection of fungal growth are available6. 
However, because it is labour intensive and expensive to use several systems at the same time, 
most laboratories only use the standard blood culture bottles. 
Because in fungemia only 1-10 colony forming units (cfu) per ml blood may be present, 
amplification technologies provide promising methods for the rapid detection of fungemia. 
Several groups have published good results when using PCR on DNA isolated from whole 
blood for the detection of candidaemia. However, one of the problems when using PCR is the 
possibility of detecting naked DNA derived from dead and degrading yeast cells instead of live 
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yeasts, which results in false-positives4,13. Also, in many cases only small sample volumes 
could be used, or a long and cumbersome sample preparation was needed2,7,9,12-14,17.  
We have shown previously, that using Nucleic Acid Sequence-Based Amplification 
(NASBA3) we were able to detect 10 molecules of rRNA when using RNA isolated from 
cultures of C. albicans, and 1-10 cfu C. albicans in one ml of whole blood. For this RNA-
amplification method, we made use of primers directed against conserved regions of the 18S 
rRNA of medically important fungi. For the identification of different Candida spp., specific 
biotinylated probes were used23. The advantage of using rRNA as target is, that as many as 
10,000 copies of rRNA can be present per cell. This accounts for the high sensitivity of our 
assay. Also, because RNA degrades relatively quickly after cell-death, amplification-products 
found are mainly derived from living yeast cells.  
The aim of our present study was to investigate whether NASBA can be used to improve 
the detection rate of Candida spp. in blood cultures. For this, we analyzed culture-positive as 
well as negative blood cultures from patients with a proven candidaemia, and compared the 
results of BacT/Alert monitoring with the results of NASBA-based detection of yeast RNA.  
 
 
MATERIALS AND METHODS 
 
 Fungal species. Candida albicans (CBS 562) was obtained from the Centraal Bureau voor 
Schimmelcultures (CBS, Baarn, the Netherlands). Yeasts were grown on Sabouraud Dextrose 
Agar (SDA) at 35-37°C for 2 days.  
 Clinical blood cultures. Clinical blood culture samples were obtained from the University 
Medical Center Utrecht between September 1998 and November 1999. During this period, all 
patients with at least one blood culture positive for Candida were included in the study. 
Furthermore, 5 uninfected patients and 5 patients who were colonized with Candida were 
randomly selected. All blood cultures were taken on clinical indication, and handled in the 
same microbiology lab. Blood from the patients was cultured in sets of blood culture bottles: 
one FAN aerobic and one regular anaerobic BacT/Alert bottle. In case of children, Pedi-BacT 
bottles were used (Organon Teknika, Boxtel, the Netherlands). Culture of the blood culture 
bottles was performed under routine laboratory conditions. Blood cultures were cultured in the 
BacT/Alert monitoring system for 7 days, or until a positive signal was obtained. For the 
NASBA-assay, one ml samples were taken from the bottles and stored at -70°C until further 
use.  
 Spiking experiments. For the spiking experiments, whole blood of healthy volunteers was 
added to BacT/Alert blood culture medium (1:4 v/v), the mixture was incubated for 24 hours 
at 37°C, and 1 ml samples were taken. C. albicans was grown on SDA plates for 2 days, and 
suspended in physiological salt solution. Ten-fold dilutions containing 106 down to 1 cfu/50 µl 
were made and spiked to 1 ml blood culture samples. These spiked samples were frozen at -
70°C for at least 20 minutes and further treated as described below. To verify the number of 
yeast cells in the solutions, samples of 100 µl physiological salt solution containing a 
calculated amount of 10 or 100 cfu C. albicans were plated on SDA. Colonies were counted 
after 2 days of culturing at 35-37°C. 
 Extraction of RNA. Blood culture samples were frozen at -70°C for at least 20 minutes. 
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After thawing, 0.9 ml Lysis Buffer (0.32 M sucrose; 10 mM Tris-HCl (pH 7.5); 5 mM MgCl2; 
1% Triton X100) was added and the samples were centrifuged for 5 minutes at 13,000 g. The 
pellet was resuspended in 100 µl Enzyme Buffer containing 2 mg/ml lyticase (Sigma-Aldrich, 
Steinheim, Germany), 2 mg/ml lysing enzymes (Sigma-Aldrich) and 0.17% ß-mercaptoethanol 
in 50 mM Tris-HCl (pH 7.5)/10 mM EDTA, and incubated at 37°C for 10 minutes. One ml 
RNAzol (Campro Scientific, Veenendaal, the Netherlands) was added and RNA was extracted 
according to the manufacturer, with minor modifications: 600 µl isopropanol was added to the 
aqueous phase instead of 500 µl; after washing with ethanol the pellet was dried for 10 minutes 
at 56°C, and RNA was dissolved for 10 minutes at 56°C in 20-40 µl water that was treated 
with UV-light for 2 hours. Samples were stored at -70°C until further use. 
 Primers and probes. The oligonucleotides used in this study are depicted in Table 1. 
When ECL-detection (electrochemiluminescence) was used, primer 2 was extended at the 5'-
end with the following sequence: 5'- GAT GCA AGG TCG CAT ATG AG-3'. The specificity 
of the probes and the sensitivity of the NASBA-assay were described previously by 
Widjojoatmodjo et al.23  
 NASBA. Five µl RNA sample was taken up in a pre-reaction mixture with a final volume 
of 15 µl, containing 53 mM Tris-HCl (pH 8.5), 16 mM MgCl2, 93 mM KCl, 6.7 mM DTT, 1.3 
mM of each dNTP, 2.7 mM of each rNTP, 20% (v/v) dimethyl sulfoxide and 0.27 µM of each 
primer. The whole mixture was first incubated at 65°C for 5 minutes followed by 5 minutes at 
41°C. Then 5 µl of an enzyme mixture containing 2.1 µg BSA, 6.4 U AMV-RT (Seigaku, 
Rockville, MD), 0.08 U RNase H and 32 U T7 RNA polymerase in 1.5 M sorbitol was added. 
The reaction mixture was incubated for 90 minutes at 41°C. 
 Controls. One positive and at least two negative controls for the amplification were used 
for each NASBA reaction. As a positive control for the amplification, 0.70 fg C. albicans 
RNA was used. In the negative controls, no template was added. Negative controls were 
positioned at the beginning and end of the series of samples that was tested. As a negative 
control for the whole procedure of isolation and amplification, 50 µl of physiological salt 
solution was added to samples containing blood and blood culture medium. These samples 
were treated as described for the spiking experiments.   
 Dot-blot analysis of NASBA products. Two µl NASBA product was spotted onto Z-
probe membrane strips (BioRad, Hercules, CA) which were rinsed with water and dried. The 
filter with the spots was dried and baked for 30 min. at 80°C. The strips were covered with 
approximately 5 ml preheated hybridization mix containing 7% SDS, 5 x SSC, 20 mM 
NaH2PO4 and 10 x Denhardt's solution. Twelve and a half µl biotinylated probe (5 µM; Table 
1) was added and hybridization was allowed for at least 2 h at 50°C. The strips were washed 
twice for 5 min. with preheated 1% SDS in 3 x SSC at 50°C. Then the strips were washed 
once with 0.1% SDS in 2 x SSPE (1 x SSPE equals 100 mM Na2HPO4 (pH 7.4), 175 mM 
NaCl, 1 mM EDTA) for 10 min. at room temperature. The strips were blocked with 0.5% SDS 
and 5% skimmed milk in 5 x SSPE for 15 min. at room temperature. The strips were washed 
once for 2 min. with 0.1% SDS in 2 x SSPE at room temperature. Two µl streptavidin-HRPO 
conjugate in 5 ml 0.1% SDS, 5 x SSPE was added to each strip and incubated for 30 min. at 
room temperature. Strips were washed twice for 1 min. and once for 10 min. with 0.1% SDS in 
2 x SSPE and twice for 2 min. with 2 x SSPE at room temperature. Excess fluid was removed 
on filter paper and 5 ml substrate  (2.5 mg diaminobenzidine, 1.25 mg CoCl2, 0.02% nickel 
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sulphate, 0.011% H2O2 in phosphate buffered saline) was added. Color development was 
stopped by rinsing with tap water.  
 ECL-detection. For ECL-detection, the NucliSens Basic Kit Detection Reagents in 
combination with the NucliSens Reader (Organon Teknika, Boxtel, the Netherlands) were 
used according to the manufacturer. Amplification products were simultaneously hybridized to 
the specific capture probes (Table 1) as well as to the generic ECL probe provided in the Basic 
Kit. This probe hybridizes to the generic sequence, incorporated by primer 2 during 
amplification. Amplification products were diluted 1:20 before hybridization with capture 
probes 1912, 1913, 1914 or 9566, and a 1:200 dilution was used when amplicons were 
hybridized with probes 2176 or UNI2. Hybridization took place at 41°C for 30 minutes. ECL-
signals were considered positive when ≥ 17% of the Instrument Reference Solution signal.  
 
 
Table 1 
The primers and probes used in this study. 
Primer Sequence (5' to 3') 
primer 1 AATTCTAATACGACTCACTATAGGGAGAGA-CATGCGATTCGAAAAGTTAa 
primer 2 GATGCAAGGTCGCATATGAG-ATGTCTAAGTATAAGCAATTTAb 
Probe Sequence (5' to 3') Target 
1912 ATCTCGACCTCTTGGAAGAGATGT C. glabrata 
1913 ATCCCGACTGTTTGGAAGGGATGT C. albicans; C. tropicalis; C. parapsilosis;  
C. viswanathii; C. guilliermondii 
1914 AGCCCGACCTCTGGAAGGGCTGTA C. lusitaniae 
2176 CAATGTCTTCGGACTCTT C. tropicalis 
9566 CCCTCGGGCCTTTTGATG C. krusei 
UNI2 CTGCGAATGGCTCATTAAATCAGT universal yeast/fungi probe 
a  italics: T7 promotor sequence 
b  italics: generic sequence used for ECL-detection 
 
 
RESULTS 
 
 Spiking experiments. NASBA-products of RNA isolated from blood cultures spiked with 
C. albicans were analyzed by dot-blot as well as used for ECL-detection. When aerobic 
medium was used, dot-blot analysis resulted in a detection limit of 104 cfu/ml, whereas with 
ECL-detection a detection limit of 103 cfu/ml was repeatedly found. When anaerobic medium 
was used, 10-100 cfu/ml could still be detected using dot-blot analysis or ECL-detection. 
 Negative controls. For the negative controls, the isolation and amplification procedures 
were performed on 1 ml samples of aerobic and anaerobic BacT/Alert blood-culture medium. 
For both types of medium, 10 different Lot-numbers were used. None of the probes used 
showed any hybridization when the NASBA-products were analyzed by dot-blot. 
In addition, blood from 10 different healthy volunteers was mixed with blood culture 
medium (aerobic and anaerobic) and processed as described. NASBA-products were dot-
blotted and hybridized with the biotinylated probes. No hybridization was observed with any 
of the Candida-probes. 
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Uninfected patients. Patients were considered not infected when no Candida spp. were 
found in any culture (blood- as well as other cultures) and no risk-factors for candidaemia were 
present. One ml samples were taken from blood cultures of these patients and processed as 
described. Ten aerobic and ten anaerobic blood cultures derived from five different patients 
were examined. None of the NASBA-products hybridized with any of the Candida-probes.  
 Patients colonized with Candida spp. Patients were considered colonized when blood 
cultures were negative for yeast, but Candida spp. were cultured from another site. Ten aerobic 
and ten anaerobic blood cultures derived from five different patients were examined. Candida 
spp.  were cultured from sputum (patients 1, 2, 3 and 5), catheter tip (patients 1, 2 and 5), urine 
(patients 1 and 4), throat swab, anal swab and wound fluid (patient 1) and bronchial lavage and 
aspirate of the sinus cavity (patient 5). One NASBA-product derived from an anaerobic blood 
culture bottle from patient 4 hybridized with probe 2176.  
 Patients with a culture-proven candidaemia. Ten different patients with at least one 
blood culture positive for Candida spp. were included. Nine patients were hospitalized in a 
university hospital, one patient was hospitalized in a children's hospital. One ml samples were 
taken from positive as well as negative blood cultures and processed as described. 
Patient information and the results of BactT/Alert monitoring and the NASBA-assay are 
depicted in Table 2. All samples that were BacT/Alert-positive, were also positive in the 
NASBA-assay. In patients 1, 2 and 3, yeast RNA was detected in cultures that remained 
negative in the BacT/Alert monitoring system. In 9 of these 12 BacT/Alert-negative/NASBA-
positives, this result was confirmed when the same Candida spp. was isolated after 
subculturing the blood culture bottles (data not shown). Table 3 shows the time-course over 
which the blood cultures of patients 1, 2 and 3 were drawn. Patient 1 was treated with 
amphotericin B at time of blood sampling for 14 out of 19 blood cultures. 
 
 
Table 3 
Time course of blood sampling and the results of BacT/Alert monitoring and the NASBA-assay for patients 1, 2 
and 3 
Patient Day no.a no. BCB (total) BacT/Alert + NASBA + Antimycotic treatmentc 
1 1 
7 
8 
9 
14 
19 
1b 
4 
2 
4 
6 
2 
1 
1 
- 
- 
- 
- 
1 
4 
- 
- 
3 
- 
no 
no 
yes 
yes 
yes 
yes 
2 1 
5 
6 
6 
- 
4 
- 
6 
no 
no 
3 1 
2 
3 
4 
2 
2 
2 
2 
- 
- 
1 
- 
2 
1 
1 
1 
no 
no 
no 
no 
BCB: blood culture bottles 
a day of blood sampling 
b data of one bottle not available 
c at time of blood sampling 
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DISCUSSION 
 
In our experiments, we have obtained a detection limit for C. albicans in blood cultures of 
103 cfu/ml for aerobic and 10-100 cfu/ml for anaerobic medium. The lower sensitivity for 
aerobic medium compared to anaerobic medium might be caused by the presence of 'Ecosorb', 
a substance containing absorbent charcoal material and Fuller's earth22. Ecosorb components 
may interfere with the RNA isolation or residual particles may inhibit the amplification. 
However, the sensitivity may not be a problem, since Shigei et al.18 and Tinghitella and 
Lamagdeleine19 have shown, that some automated blood culture instruments may fail to detect 
yeasts in spite of good growth of the organisms in the culture bottles, as was demonstrated by 
confluent growth after subculturing. Flahaut et al.4 have used PCR for the detection of C. 
albicans in clinical samples, and report a detection limit of 20 cfu/ml for blood cultures. 
However, since they do not mention the type of blood culture medium used, it is not possible 
to compare their results with ours. 
In the experiments where blood cultures from patients colonized with Candida spp. were 
used, we observed that one of the NASBA-products hybridized with probe 2176, which is used 
for the identification of Candida tropicalis. However, if the amplification product was 
obtained from Candida tropicalis, it should also hybridize with probe 1913, specific for 
Candida albicans, C. tropicalis, C. viswanathii, C. parapsilosis and C. guilliermondii, which it 
did not23. Probe 2176 cross-hybridizes with Saccharomyces cerevisiae, an organism that is one 
of the main causes of contaminations in fungal amplification assays10. Therefore, it is likely 
that our NASBA-product was derived from a S. cerevisiae contamination. All other samples 
from colonized patients, and also all samples from uninfected patients, healthy volunteers and 
culture medium alone were negative, which indicates that our assay has a low risk of 
generating false-positives.  
When looking at clinical blood cultures from patients with a culture-proven candidaemia, 
yeast RNA was detected in cultures that had remained negative in the BacT/Alert monitoring 
system in three out of ten patients. With the NASBA-assay, the number of positive blood 
cultures increased from 21% to 34%. In patient 1, six blood culture bottles were positive only 
in the NASBA-assay. Candida glabrata was recovered after subculturing these six blood 
culture bottles, proving that these findings were not false-positives. Three blood culture bottles 
were positive in the NASBA-assay after the patient had been treated with amphotericin B for 7 
days. In this case, BacT/Alert monitoring alone would have suggested that the infection was 
adequately treated.  
For patient 2, the NASBA-assay led to detection of the yeast in the anaerobic bottles of two 
blood-culture sets, of which the aerobic bottles had already been positive in the BacT/Alert 
monitoring system. In this case, the additional positive bottles supported the diagnosis.  
In the third patient, yeast was detected in four blood-culture bottles that had remained 
negative in the BacT/Alert monitoring system. We were not able to recover the yeast by 
subculturing in three of these four BacT/Alert-negative/NASBA-positives. However, since the 
patient was not treated with antimycotic agents at any time, it is not likely that the 
amplification product was derived from 'naked RNA' from degrading yeast cells. Yeast RNA 
was detected in blood culture bottles that were taken two days earlier than the first blood-
culture that became positive in the BacT/Alert monitoring system. Even though this finding 
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supports our hypothesis that by using NASBA it may be possible to improve the detection rate 
as well as shorten the time to detection, in this case it was not significant since the patient had 
died before candidaemia was diagnosed. 
Our study is the first to describe the use of RNA-amplification for detection of yeasts in 
blood cultures. Flahaut et al.4 have used PCR for the detection of C. albicans in clinical 
samples. In their study, the results of the PCR were in complete accordance with the results of 
blood culturing. To our knowledge, we have shown for the first time that it is possible to 
improve the detection rate of yeasts in blood cultures by using an amplification technology.  
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SUMMARY 
 
 The number of life-threatening opportunistic fungal infections has shown a dramatic 
increase. However, the diagnosis of candidaemia remains difficult. Nucleic acid amplification 
assays may improve the detection rate and decrease the time needed for detection and 
identification of Candida spp. Whole blood samples of patients suspected of having 
candidaemia were analyzed using Nucleic Acid Sequence-Based Amplification (NASBA). 
Furthermore, aliquots of blood cultures of the patients after 2 days of culturing were tested. 
Eleven data sets from ten patients in two hospitals were generated. None of the whole blood 
samples was positive in the NASBA assay. Eight samples were positive in the NASBA assay 
after two days of culturing, whereas only two additional positive samples were found after 
longer incubation periods. Thus, a two-day culture step is sufficient to greatly improve the 
sensitivity of the NASBA assay. The NASBA assay detected Candida RNA in three patients. 
In one patient, the yeast was not detected by automated blood culturing, in another patient the 
NASBA assay detected the infection two days earlier than the blood culture system.  
 
 
KEY WORDS 
 
 Candida spp., Nucleic Acid Sequence-Based Amplification (NASBA), blood culture 
 
 
INTRODUCTION 
 
The number of life-threatening opportunistic fungal infections in immunocompromised 
patients has shown a dramatic increase1. Candida spp. account for the majority of these 
infections. The attributable mortality of Candida infections is approximately 38%19, and crude 
mortality rates exceed 50%7,12,18. The diagnosis of candidemia remains difficult. Automated 
blood culture systems are routinely used, but fail to detect yeasts in many cases2,11. 
Furthermore, prolonged incubation times or terminal subculturing of negative blood culture 
bottles may be necessary before yeast growth can be detected3,14,17.  
Because of their sensitivity and speed, nucleic acid amplification assays may play an 
important role in improving the detection rate and decreasing the time needed for detection and 
identification of Candida spp. As little as 10 molecules of rRNA can be detected with a 
Nucleic Acid Sequence-Based Amplification (NASBA-) assay20. This assay makes use of 
primers directed against conserved regions of the 18S rRNA of medically important fungi and 
specific probes for the identification of different Candida spp. When using whole blood 
samples, 1-10 cfu of C. albicans could still be detected.  
In a previous study, we showed that the NASBA assay could detect candidemia, whereas no 
Candida RNA was detected in blood culture medium alone, or in blood cultures from healthy 
volunteers, uninfected patients or patients colonized with Candida spp. When we used the 
NASBA assay to analyze culture-positive as well as negative blood cultures from patients with 
a proven candidemia after 7 days of culturing, we showed that compared with automated blood 
culturing, the number of positive blood cultures increased from 21% to 34%4.  
Chapter 4 
 47
Here, we present the results of a clinical evaluation of the NASBA assay. Whole blood 
samples of patients suspected of having candidemia were analyzed. However, since 
candidemia is characterized by a low number of yeast cells in the bloodstream, a short culture 
step may further increase the detection rate. Therefore, aliquots of blood cultures from the 
patients after 2 days of culturing were also tested. The results were compared with automated 
blood culturing as well as results from the NASBA assay on aliquots of blood cultures after 7 
days of culturing.  
 
 
MATERIALS AND METHODS 
 
 Clinical samples. Blood and blood culture samples were obtained from the University 
Medical Center (UMC), Utrecht, the Netherlands and the Catharina Hospital, Eindhoven, the 
Netherlands, between March 2000 and June 2001. The study design was approved by the 
Medical Ethics Committee of the UMC Utrecht (protocol no. 99/104). Patients in the intensive 
care unit (ICU) were included when there was a clinical suspicion of candidemia and a 
presence of two or more systemic inflammatory response syndrome (SIRS)-criteria: 
temperature < 36°C or > 38°C; tachycardia > 90 beats/min.; CO2 < 32 mm Hg; respiratory rate 
> 24 breaths/min.; leukocytes < 4 x 109/l or > 12 x 109/l; > 10% immature (band) forms. 
Patients in the hematology ward were included when they had neutropenia (# 100 
granulocytes/µl) and did not respond to broad spectrum antibiotic treatment for 48-72 hours. In 
the Catharina Hospital Eindhoven, the inclusion criteria also included culturing of yeasts from 
2 or more foci. Patients or their relatives were required to comprehend and sign an informed 
consent form. EDTA-blood was drawn from the patients on day 1 (before treatment with 
antimycotic agents was started), divided into 1 ml aliquots, and stored at -70°C. Two blood 
culture sets were drawn on day 1: one from a central venous catheter (if present) and one from 
a peripheral vein (if possible). Each blood culture set consisted of one aerobic and one 
anaerobic blood culture bottle (BacT/Alert, Organon Teknika, the Netherlands). In the UMC 
Utrecht, FAN aerobic bottles were used. On days 3 and 5 another blood culture set was drawn 
from a peripheral vein (if possible, otherwise from the central venous catheter). Blood cultures 
were cultured in the BacT/Alert monitoring system for 7 days. After 2 days of culturing, three 
1 ml samples were taken from each bottle and stored at -70°C until use in the NASBA assay. 
This was repeated after 7 days of culturing, or when blood cultures were positive in the 
BacT/Alert monitoring system. The species was identified using CHROMagar plates 
(bioMérieux, Den Bosch, the Netherlands) and VITEK analysis (bioMérieux). 
 Extraction of RNA. Blood and blood culture samples were frozen at -70°C for at least 20 
minutes. After thawing, 0.9 ml lysis buffer (0.32 M sucrose; 10 mM Tris-HCl (pH 7.5); 5 mM 
MgCl2; 1% Triton X100) was added and the samples were centrifuged for 5 minutes at 13,000 
g. The supernatant was removed, and this step was repeated once. The pellet was then 
resuspended in 100 µl enzyme buffer containing 2 mg/ml lyticase (Sigma-Aldrich, Steinheim, 
Germany), 4 mg/ml lysing enzymes (Sigma-Aldrich) and 0.17% ß-mercaptoethanol in 50 mM 
Tris-HCl (pH 7.5)/10 mM EDTA, and incubated at 37°C for 10 minutes. When FAN aerobic 
blood cultures were used, the samples were centrifuged for 1 minute at 13,000 g , and the 
supernatant was transferred to a fresh tube. One ml RNAzol (Campro Scientific, Veenendaal, 
Clinical evaluation of NASBA 
 48
the Netherlands) was added and RNA was extracted according to the manufacturer's 
instructions, with minor modifications: 600 µl isopropanol was added to the aqueous phase 
instead of 500 µl; after washing with ethanol the pellet was dried for 10 minutes at 56°C, and 
RNA was dissolved for 10 minutes at 56°C in 40 µl water that was treated with UV-light for 2 
hours. Samples were stored at -70°C until further use. 
 Primers and probes. The oligonucleotides used in this study are shown in Table 1. The 
specificity of the probes and the sensitivity of the NASBA assay have been described 
previously4,20.  
 
 
Table 1 
The primers and probes used in this study 
Primer Sequence (5' to 3') 
primer 1 AATTCTAATACGACTCACTATAGGGAGAGA-CATGCGATTCGAAAAGTTAa 
primer 2 GATGCAAGGTCGCATATGAG-ATGTCTAAGTATAAGCAATTTAb 
Probe Sequence (5' to 3') Target 
1912 ATCTCGACCTCTTGGAAGAGATGT C. glabrata 
1913 ATCCCGACTGTTTGGAAGGGATGT C. albicans; C. tropicalis; C. parapsilosis;  
C. viswanathii; C. guilliermondii 
1914 AGCCCGACCTCTGGAAGGGCTGTA C. lusitaniae 
2176 CAATGTCTTCGGACTCTT C. tropicalis 
9566 CCCTCGGGCCTTTTGATG C. krusei 
a  italics: T7 promotor sequence 
b  italics: generic sequence used for ECL-detection 
 
 
 NASBA. Five µl RNA samples were taken up in a pre-reaction mixture with a final 
volume of 15 µl, containing 53 mM Tris-HCl (pH 8.5), 16 mM MgCl2, 93 mM KCl, 6.7 mM 
DTT, 1.3 mM of each dNTP, 2.7 mM of each rNTP, 20% (v/v) dimethyl sulfoxide and 0.27 
µM of each primer. The whole mixture was first incubated at 65°C for 5 minutes followed by 5 
minutes at 41°C. Then 5 µl of an enzyme mixture containing 2.1 µg BSA, 6.4 U AMV-RT 
(Seigaku, Rockville, MD), 0.08 U RNase H and 32 U T7 RNA polymerase in 1.5 M sorbitol 
was added. The reaction mixture was incubated for 90 minutes at 41°C. 
 Controls. One positive and at least two negative controls for the amplification were used 
for each NASBA reaction. As a positive control for the amplification, 0.70 fg C. albicans 
RNA was used. In the negative controls, no template was added. Negative controls were 
positioned at the beginning and end of the series of samples that was tested. As a positive 
control for the whole procedure of isolation and amplification, two blood samples of each 
patient were spiked with 50 µl of physiological salt solution containing 102 and 104 colony 
forming units (cfu) of C. albicans (CBS 562, Centraal Bureau voor Schimmelcultures, Utrecht, 
the Netherlands).    
 ECL-detection. For electrochemiluminescence (ECL)-detection, the NucliSens Basic Kit 
Detection Reagents in combination with the NucliSens Reader (Organon Teknika, Boxtel, the 
Netherlands) were used according to the manufacturer's instructions. Amplification products 
were simultaneously hybridized to the specific capture probes (Table 1) as well as to the 
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generic ECL probe provided in the Basic Kit. This probe hybridizes to the generic sequence, 
incorporated by primer 2 during amplification. Amplification products were diluted 1:20 
before hybridization with capture probes 1912, 1913, 1914 or 9566, and a 1:200 dilution was 
used when amplicons were hybridized with probe 2176. The ECL procedure involves standard 
use of 5 ml tubes (Falcon, Becton Dickinson, le Pont de Claix, France) for the relatively small 
sample volumes, which greatly reduces the risk of carry-over contaminations. Furthermore, 
fresh filtertips were used for each pipeting step and all contaminated waste was disposed in 
closed plastic bags. Hybridization took place at 41°C for 30 minutes. ECL-signals were 
considered positive when ≥ 50% of the positive control (0.70 fg C. albicans RNA).  
 
 
RESULTS 
 
 Ten patients were included in the trial: 4 patients from the UMC Utrecht and 6 patients 
from the Catharina Hospital Eindhoven. One patient was suspected of candidemia on two 
different occasions. From this patient, two data sets were obtained.  
 None of the whole blood samples was positive in the NASBA assay. Blood cultures as well 
as the NASBA assay were negative for patients 1, 2, 3, 4 (two data sets), and 9. Bacteria, but 
not yeasts, were cultured in blood cultures of patients 6, 8 and 10 (patient 6: Enterococcus 
faecalis and Escherichia coli; patient 8: Staphylococcus epidermidis; patient 10: 
Staphylococcus epidermidis and Staphylococcus haemolyticus). NASBA assays performed on 
samples from patients 6 and 8 were all negative for yeast. However, several blood culture 
samples of patient 10 hybridized with probe 1913 or 2176 in the NASBA assay (Table 2). 
 Blood cultures from two patients were positive for C. albicans (patients 5 and 7, Table 2). 
All C. albicans positive cultures were taken on day 1: three out of four blood cultures (two 
anaerobic bottles and one aerobic bottle) of patient 5, and one (aerobic) blood culture of 
patient 7. Blood cultures taken on days 3 and 5 of patient 5 showed bacterial growth 
(Enterococcus faecalis and Staphylococcus aureus, Table 2). Several samples of patients 5 and 
7 hybridized with probes 1913 and/or 2176 in the NASBA assay (Table 2). 
 
 
DISCUSSION 
 
 Eleven data sets from ten patients in two hospitals were obtained over a period of 16 
months. This low number is due in part to the fact that during the study the therapeutic 
regimen in the University Medical Center Utrecht was changed: all patients at the surgical ICU 
received fluconazole-prophylaxis during the second half of the study period, and therefore did 
not meet the inclusion criteria (according to which the first samples should be obtained before 
antimycotic treatment was commenced). However, the number of patients that were included 
during the first half of the study period and from the second hospital was still low.  
 Although some patients who fitted the inclusion criteria may have been missed, these 
numbers are indicative of the low number of patients suspected of candidemia in the 
Netherlands. It is possible that this truly reflects a minimal number of systemic Candida 
infections. It is known that in Europe, Candida spp. account for less bloodstream infections  
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Table 2 
Comparison between BacT/Alert monitoring of clinical blood cultures and NASBA detection of yeast RNA 
Patient 
no. 
 
Sample1 
 
BacT/Alert2 
NASBA2 
day 2 
NASBA2 
day 7 
5 1a - 1913 n.d. 
 1b Candida albicans 1913 n.d. 
 1c Candida albicans - n.d. 
 1d Candida albicans - n.d. 
 3a - - - 
 3b (Enterococcus faecalis) - - 
 5a (Enterococcus faecalis) - - 
 5b (Staphylococcus aureus) 1913 - 
7 1a Candida albicans - 19133 
 1b - - -3 
 1c - 2176 - 
 1d - - - 
 3a - - - 
 3b - - - 
 5a - - - 
 5b - 1913 + 2176 - 
10 1a - 2176 2176 
 1b - 2176 1913 
 1c - - 1913 
 1d - - - 
 3a (Staphylococcus epidermidis) 1913 - 
 3b (Staphylococcus epidermidis) - - 
 5a (Staphylococcus epidermidis; S. haemolyticus) - - 
 5b (Staphylococcus epidermidis; S. haemolyticus) - - 
1 1a = aerobic blood culture, day 1, central venous catheter 
 1b = anaerobic blood culture, day 1, central venous catheter 
 1c = aerobic blood culture, day 1, peripheral blood 
 1d = anaerobic blood culture, day 1, peripheral blood 
 3a = aerobic blood culture, day 3 
 3b = anaerobic blood culture, day 3 
 5a = aerobic blood culture, day 5 
 5b = anaerobic blood culture, day 5 
2 - = negative 
 n.d. = no data (cultures were positive for yeast after 2-4 days of culturing) 
 day 2 = NASBA on blood culture samples after 2 days of culturing 
 day 7 = NASBA on blood culture samples after 7 days of culturing 
 1913 = NASBA product hybridized with probe 1913 
 2176 = NASBA product hybridized with probe 2176 
3 samples were taken from blood cultures on day 3 instead of day 7 
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than, e.g., in North America, where Candida spp. are the fourth most common bloodstream 
pathogens8. In Europe, Candida spp. rank 8th6. However, it is also believed that the number of 
systemic Candida infections is underestimated. Tan et al. reported in 1992 that the number of 
systemic mycoses in the Netherlands may be as high as hundreds per year, even though only a 
few cases were reported in their survey15. Although these data are quite old, the fact that only 
four patients from the University Medical Center Utrecht were included in our study (and 
therefore suspected of having candidemia) over a period of 16 months, whereas around 40 
blood cultures positive for Candida spp. are seen annually in this hospital, supports this latter 
hypothesis. Furthermore, taking into account that in up to 65% of the cases automated blood 
culture systems fail to detect yeasts11, the true number of systemic Candida infections may be 
much higher than expected. 
 We have previously established a detection limit for C. albicans of 1-10 cfu/ml blood20. In 
the present study, none of the whole blood samples was positive in the NASBA assay. 
Candida spp. were cultured from the blood of two of the patients, and Candida RNA was 
detected in blood cultures of three. It seems likely that the other patients were not infected. The 
number of cells in the blood of the three patients with Candida RNA-positive blood culture 
samples may have been too low to detect without a culture step. The number of Candida cells 
in candidemia has been quantitated by using colony counts obtained directly on blood agar 
plates by the lysis centrifugation technique. It was shown that 26.5% of all samples had < 1 
cfu/ml blood, and that another 27.9% had between 1 and 10 cfu/ml13. Eight samples were 
positive in the NASBA assay after two days of culturing. Only two additional positive samples 
were found: one after three days, and one after seven days of culturing. This indicates that a 
two-day culture step is sufficient to greatly improve the sensitivity of the NASBA assay. 
 One sample each of patients 3 and 9 hybridized with probe 2176 in the NASBA assay 
(results not shown). When NASBA products hybridize with probe 2176 as well as probe 1913, 
the species is identified as C. tropicalis20. However, in this case the products hybridized with 
probe 2176 only. Probe 2176 cross-hybridizes with Saccharomyces cerevisiae, which is one of 
the main causes of contaminations in fungal amplification assays9. Therefore, it is likely that 
these NASBA-products were derived from a S. cerevisiae contamination. 
 The anaerobic blood culture taken from the central venous catheter of patient 5 on day 1 
was positive for C. albicans after 4 days of growth (Table 2). Samples from both bottles of this 
blood culture set hybridized with probe 1913 in the NASBA assay. This probe hybridizes with 
C. albicans, C. tropicalis, C. viswanathii, C. parapsilosis and C. guilliermondii. Because C. 
albicans was grown from this blood culture, it is most likely RNA of this species which was 
detected. Since the samples for the NASBA assay were taken after two days of growth, the 
NASBA assay clearly led to earlier detection. Both the aerobic as well as the anaerobic blood 
culture taken from a peripheral vein instead of the central venous catheter of the same patient 
(patient 5) on the same day (day 1) showed growth of C. albicans. However, samples taken 
from these bottles did not hybridize with any of the Candida probes used. It is known that 
nucleic acid amplification assays can be inhibited when large amounts of target DNA are 
present. Therefore, the extracted RNA from these samples was diluted 5 and 10x, and another 
NASBA was performed (results not shown). Again, the samples did not hybridize with any of 
the probes. Since yeast growth was detected in these blood cultures very rapidly (in the aerobic 
bottle after 2 days, and in the anaerobic bottle after 3 days of culturing), it is possible that the 
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number of yeast cells in the samples was extremely high. In that case, a greater than 10x 
dilution may have been necessary in order to detect target RNA. This was not further 
examined, due to lack of material. 
 Blood cultures from the same patient (patient 5) taken on days 3 and 5 showed bacterial, 
but not yeast growth. However, a sample taken after two days of culturing from a blood culture 
of day 5 hybridized with probe 1913 (Table 2). A sample taken from the same blood culture 
bottle after seven days of culturing did not show any results in the NASBA assay. It is possible 
that the yeast cells were degraded by antifungal agents present in the blood of the patient. 
Patient 5 had been treated with fluconazole for 5 days at the time of blood sampling for this 
culture. The fact that yeast RNA was still detectable in a sample that was drawn when the 
patient was receiving antifungal treatment may indicate treatment failure. This may have 
remained undetected by the automated blood culture system because of bacterial overgrowth. 
 One blood culture from patient 7 showed growth of C. albicans after three days. A sample 
from this bottle taken after three days of culturing was also positive in the NASBA assay (1a, 
Table 2). A sample from another blood culture bottle from day 1 hybridized with probe 2176 
(1c, Table 2). Another sample, taken after two days of culturing of a blood culture from day 5, 
hybridized with probe 2176 as well as 1913 (indicative for C. tropicalis; 5b, Table 2). Since 
only C. albicans was cultured and no C. tropicalis was ever found in any culture from this 
patient, the most likely explanation for these results is that sample 1c is a S. cerevisiae 
contaminant, as described above, and sample 5b contains a mixture of C. albicans and S. 
cerevisiae RNA.  
 Several samples from patient 10 hybridized with either probe 2176 or 1913 (Table 2). 
Since all negative controls were free of contaminants and because of the stringent measures for 
prevention of contaminations that are taken in our laboratory, it is not likely that all samples 
which hybridized only with probe 2176 are the result of S. cerevisiae contaminations of the 
NASBA assay. In rare cases, S. cerevisiae causes bloodstream infections (Taylor et al. reported 
one case in their hospital over a seven year period16). A combined infection with S. cerevisiae 
and C. albicans is therefore possible. It is, however, striking that all three samples which 
hybridized with probe 2176 were taken from one blood culture set. S. cerevisiae, also known 
as 'baker's yeast', is used widely in industrial baking and brewing, and is commonly present in 
the environment. Since the three samples were taken from blood cultures which were drawn at 
the same time from a central venous catheter, it is very well possible that the blood cultures 
were contaminated with yeast cells from the skin of either the patient or the health care worker, 
for instance. The fact that blood cultures in many cases fail to detect yeasts might explain why 
they were not detected by the automated blood culture system.  
 Three samples from patient 10 hybridized with probe 1913, indicating that this patient 
possibly suffered from candidemia. No Candida spp. were cultured from the blood of this 
patient. However, we have previously shown, that the NASBA assay performed on aliquots of 
blood cultures is more sensitive than the BacT/Alert monitoring system4.  
 Our NASBA assay uses separate amplification- and detection procedures. Real-time 
detection of C. albicans with the Light Cycler system has been used successfully10. It is 
possible to combine NASBA amplification with the use of molecular beacons. This results in 
an isothermal real-time detection assay, without the need of expensive thermal cyclers. 
Quantification of the NASBA products is possible with ECL- as well as molecular beacon 
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detection5. 
 In conclusion: in three out of ten patients the NASBA assay detected Candida RNA. In one 
patient the yeast was not detected by automated blood culturing, in another patient the NASBA 
assay detected the infection two days earlier than the blood culture system. This is encouraging 
for the use of NASBA for the detection of systemic Candida infections. However, this study 
should be repeated with a larger number of patients before sound conclusions can be made.  
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Nucleic Acid Sequence-Based Amplification (NASBA) is an isothermal RNA amplification 
method based on the simultaneous action of three enzymes: Avian Myeloblastosis Virus 
Reverse Transcriptase (AMV-RT), RNase H and T7 RNA polymerase1. The method is 
extremely sensitive. When rRNA is used as a target, as many as 10,000 copies can be present 
per cell. Furthermore, hundreds of RNA copies are generated in each amplification 'cycle', 
each of which serve as a target for the next round (in comparison: with PCR only two copies 
are generated in each cycle). This results in a large amount of product in a short period of time. 
 NASBA was successfully used in our laboratory for the detection of Candida spp. in blood 
and blood cultures2,3. Primers and probes for the detection of several Candida spp. were 
developed and used in an in-house NASBA assay3. Yeast RNA was extracted by using 
RNAzol (Campro Scientific, Veenendaal, the Netherlands), and amplification products were 
detected using the Basic Kit electrochemiluminescence (ECL) detection module (Organon 
Teknika, Boxtel, the Netherlands)2. The aim of this study was to replace our in-house NASBA 
assay by the Basic Kit amplification module (Organon Teknika). 
 The Basic Kit amplification module contains a reagent sphere (comprised of a.o. dNTP's 
and NTP's), reagent sphere diluent, a separate stock of KCl for optimization of the assay, 
enzyme mix, and NASBA-water. The primers are not included but have to be designed by the 
user (in our case, we could use the primers from our in-house NASBA assay).  
We spiked a mixture of blood from a healthy volunteer and aerobic blood culture medium 
(BacT/Alert FAN medium, Organon Teknika) with a 10-fold dilution of Candida albicans cfu. 
RNA was extracted as described2. After amplification using the Basic Kit amplification 
module (according to the manufacturer; 70 mM KCl), the NASBA products were hybridized 
with a probe for C. albicans and a universal yeast/fungi probe3. Amplification products were 
diluted 1:20 before hybridization with the albicans probe, and a 1:200 dilution was used when 
amplicons were hybridized with the yeast/fungi probe. Hybridization took place at 41°C for 30 
minutes. For detection, the Basic Kit ECL detection module was used as described2. ECL-
signals were considered positive when ≥ 17% of the Instrument Reference Solution (IRS) 
signal, and increased, but not positive when < 17% of the IRS, but > 3x the signal of the Assay 
Negative (AN: probe + detection diluent). The results are depicted in Table 1a. Although all 
negative controls were correct when the albicans probe was used, both negative controls and 
the 0 cfu sample hybridized with the yeast/fungi probe. 
 We then used the Basic Kit amplification module to detect yeast RNA in a mixture of blood 
with either FAN-aerobic or standard anaerobic blood culture medium (BacT/Alert, Organon 
Teknika) spiked with a 10-fold dilution of C. albicans cfu (Table 1b). In this experiment, two 
of the four negative controls showed increased signals after hybridization with the albicans 
probe. For comparison, we performed an in-house NASBA (Table 1c). Although the signal for 
the positive control was low when the albicans probe was used, there were no problems with 
the negative controls.  
A number of experiments were performed in order to find the cause of these 
contaminations. First, the water from the kit (NASBA-water) was exchanged with water that 
was treated with UV-light for two hours. This UV-treated water had proved to be free of 
contaminations in our in-house NASBA assay. The results are depicted in Table 2a. When 
UV-treated water was used in combination with the Basic Kit amplification module, problems 
occurred with the yeast/fungi probe. When the NASBA-water was used, both the albicans as  
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Table 1 
a:  NASBA with the Basic Kit amplification module on a 10-fold dilution of C. albicans cfu in blood + 
aerobic blood-culture medium 
 AN neg. 0 1 10 102 103 104 105 106 pos. neg. 
albicans - - - - - - + + + + + - 
yeast/fungi - + + + + + + + + + + + 
 
b: NASBA with the Basic Kit amplification module on a 10-fold dilution of C. albicans cfu in blood + 
aerobic and anaerobic blood-culture medium 
 AN neg. neg. 0 1 10 102 103 104 pos. neg. neg. 
albicans, aerobic - + - +/- + + 
albicans, anaerobic 
- +/- - 
- - - + - + 
+ - +/- 
 
c: In house-NASBA 
 AN neg. neg. neg. pos. neg. neg. neg. 
albicans - - - - +/- - - - 
yeast/fungi - - - - + - - - 
 
AN: assay negative (probe + detection diluent) 
neg.: negative control (no template added to NASBA) 
pos.: positive control (0.70 fg C. albicans RNA added to NASBA) 
albicans: probe for detection of C. albicans; C. tropicalis; C. parapsilosis; C. viswanathii and C. guilliermondii 
yeast/fungi: universal probe for detection of yeasts and fungi 
+: positive after ECL detection 
-: negative after ECL detection 
+/-: increased, but not positive, signal after ECL detection 
 
 
well as the yeast/fungi probe showed hybridization with negative controls. To further examine 
the NASBA-water, we used this water in our in-house NASBA assay (Table 2b). False positive 
results occurred in 2 of the 4 negative controls. In conclusion: the NASBA-water is a source of 
contaminations, but it is not the only source. 
 To examine the role of the enzyme mix, we performed an experiment with the Basic Kit 
amplification module on two series of positive and negative controls. In one series, the enzyme 
mix of the kit was exchanged with our in-house enzyme mix (Table 2c). When the Basic Kit 
enzymes were used, all negative and positive controls were correct when the albicans probe 
was used. However, all negative controls were positive after hybridization with the yeast/fungi 
probe. When the in-house enzymes were used, one of the negative controls showed an 
increased (but not positive) signal after hybridization with the albicans probe, and all negative 
controls showed an enhanced or positive signal after hybridization with the yeast/fungi probe. 
We then performed the same experiment with the in-house NASBA assay (Table 2d). When 
the Basic Kit enzyme mix was used, all negative and positive controls were correct with both 
probes. When the in-house enzyme mix was used, three of the negative controls showed 
enhanced (but not positive) signals after hybridization with the yeast/fungi probe. Therefore, it 
seems like the enzyme mix from the Basic Kit amplification module is 'cleaner' than the in-
house enzyme mix.  
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Table 2 
a: NASBA with the Basic Kit amplification module: one series with NASBA-water (kit), one series with 
UV-treated water 
    UV-treated water NASBA-water    
 AN neg. neg. neg. pos. neg. neg. neg. neg. pos. neg. neg. 
albicans - - - - + - +/- - + + - - 
yeast/fungi - + + + + + + + + + + + 
 
b: In-house NASBA: NASBA-water (kit) instead of UV-treated water 
 AN neg. neg. pos. neg. neg. 
albicans - - - + - - 
yeast/fungi - + + + - - 
 
c: NASBA with the Basic Kit amplification module: one series with enzyme mix (kit), one series with in-
house assay enzymes 
    Basic Kit enzymes In-house assay enzymes   
 AN neg. neg. pos. neg. neg. neg. neg. pos. neg. neg. neg. 
albicans - - - + - - - +/- + - - - 
yeast/fungi - + + + + + +/- + + + + + 
 
d: In-house NASBA: one series with enzyme mix (kit), one series with in-house assay enzymes 
    Basic Kit enzymes In-house assay enzymes   
 AN neg. neg. pos. neg. neg. neg. neg. pos. neg. neg. 
albicans - - - + - - - - + - - 
yeast/fungi - - - + - - +/- +/- + - +/- 
 
AN: assay negative (probe + detection diluent) 
neg.: negative control (no template added to NASBA) 
pos.: positive control (0.70 fg C. albicans RNA) 
albicans: probe for detection of C. albicans; C. tropicalis; C. parapsilosis; C. viswanathii and C. guilliermondii 
yeast/fungi: universal probe for detection of yeasts and fungi 
+: positive after ECL detection 
-: negative after ECL detection 
+/-: increased, but not positive, signal after ECL detection 
 
 
To further examine the source of the contaminating RNA, all available probes were used to 
hybridize with amplification products obtained with the Basic Kit amplification module (Table 
3). Amplification products were diluted 1:20 before hybridization with the albicans, glabrata, 
lusitaniae, and krusei probes, and a 1:200 dilution was used when amplicons were hybridized 
with the tropicalis or the yeast/fungi probe. It is obvious that although some problems occur 
when the albicans or the tropicalis probe are used, numerous false positive results are obtained 
when the yeast/fungi probe is used. Therefore, the source of the contaminating RNA remains 
unclear. 
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Table 3 
NASBA with the Basic Kit amplification module 
 AN neg. neg. neg. neg. pos. neg. neg. neg. neg. 
glabrata - - - - - - - - - - 
lusitaniae - - - - - - - - - - 
krusei - - - - - - - - - - 
tropicalis - - - - +/- - - - - + 
albicans - + - - - + - - - - 
yeast/fungi - + + + + + + - + + 
AN: assay negative (probe + detection diluent) 
neg.: negative control (no template added to NASBA) 
pos.: positive control (0.70 fg C. albicans RNA) 
glabrata: probe for detection of C. glabrata 
lusitaniae: probe for detection of C. lusitaniae 
krusei: probe for detection of C. krusei 
tropicalis: probe for detection of C. tropicalis (cross-hybridizes with Kluyveromyces marxianus, K. lactis, 
Saccharomyces cerevisiae) 
albicans: probe for detection of C. albicans; C. tropicalis; C. parapsilosis; C. viswanathii and C. guilliermondii 
yeast/fungi: universal probe for detection of yeasts and fungi 
+: positive after ECL detection 
-: negative after ECL detection 
+/-: increased, but not positive, signal after ECL detection 
 
 
In conclusion: components of the Basic Kit amplification module are contaminated with 
fungal RNA. The water from the kit, NASBA-water, is part of the problem, but some other 
components are contaminated as well. The enzymes of the kit, however, are free of 
contaminations, and even cleaner than the in-house enzyme mix that was used in our 
laboratory. It was decided to continue the use of the in-house NASBA assay, but the enzyme 
mix was replaced by Basic Kit enzymes.  
 Because of the complicated production process of the reagent spheres, these spheres may 
very well be a source of contaminations. It is our experience, that companies apply the concept 
that a room or manufacturing hall is 'clean', unless it is used by people working with nucleic 
acids. However, microorganisms, cells and nucleic acids are everywhere. Therefore, it is 
advised to consider a room contaminated, and limit work to small areas that can easily be 
cleaned. Furthermore, all reagents (including water) have to be free of contaminating nucleic 
acids.  
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Since the first publication in 1985 on primer-mediated enzymatic amplification of DNA 
sequences, better known as the Polymerase Chain Reaction (PCR), the number of papers 
describing the use of this technique has increased exponentially until 1999, and seems to have 
reached a more or less stable level of about 15.000 papers each year (PubMed bibliographic 
database search on 'polymerase chain reaction')65. Within a few years, other nucleic acid 
amplification methods were developed, e.g. Nucleic Acid Sequence-Based Amplification 
(NASBA)13, Ligation Chain Reaction (LCR)84, and Transcription-Mediated Amplification 
(TMA)35. 
 Very soon after the introduction of the PCR, people realized that the advantage of this 
nucleic acid amplification assay, its great sensitivity, is also its drawback: even the smallest 
amount of contaminating DNA can be amplified. In 1988, Lo et al. reported the first false-
positive results: PCR primers directed against hepatitis B virus (HBV) were contaminated with 
plasmid DNA containing a full length HBV insert39. This observation resulted in numerous 
reports on how to recognize and avoid false-positive results caused by contaminations, and 
how to eliminate contaminating DNA. Most of these papers were published between 1990 and 
1993. Does this mean that we have tackled this problem? Unfortunately: no. Of all papers on 
PCR, the percentage of papers dealing with contaminations or false-positive results has been 
about 2% over the years, and is not declining. Also, despite the great sensitivity and speed of 
the amplification methods, they are still not generally used as standard methods in routine 
laboratories.  
 In this review, we would like to focus on the implications of contaminations in diagnosis 
and research on infectious diseases. Although most researchers using nucleic acid 
amplification methods will be familiar with carry-over contaminations, where DNA fragments 
from previous experiments are re-amplified, other sources of contamination can be very 
unexpected. Furthermore, we will review literature on different methods for prevention and 
destruction of contaminating DNA. We will discuss the functionality and draw-backs of these 
methods, and give recommendations on how to improve laboratory practice. 
 
 
FALSE-POSITIVE RESULTS AND CONTAMINATIONS 
 
False-positive results of nucleic acid amplification assays can have several causes, 
including contaminations. Because terms like 'false-positive' and 'contamination' will be used 
frequently in this review, it is necessary to emphasize our interpretation of these words. 
False-positive results caused by a 'true contaminant'. This type of contamination will 
generally affect every sample in the assay. It occurs when unwanted target DNA is introduced 
in the assay through e.g. reagents, laboratory disposables, equipment, or the environment 
(including carry-over contaminations between tests).  
False-positive results caused by a 'sample contaminant'. This type of contamination will 
generally only affect a limited number of samples in an assay. It occurs when unwanted target 
DNA is introduced in certain samples due to e.g. sample to sample contamination, or leakage 
between samples on agarose gels.  
Other false-positive results. False-positive results that are not caused by the presence of 
target DNA, but e.g. by nonspecific products due to sub-optimal assay conditions.  
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 In conclusion: a contamination will always lead to a false-positive result, but a false-
positive result is not always caused by a contamination.   
 
 
FALSE-POSITIVE RESULTS AND THEIR IMPLICATIONS 
 
False-positive results can have considerable implications, both in research as well as in the 
clinic. The following examples show, that amplification assays are not always as reliable as is 
sometimes believed.  
In search of causes of infectious diseases, PCR has been used as a tool to demonstrate an 
association between infectious disease and the presence of microbial DNA. Boyd et al. used 
PCR and in situ hybridization to study the involvement of human papilloma virus (HPV) in 
cutaneous lichen planus9. Initial results on archival paraffin-embedded biopsy material were 
encouraging. However, more in-depth evaluation revealed nucleic acid contamination, 
probably due to sample contamination from HPV-positive material or adjacent wells, and a 
correlation between cutaneous lichen planus and HPV could not be verified.  
 A case where a false-positive result almost led to the assumption that an HIV-1 vaccine-
induced immune response led to an abortive infection with abrogation of seroreactivity (a very 
tempting theory) was described by Schwartz et al.72. A plasma-sample of an HIV-1 
seronegative patient who had participated in an HIV-1 vaccine trial tested positive in an RT-
PCR assay. Although this result was not confirmed by other assays, retrospective analysis of 
serum RNA samples obtained from earlier occasions in the vaccine trial showed a cluster of 
positive results over a limited period, convincing some investigators of the validity of the 
original positive result and leading to the hypothesis mentioned above. Eventually, all 
previously reactive samples were retested by RT-PCR in a quality-controlled laboratory. All 
samples were now negative for HIV-1 RNA, including the cluster that had previously been 
reported as positive and the original positive plasma sample. It is not clear what caused the 
false-positive results in the first RT-PCR assays.  
 A number of papers report cases where contaminations had far-reaching consequences for 
the patients involved. In one case, PCR analyses of pleural fluid of a patient diagnosed with 
chronic lymphocytic leukemia (CLL) were positive for Mycobacterium tuberculosis on two 
different occasions. Therefore, antituberculosis therapy was commenced, while treatment for 
CLL was postponed. Staining and cultures for M. tuberculosis were negative. After 9 months, 
PCR for M. tuberculosis was still positive even though there was no evidence of tuberculosis 
with standard diagnostic tests. Antituberculous treatment was discontinued and high-dose 
chemotherapy was begun. Active tuberculosis was never ascertained, and the postponement of 
chemotherapy was apparently based on false-positive results. Again, the source of this 
contamination is not clarified76.  
 One well-known case of false-positive results in diagnostic tests even led to the patient's 
death53. A 30-year old woman was diagnosed with chronic Lyme disease based on one PCR 
assay of blood positive for Borrelia burgdorferi. MRI of the brain and CSF examination were 
unremarkable, and several EIAs, Western blot assays, and PCR assays on blood, urine and 
CSF were negative or indeterminate. A Groshong catheter was placed and the patient was 
treated with intravenous antibiotic drugs for 27 months. This therapy was discontinued when 
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an impaired liver function and thrombocytopenia were observed. EIAs, Western blot- and PCR 
assays performed in another hospital were all negative for B. burgdorferi. One month later the 
patient died as a result of a large Candida parapsilosis septic thrombus located on the tip of 
the catheter, obstructing the tricuspid valve. At autopsy, there were no indications of Lyme 
disease. The one positive PCR assay on which the whole therapy was based, was probably the 
result of a DNA contamination. Interestingly, the laboratory that reported this false-positive 
result reported another positive B. burgdorferi PCR result which proved to be false-positive as 
well. Luckily, in this case the patient was referred for a second opinion, and did not receive 
unnecessary therapy47.  
 Quality control studies. In none of the cases described above, a cause of the false-positive 
results is identified. It is striking that in many cases the results of the amplification assays 
differ between laboratories47,53, sometimes even when the same samples are used72. Because 
false-positive results can have very unfortunate effects on research and especially in the clinic, 
extensive quality control of amplification tests is essential. This quality control should be 
executed continuously by the technicians or researchers themselves, but also at regular 
intervals by an independent organization. Surprisingly, only a limited number of such 
independent, multi-center studies have been published, and the results were generally 
alarming.  
 Four examples of multi-center quality control studies (PCRs on hepatitis B-, C and G virus, 
GB virus C, and Mycobacterium tuberculosis) show a false-positive rate of 9% up to 
57%5,49,60,86. Interestingly, in all cases there was no association between good results and the 
methods used for nucleic acid extraction, the primers used in the amplification, the use of 
nested PCR, detection by Southern blot analysis with or without radioactive probes, or the use 
of standardized commercially available kits. This indicates that the way in which the technique 
is handled is more critical than the assay itself. Besides continuing with and increasing the 
number of multi-center quality control studies, more attention should be paid to the in-house 
aspects of quality control, before amplification assays can be used reliably in the diagnosis of 
infectious diseases. 
 Comparisons with other test methods. The examples describing the implications of false-
positive results have one remarkable similarity: in all cases there were results of several other 
(non-amplification) tests contradicting the (false-) positive results on which the theory or 
diagnosis was based. From these examples, and from the results of quality control studies as 
described above, clinicians should be aware that interpretation of PCR test results should be 
done with great care. In some cases, even though the amplification assay is truly positive, the 
result may not be of clinical significance: the sensitivity of nucleic acid amplification assays 
may lead to detection of microorganisms in patients that have no clinical consequences, and 
DNA derived from dead or degrading microorganisms may yield positive results. And of 
course, there is always a chance of false-positive results caused by contaminating DNA. 
Therefore, PCR results should always be validated by comparing them with conventional 
diagnostic methods as well as clinical data.  
 Several people reported situations where extensive retesting was performed because clinical 
findings and results of standard diagnostic methods did not agree with PCR results37,47,72,74. It 
is needless to say that besides the discomforting uncertainty for patients and clinicians, this 
results in a considerable increase in costs. Therefore, all possible efforts should be made to 
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improve the reliability of amplification assays.  
 Although we unequivocally recommend to compare PCR results with other available data, 
we would like to make one comment. As was observed by Jehuda-Cohen for HIV-1, it is 
sometimes claimed that all positive PCR results that are not matched by positive ELISA 
serology are false-positive30. However, although the 'golden standard' is always the best 
diagnostic method that is available, that does not mean there is no room for improvement. For 
example, blood culture is considered the golden standard for the detection of disseminated 
yeast infections. However, in many cases automated blood cultures fail to detect yeasts (up to 
65%)44. We have shown by using NASBA that we were able to improve the detection rate of 
yeasts in blood cultures6. It is therefore possible that a positive amplification result which is 
not confirmed by other tests, is in fact of clinical significance. In summary: regard all available 
test results and clinical data, but also be aware of the limitations of the tests that are used.  
 
 
PREVENTION: REDUCTION OF RISK FACTORS 
 
The prevention of false-positive results in nucleic acid amplification assays can be divided 
into two parts. First: the risks of contamination should be kept as low as possible. Second: if 
contamination occurs, it should be destroyed. Several factors form a risk of causing false-
positive results, some of which may be very unexpected. Below, we describe some of these 
risk factors and methods for risk reduction. In the next chapter, we will focus on the 
destruction of contaminating DNA.  
 Risk factors. (i): Reagents. It is known that some reagents may be contaminated with 
DNA. For many applications involving yeasts or fungi, a pretreatment protocol is necessary to 
lyse the cells before DNA extraction. In most cases, lyticase, lysing enzymes and/or zymolyase 
are used. Rimek et al. have found that different batches of Zymolyase-20T from two different 
companies contained fungal DNA62. The fragment that was amplified in the negative controls 
of their panfungal PCR assay showed 100% sequence identity to the Saccharomyces sensu 
stricto complex (S. cerevisiae, S. pastorianus, S. paradoxus and S. bayanus) and to 
Kluyveromyces lodderae. The same contamination was described by Loeffler et al.40. They 
found fungal DNA in specific lot numbers of zymolyase powder, but also in batches of lyticase 
and lysing enzymes. The zymolyase appeared to be contaminated with DNA from S. 
cerevisiae. The origin of the DNA found in lyticase and lysing enzymes could not be specified.  
 Several components of PCR mixtures have also been shown to contain contaminating 
DNA. Different tubes of one lot number of 10x PCR buffer were contaminated with DNA 
from Acremonium spp.40. Furthermore, commercial primer preparations used by Goldenberger 
and Altwegg were the source of contaminations in an assay using broad range primers directed 
against 16S rDNA24. The origin of this contamination was not further specified. Another 
example of contaminated primers was reported by Lo et al.39. Their primers were contaminated 
by plasmid containing a full length HBV insert. Although it is not mentioned, it is most likely 
that this contamination originated from their own laboratory, as opposed to the other examples 
which can all be traced back to the manufacturers.  
 Contamination of Taq DNA polymerase with bacterial DNA has been reported several 
times8,16,28,43,61,71. All researchers have used several polymerases from different suppliers, often 
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including low-DNA Taq DNA polymerase, and although quantitative differences between the 
products from different companies are observed, all preparations yielded false-positive results. 
In three of the studies, universal primer systems directed against rDNA sequences were used. It 
is, however, important to note that false-positive results were also obtained when more specific 
primer systems were used (16S rDNA sequences of mycobacteria28, 5S rDNA sequences of 
Legionella43, rDNA sequences of Escherichia coli 61). When an attempt was made to specify 
the identity of the contaminating DNA, all authors agreed that the bacteria in which the Taq 
polymerase is produced (E. coli and Thermus aquaticus) can be ruled out as a source. 
However, the exact identity could not be revealed. It is generally believed that more than one 
strain or species is responsible for the occurrence of false-positive results when using Taq 
DNA polymerases, which is most likely the main reason why identification is difficult. Even 
though it is not unequivocally proven, all findings point to the involvement of either the 
buffers, the chromatography columns, or the water used in the purification of the enzyme. 
Thus, it is likely that other biological products are also contaminated, and indeed the 
purification is also assumed to be the source of the contamination in some primer 
preparations24.  
 (ii): Laboratory disposables and equipment. Besides the reagents, laboratory disposables 
and equipment can also be the source of contaminating DNA. An obvious example is the need 
to disinfect the rubber septum of evacuated sample tubes or blood culture bottles before 
drawing blood. Besides leading to false-positive cultures, this can also cause problems when 
blood is used for diagnostic amplification methods27.  
 Another problem can occur when people disregard the fact that 'sterile' does not necessarily 
mean 'DNA-free'. In a study performed by Kaul et al., it was shown that 3.6% of sterilized 
bronchoscopes used for broncho-alveolar lavages (BAL) contained amplifiable Mycobacterium 
tuberculosis DNA32. When looking at 277 M. tuberculosis PCR results in retrospect 
(validation- and clinical samples), 5 false-positive samples were detected, 4 of which were 
BAL samples.  
 Even the single use plasticware, that has taken over the washable glassware in our 
laboratories, is not always free of contaminating DNA. For example, according to Schmidt et 
al. reaction tubes show contamination rates of 20% up to 80-90%, depending on the supplier70. 
The vast majority of these contaminations is of human origin, although in one case the sample 
did not show any similarity with a human reference sequence.  
 (iii): Environment. Microorganisms and their DNA are present everywhere around us. For 
example, fungal spores like conidia from Aspergillus spp. can be present in the air. This can 
lead to false-positive results due to airborne spore inoculation during DNA extraction, as was 
detected by Loeffler et al.40. However, the following examples show that it is also very 
important to be aware of all activities that takes place in your laboratory, and even in your 
building. Situations that are routine for one person, can turn out to be an unexpected and huge 
problem for the other.  
Porter-Jordan and Garrett found false-positives when using a PCR for human cytomegalovirus 
(CMV)58. Upon further examination, they realized that this contamination could originate from 
a laboratory situated one floor below theirs, where CMV culture material was autoclaved 
before disposal. It turned out that autoclaved positive material included small DNA fragments 
contaminating the environment, which may have produced positive signals in their PCR 
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assays.  
 A second example was described by Taranger et al.74. They found a discrepancy of 57% 
between PCR (91% positive) and culture results (34% positive) for Bordetella pertussis in one 
pediatric outpatient clinic, while in another clinic no PCR-positive and culture-negative 
samples were seen. All tested surfaces in the two rooms where vaccinations and diagnostic 
work-ups were done (e.g. laboratory benches, steel tables for equipment, the staff's clothes and 
the skin of the hands of the staff), were contaminated with B. pertussis positive material. 
However, even though the same environmental findings were made in the vaccination room of 
the second clinic, in this clinic vaccinations were given in rooms located far away from the 
examination rooms where patient samples were taken for diagnostic purposes. This 
environmental contamination was caused by droplets from a whole cell pertussis vaccine.  
In our own laboratory we recently encountered a problem with contamination of a 
diagnostic test in which PCR is used to detect TEM ß-lactamases in clinical isolates 
(unpublished observations). At a certain time, all negative controls started to become false-
positive, and this problem could not be resolved by extensive cleaning of the working areas 
and the use of new reagents. A research group sharing the same laboratory areas used cloning- 
and expression systems for the production of proteins. It became clear that the vector applied 
in their cloning- and expression systems contains a commonly used ampicillin-resistance 
selection marker, which is a TEM ß-lactamase-gene. Since the focus of this research was to 
study proteins, this work was done in a regular laboratory room. Therefore, the researchers 
were not restricted in entering areas where PCR-premixes were prepared, and often, after 
purification and analysis of expressed proteins, non-related PCRs were performed. No one 
realized that the protein preparations were highly contaminated with vector-associated DNA, 
resulting in high copy TEM ß-lactamase-gene contamination of the environment.  
 Risk reduction. (i): Communication. From these examples we can conclude that 
communication is very important, especially in larger laboratories where several research 
groups make use of the same rooms and equipment. Even non-molecular biologists may be 
working with large amounts of DNA (culturing, plasmids, etc.), and form an unexpected risk 
of contaminations. The same holds true for researchers using species-specific amplification 
assays: these tests may not be very sensitive for contaminations, other tests performed in the 
same area may be. All researchers using the same laboratory space and equipment should 
conduct themselves to the precautions necessary for the assay that is most sensitive to 
contaminations, without any exceptions.  
 The difficulty with contaminated reagents is that it is impossible for a laboratory to prevent 
such contaminations. It is therefore very important to communicate such problems with the 
manufacturer. In our experience, companies are not always aware of the very diverse range of 
sources that can cause contamination of their products. It is often believed that a room (or 
manufacturing hall) is 'clean', unless it is used by people working with DNA. However, 
microorganisms, cells and DNA are everywhere. Even though this will be difficult to 
implement in a production process, it may be sensible for companies to apply the concept that 
a room is 'dirty', except for small areas that can easily be cleaned.  
 (ii): Separation of workflow. The amount of contaminating DNA/RNA varies: in general, 
during sample preparation only low amounts of nucleic acids are generated (so called 'low 
copy', corresponding with low risk), whereas handling of recombinant plasmids or phages and 
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amplification techniques reveal high amounts of DNA (so called 'high copy', corresponding 
with high risk). Therefore, attention must be paid to the work-flow. Laboratories should be 
subdivided in 'no copy', 'low copy' and 'high copy' working areas, if possible equipped with 
overpressure (no copy, i.e. clean areas) or underpressure (high copy, i.e. contaminated areas). 
These working areas can comprise separate rooms, biosafety hoods or for this purpose 
designed cabinets26,36,54. Also, flowcabinets can be used in which the direction of flow ensures 
that aerosols are pushed down to the base of the cabinet, away from the top of the reaction 
tubes51. Activities in which no DNA is involved (preparation of PCR-mixes) should be 
performed first, after which activities can be build up via low copy (extraction of low copy 
nucleic acids, adding template to premixes) to high copy operations (analysis of amplification-
products or other sources of high copy DNA). Subsequently, the no- and low copy work area 
should not be entered again that particular day. Furthermore, it is recommended to aliquot 
reagents in an area that is free of nucleic acids, and to use different freezers and refrigerators 
for storage of reagents and samples. 
Providing every work area with separate sets of supplies and equipment like racks, pipettes, 
test tube holders, centrifuges, etc. substantially reduces the risk of carry-over contamination. 
Appropriate disposable clothing should be present in each room, and these should be changed 
frequently (e.g. gloves, masks, coats, mob caps, goggles)34,36,79. Additionally, it is 
recommended to clean the working areas, equipment, and literally everything which is 
routinely touched by hands like doorknobs, handles of freezers, telephones etc. on a regular 
base. Sodium hypochlorite and HCl are mentioned as cleaning agents for work areas and 
equipment. Prince et al. recommend a concentration of 0.08% sodium hypochlorite (w/v, 5 
min) for fragments as small as 76 bp59. This concentration should be stable for 1 week. 
However, our own observations revealed that a 0.4% (w/v) hypochlorite solution of 1 week old 
needs an incubation time of 30 minutes before an RNA target of 200 bases is not detectable by 
NASBA anymore. Better results were obtained after a 5 minute incubation with a daily 
prepared 0.4% (w/v) solution (unpublished data).  
Results for decontamination by depurination with 1 M HCl15,36,59, possibly in combination 
with detergent to reduce surface tension and/or UV treatment70, are controversial. Schmidt et 
al. described that long-term treatment (2.5 h) with HCl did not yield complete destruction70 
and even 2 M HCl did not completely destroy DNA detectable by PCR59. UV irradiation of 
surfaces like laboratory benches, floors, instruments, microcentrifuge tubes and racks is 
recommended, but it is much less effective in eliminating dried DNA. Destruction of 
contaminating DNA by UV-irradiation is described in more detail below. Cleaning agents, like 
HNO3, ethanol, and commercial cleaners as Extran (cleaner for laboratory use) are not 
effective70. 
Furthermore, it is advised to monitor DNA contamination by routine wipe tests as described 
by Cone et al.15. However, the wipe test can be false negative due to inhibitory substances 
originating from laboratory surfaces, so routinely test a duplicate of each wipe test sample with 
an amplification positive control45. 
 (iii): Prevention of aerosol formation. To prevent contamination by aerosols containing 
nucleic acids, the use of positive displacement pipettes26,36 or disposable filtertips/plugged 
pipette tips26,46,55 is advised. However, differences in the quality of filtertips from different 
suppliers is observed55 (personal observation). To avoid aerosols, reaction tubes should be 
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opened with caution26,36. Furthermore, it is advisable to use the minimum number of cycles 
during amplification reactions, to produce only as much amplicon as is needed to obtain the 
desired results.  
 Another approach to reduce the risk of contaminations, is to carefully handle waste disposal 
in order to prevent aerosol formation. Disposables which contain RNA/DNA, like pipette tips 
and reaction tubes, but also electrophoresis buffer, are important potential sources of 
contaminations. It is recommended to collect nucleic acid contaminated plastic ware in 
disposable bags and to close the bags directly after activities are finished. Electrophoresis 
buffer can be decontaminated with sodiumchlorite directly after use (see above).  
 
 
PREVENTION: DESTRUCTION OF CONTAMINATING DNA 
 
Prevention of DNA contamination is part of the job, but if contamination occurs, one has to 
try to eliminate this problem. In course of time a lot of suggestions have been published. The 
conditions for using a protocol should be established and evaluated for each target system. In 
general, destruction of contaminating DNA can be performed before amplification, to avoid 
false-positive results in the experiment that is performed, and/or after amplification, to reduce 
the risk of contaminating following experiments.  
In this chapter we will focus on different methods for destruction of contaminating DNA 
and their draw-backs. Procedures which achieve elimination of contaminating DNA in general 
are: irradiation with or without the addition of (iso)psoralen, enzymatic treatment, and the use 
of hydroxylamine hydrochloride. Two other methods specifically destroy amplification 
products: the use of modified primers and the Uracil DNA glycosylase-dUTP approach. In 
addition, we will pay attention to specific decontamination methods for reagents and 
disposables.  
Destruction of contaminating DNA. (i): UV-irradiation. UV-irradiation is mainly used to 
treat PCR premixes and to decontaminate work areas or equipment, and is extensively 
described. Both single wavelength (254, 300 or 365 nm) and double wavelength (254 nm and 
300 nm) treatments have been examined11,20,22,24,46,50,64,67-69. The mechanism is based on 
oxidation of bases, induction of single and double strand breaks, and formation of cyclobutane 
rings between neighboring pyrimidine bases. The cyclobutane rings form intrastrand 
pyrimidine dimers that inhibit polymerase mediated chain elongation7,25.  
UV-treatment is not always effective11,20,46,51,66. Its efficiency depends on the intensity, 
wavelength, and exposure-time20,51,64,67. In case of treatment of PCR premixes: the presence of 
nucleotides influences the elimination of contaminating DNA in a dose dependent manner51. 
Furthermore, size and internal sequence of the contaminating DNA fragment are 
important11,25,29,46,50,64,67-69. However, these findings are contradicted22,68,69.  
UV-irradiation may influence the activity of PCR reagents. Although nucleotides and 
primers are relatively resistant24, the activity of primers20,22,50 and undoubtedly of Taq 
polymerase11,24,46,50,69 and uracil N glycosylase24 is affected. It may be wise to add these 
components after UV-irradiation of the premixes. This illustrates an important drawback of 
this decontamination technique: after sterilization, cups have to be reopened to add reagents 
and template DNA, which enlarges the risk of contaminations. Besides, reagents like Taq 
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polymerase can contain contaminants themselves (as described above), which will remain 
unaffected. Furthermore, Niederhauser et al. showed that degraded amplification products and 
primer artifacts account for a decreased amplification sensitivity48. Another note of concern is 
that Linquist et al. reported that UV-irradiation of polystyrene pipettes releases PCR 
inhibitors38. 
UV-irradiation is also recommended for elimination of contaminating DNA/RNA from 
surfaces like laboratory benches, floors, instruments, microcentrifuge tubes and racks36,46, but 
it is much less effective in eliminating dried DNA66,68,69. Guidelines for eliminating dried DNA 
by UV-irradiation are clearly described by Cone et al.14. A point of consideration for 
eliminating dried DNA is that the surface must be perpendicular to the light source to achieve 
maximal light intensity. Additionally, other materials dried with the target DNA such as 
irrelevant DNA and nucleotides can shield the target, making inactivation less efficient. It is 
also important to note that UV lamps will still look blue even though their UV output has 
decreased.  
 In summary: the efficacy of this method has not been uniform. UV-irradiation should be 
seen as an additional precaution rather than a replacement for careful laboratory practice. 
Intensity, wavelength, duration of exposure and effects on the sensitivity of the PCR have to be 
determined empirically. 
(ii): UV-irradiation in combination with (iso)psoralen. Several publications describe the 
combination of (iso)psoralen and long wavelength UV photoactivation (320-400 nm) for 
sterilization of PCR amplicons12,29,29,31,33,46,54,64,79. (Iso)psoralens are known to intercalate 
between base pairs of nucleic acids. This results in the formation of cyclobutane adducts with 
pyrimidine bases and cross-links when excited by 320-400 nm light12,31, which inhibit the 
extension by polymerases56,57,73. In general, (iso)psoralens are added prior to amplification 
while photoactivation by UV takes place after amplification.  
Isopsoralen modified PCR-products can be probed by hybridization and are therefore 
favored above psoralen12,29. However, lower hybridization stringencies may be required to 
compensate for the presence of isopsoralen in the amplified DNA12,29,54 and a significant loss 
of sensitivity is observed at high concentrations64. This loss of sensitivity can be corrected by 
adding glycerol or DMSO12,29,64. Isopsoralen inactivation of contaminating DNA depends on 
the length and nucleotide base composition of the amplicon54.  
In summary: (iso)psoralen treatment in combination with long wavelength UV irradiation is 
an effective method for sterilizing PCR amplicons. Since each amplicon has its own base 
sequence and length, optimal sterilization conditions must be evaluated on a test by test basis. 
Note that (iso)psoralen must be handled with care due to their mutagenic properties. 
(iii): γ-Irradiation. Inactivation of DNA templates by γ-irradiation is described by Deragon 
et al.18. The efficiency depends on several factors including the length of the DNA fragment 
and the precise composition of the PCR mixture. Irradiation conditions (like dose) have to be 
established for each amplification system. Unfortunately, laboratories routinely have no γ 
sources available.  
(iv): Enzymatic treatment. Several kinds of enzymes have been described for sterilizing 
PCR-reagent mixtures like DNase I, exonuclease III, and restriction enzymes10,17,23,63,82,83,87. 
DNA is degraded whereas other components like the Taq polymerase remain unaffected. After 
inactivation of the nucleases by heating, target DNA must be added. This implies that cups 
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have to be reopened, which enlarges the risk of environmental contaminations. Another 
disadvantage is that an enzyme combination is used (Taq polymerase and a nuclease). 
Therefore, reaction conditions have to be optimal for both enzymes used.  
(v): Hydroxylamine hydrochloride treatment. Aslanzadeh describes the use of 
hydroxylamine hydrochloride as an effective alternative for the destruction of amplicons after 
amplification1. Hydroxylamine is a mutagenic agent, which disrupts normal nucleic acid 
pairing. Hydroxylamine hydrochloride modified PCR-products do not appear to bind to and 
modify other PCR reagents such as Taq polymerase.  
Destruction of amplification products. (i): Primer modification. A PCR sterilization 
method which only affects amplification products is the use of primers containing a 3'-terminal 
ribose residue. Taq DNA polymerase is able to both extend and copy a single ribose residue 
efficiently, which generates a cleavable ribonucleotide linkage within the amplified product81. 
Cleavage can be established either by RNase A treatment (prior amplification) or NaOH 
treatment (after amplification). In case of RNase treatment, addition of a sulfhydryl reducing 
agent and thermal denaturation is necessary to inactivate the enzyme, which do not affect the 
activity of Taq DNA polymerase. Efficiency of treatment with NaOH varies, depending on the 
number and position of the 3' ribose residues64. Also, cups have to be opened after 
amplification to add the base, risking the possibility of aerosol formation. Amplicons 
generated with 3'-ribose primers can be used for sequencing, cloning, and all other research 
applications of PCR-products. 
(ii): Uracil DNA glycosylase. The use of the uracil DNA glycosylase (UDG) or uracil N 
glycosylase (UNG)-dUTP approach is another method to combat carry-over contamination of 
amplification products. The method is introduced by Longo et al.41 and nowadays commercial 
diagnostic tests which use this system are available26. UDG removes the uracil residues from 
the sugar moiety of either single- or double stranded DNA, creating abasic sites in the 
phosphodiester backbone41. This method involves substituting dUTP for dTTP in all PCRs to 
ensure that all DNA arising from these amplifications will contain dUTP. Since UDG does not 
function on dT-containing DNA, dUTP, UTP or RNA, amplification of natural target RNA or 
DNA is not affected. If all amplification products contain dUTP, contamination can be 
eliminated prior amplification without reopening of cups to add polymerase or template. 
However, fidelity of incorporation of dUTP in place of dTTP is not known for all polymerases. 
In some cases, PCR does not proceed with quite the same efficiency when dTTP is completely 
replaced with dUTP41. This inefficiency appears to be sequence specific and is not necessarily 
related to the length of the fragment to be amplified26. Poor reaction efficiency is probably due 
to lower incorporation efficiency of dUTP by Taq polymerase or to changes in primer 
annealing on dUTP substituted templates. Higher concentrations of dUTP with compensating 
magnesium concentrations can increase product yields26,41,52,54.  
Although there is no significant activity during typical PCR thermal cycling75, UNG is not 
completely inactivated at the elevated temperatures in the amplification procedure. So 
following thermal cycling, prolonged incubation at either 4 or 25°C increases the risk of 
degradation. Therefore it is recommended to set soak files at 72°C to protect amplified dUTP 
containing products, or to use UDG inhibitor protein75. According to others, dUTP sites are 
heat labile and break during temperature cycling26. 
DNA containing dUTP is normal in most respects (e.g., it is cut by many restriction 
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enzymes and hybridizes to oligonucleotide probes)4, although Bebee et al. found that 
restriction endonuclease cleavage is dependent on the specific endonuclease used as well as the 
sequences flanking the endonuclease recognition site3. For cloning, amplification products 
must be introduced into an UDG-deficient E. coli host to avoid destruction of the amplified 
DNA. Last but not least: high degrees of contamination can not be destroyed completely by 
this system, which results in false-positive signals52. 
Effectiveness and combinations. A comparison of three different methods for elimination 
of amplification products (pre-PCR treatment of a dU-containing PCR product with UNG, post 
PCR UV-irradiation in combination with isopsoralen, and post-PCR alkaline primer 
hydrolysis) showed that all three methods are effective and were able to eliminate up to 109 
copies of the product64. Also, the combination of different protocols like treatment with UV 
(amplification reactions excluding polymerase, primers, and template) followed by DNase I 
treatment of polymerase and primers, appear to be practicable63. Methods which sterilize the 
whole PCR-mixture directly before amplification starts are preferable, because reopening of 
cups enlarges the risk of cross-contamination. For this, Udaykumar et al. have introduced the 
use of a wax-barrier77. 
 Decontamination of reagents and disposables.  Methods which have been described to 
eliminate contaminating DNA from buffers, primers, and disposables are ultrafiltration 70,80 
and autoclaving under conditions that provide bacterial decontamination36,46. However, 
effectiveness is controversial20,70. Several preparative methods have been described to 
eliminate contaminating DNA from the Taq polymerase as anion exchange chromatography19, 
polyethyleneimine precipitation followed by centrifugation and dialysis21, and an 
aqueous/organic biphasic system42. 
 
 
CONTROLS 
 
In the end it is worthwhile to check whether precautions and sterilizing protocols have 
functioned. Therefore, it is recommended to run negative sample- and assay controls with 
every test. Negative sample controls should be similar to the tested samples, but should not 
contain any target DNA. For example, blood from healthy individuals or culture medium can 
be used. These control samples should be subjected to all preparation steps in parallel with the 
extracted samples. Assay-controls should consist of all PCR components except template 
DNA. Negative controls should be added for every batch of 10 samples analyzed79. It is 
desirable to place one negative control at the beginning of a series of samples (to check 
whether the sample itself, the reagents, and the environment are free of contaminations), and 
other negative controls in-between and at the end of a series of samples (to check whether 
cross-contamination between samples has occurred). However, although the presence of 
contaminated reagents or gross contaminations of the environment should be observed by 
using these controls, sporadic contaminations can occur and will be more difficult to 
recognize.  
 When there is a suspicion of the environment being contaminated, negative controls 
prepared in the different laboratory spaces can be used. These controls are similar to sample- 
or assay controls, but differ with respect to the preparation area. At least one control should be 
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prepared in each area used for the assay: sample controls where DNA is extracted, assay 
controls in the areas where premixes are made (no-copy area) and where DNA is added to the 
premixes (low-copy area)78. If the contaminated room or area is located, wipe tests can be used 
to check whether the source can be localized to specific benches or other surfaces, equipment, 
or even labcoats15.  
It is recommended to record the lot numbers of reagents used so that if contamination 
occurs, it can more easily be traced. A possible way to check the reagents for the presence of 
contaminating DNA is to prepare PCR mixes lacking individual components, and to treat these 
mixes with UV-light. After UV-treatment, the lacking component is added, and a PCR 
performed. If a product is formed, the component which was not exposed to UV-light is 
contaminated. Since Taq DNA polymerase is sensitive to treatment with UV-light (see above), 
it may be wise to add this enzyme only after the UV-treatment, together with the other missing 
component24.  
The enzymes used for cell-lysis can be examined by dissolving them in (clean) water, 
followed by heat-inactivation at 95°C, DNA extraction and concentration by standard methods, 
and amplification62. Obviously, using a DNA extraction- and amplification assay to look for 
contaminating DNA is risky: besides the risk of introducing contaminating DNA from yet 
another source, it is possible that the contaminant remains undetected because the amount of 
contaminating DNA in the sample is too low, or some of it is lost during sample preparation.  
 To prevent recurrence of the same problem, it is often important to not only localize but 
also identify the source of the contamination. At this point, it is wise to check with other 
researchers using the same or neighboring laboratory spaces which microorganisms, plasmids 
or DNA sequences are used. If plasmids containing target DNA are commonly used, an 
amplification with primers that span the vector-insert junction can help identifying the plasmid 
as the source of the contamination39. Otherwise, sequencing of the PCR product, if necessary 
preceded by cloning into a vector, followed by sequence similarity searches in sequence data 
banks may be essential. 
 Contamination or? Besides contaminating DNA, positive results of negative controls may 
also be caused by sub-optimal assay-conditions. Sub-optimal PCR assays may lead to 
nonspecific bands after gel analysis. Optimizing the annealing temperature may help avoiding 
this problem. However, instead of using gel analysis, based only on the size of the product 
obtained, it is advised to use a more specific detection assay using template-specific probes 
(e.g. Southern- or Northern blotting) when possible, to circumvent problems with nonspecific 
products. In some cases, a simple RFLP analysis will be sufficient to distinguish false-positive 
results from targets. More complex techniques like SSCP or sequencing may also be 
helpful28,61,85. However, this will only work when nonspecific products are formed, or when 
the primers recognize more species or strains than anticipated. In case of carry-over 
contaminations, these methods will not be of any help. 
Another problem occurring during gel analysis is 'leaking': when a slot contains a large 
amount of target DNA, this may leak into neighboring slots in the gel and cause a false-
positive result in an adjacent lane. Obviously, in this case blotting of the gel and hybridizing 
with a specific probe will still lead to a false-positive result. When high amounts of PCR 
product are expected, it is best to skip lanes between samples9.  
 When equipment is re-used, the cleaning method may not always be sufficient. In some 
False-positive results and contaminations 
 74
cases additional testing may be necessary to distinguish false-positives from positives. Upon 
realizing that sterilized bronchoscopes were the source of contaminations, Kaul et al. started to 
request a sterile prewash of the bronchoscope for analysis along with the actual patient sample 
when BAL samples are submitted for PCR testing32.  
 Balfe described a statistical method which can be used to determine whether positive results 
of PCR reactions carried out in a microtiter plate are unlikely to have occurred by chance, and 
hence whether these results are false. A similar method for tube-based PCRs is also available. 
These methods are based on expected probability distributions2. 
 
 
CONCLUDING REMARK 
 
The most important conclusion is the fact that although most nucleic acid amplification 
assays are basically useful both in research as well as in the clinic, problems can occur when 
procedures for prevention of nucleic acid contaminations are insufficient. This review may be 
a guide to improve laboratory practice and reduce the number of false-positive results.  
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ABSTRACT 
 
 Non-C. albicans Candida species are isolated in increasing frequencies. These species show 
differences in resistance to antimycotic agents and virulence. Therefore, it is important to be 
able to correctly identify the causative organism to the species level. Phenotypic identification 
methods are not always reliable. Especially identification of C. dubliniensis remains 
problematic, due to the high degree of phenotypic similarity between this species and C. 
albicans. Molecular identification methods may be more reliable. The use of Amplified 
Fragment Length Polymorphism (AFLP) analysis as an identification method for medically 
important Candida species was investigated. Our results show very clear differences between 
medically important Candida species. Furthermore, when screening a large collection of 
clinical isolates previously identified on CHROMagar as C. albicans we found a 
misidentification rate of 6%. AFLP is universally applicable and the patterns can easily be 
stored in a general accessible database. Therefore, AFLP might prove to be a reliable method 
for the identification of medically important Candida species. 
 
 
INTRODUCTION 
 
In the past decade, life-threatening forms of candidiasis increased dramatically1. The 
attributable mortality of these infections is as high as 38%34, whereas crude mortality rates 
exceed 50%10,27,33. For a long time, Candida albicans was the main cause of invasive fungal 
infections. However, the number of infections by this species is declining, whereas non-
albicans Candida species like C. glabrata, C. krusei and C. parapsilosis are increasingly 
isolated. At present, non-albicans Candida species account for approximately 50% of all 
Candida infections14.  
In case of candidiasis, it is important to be able to correctly identify the causative organism 
to the species level. Different species show differences in resistance to antimycotic agents. C. 
krusei is innately resistant to fluconazole, and C. glabrata is able to acquire resistance to this 
drug rapidly. Furthermore, C. glabrata infections have been associated with a high mortality11. 
A particular problem is formed by the recently recognized species Candida dubliniensis. Like 
C. glabrata, this species is capable of acquiring stable fluconazole resistance rapidly22,23. 
Identification of C. dubliniensis remains difficult, due to the high degree of phenotypic 
similarity between this species and C. albicans. However, it is known that genotypically there 
is more variation between the species30. Therefore, molecular identification methods may be 
more reliable than methods based on phenotypic characteristics.  
Amplified Fragment Length Polymorphism (AFLP) analysis is a relatively new technique 
which discriminatory power makes it suitable for identification as well as strain typing29,32. In 
short: genomic DNA is digested with two restriction enzymes (e.g. EcoRI and MseI), and 
double-stranded oligonucleotide adapters are ligated to the fragments. These adapters serve as 
targets for the primers during PCR amplification. To increase the specificity, it is possible to 
elongate the primers at the 3' end with 1-3 selective nucleotides. One of the primers is labeled 
with a fluorescent dye. The fragments are separated and analyzed using software packages like 
BioNumerics (Applied Maths, Sint-Martens-Latem, Belgium). The advantage of AFLP is that 
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only a limited amount of DNA is needed, since the fragments are PCR-amplified. Furthermore, 
since stringent annealing temperatures are used during amplification, the technique is more 
reproducible and robust compared to other methods such as Randomly Amplified Polymorphic 
DNA analysis (RAPD)13,29. This paper describes the use of AFLP as an identification method 
for medically important Candida species, including C. dubliniensis.  
 
 
MATERIALS AND METHODS 
 
Yeast strains. The yeast strains and isolates used are listed in Table 1. Reference strains 
were obtained from the Centraalbureau voor Schimmelcultures (CBS), Utrecht, the 
Netherlands, and the American Type Culture Collection (ATCC), Manassas, USA. Clinical 
isolates were obtained from the European SENTRY collection (Eijkman-Winkler Center, 
Utrecht, the Netherlands)26 and from the Haematology ward of the VU University Medical 
Center (VUMC), Amsterdam, the Netherlands. The SENTRY isolates were identified using 
CHROMagar plates (CHROMagar, Paris, France). The isolates from the VUMC were 
identified using the Germ-tube test. Isolates that were negative in this assay were further 
identified using Vitek YBC (bioMérieux, Boxtel, the Netherlands).  
 
 
Table 1 
Reference strains and clinical isolates used in this study 
Spp.1 Strains/isolates Origin Source 
C. albicans CBS 562 
 
CBS 1905 
CBS 1912 
ATCC 90028 
ATCC 90029 
04A080 (SENTRY) 
06A309 (SENTRY) 
07C069 (SENTRY) 
08E058 (SENTRY) 
10A173 (SENTRY) 
10C007 (SENTRY) 
11A134 (SENTRY) 
11C034 (SENTRY) 
12E033 (SENTRY) 
15A020 (SENTRY) 
15A206 (SENTRY) 
15A561 (SENTRY) 
16A232 (SENTRY) 
16A438 (SENTRY) 
16C088 (SENTRY) 
17A381 (SENTRY) 
19A164 (SENTRY) 
19A519 (SENTRY) 
Uruguay 
 
unknown 
Norway 
Iowa, USA 
Iowa, USA 
Paris, France 
Lille, France 
Freiburg, Germany 
Dusseldorf, Germany 
Genoa, Italy 
Genoa, Italy 
Roma, Italy 
Roma, Italy 
Utrecht, the Netherlands 
Coimbra, Portugal 
Coimbra, Portugal 
Coimbra, Portugal 
Sevilla, Spain 
Sevilla, Spain 
Sevilla, Spain 
Madrid, Spain 
Lausanne, Switzerland 
Lausanne, Switzerland 
skin of man with interdigital 
   mycosis 
man 
sputum of asthma patient 
blood 
blood 
blood 
blood 
pneumonia 
wound/skin/soft tissue 
blood 
pneumonia 
blood 
pneumonia 
wound/skin/soft tissue 
blood 
blood 
blood 
blood 
blood 
pneumonia 
blood 
blood 
blood 
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C. albicans 
(contin.) 
19A567 (SENTRY) 
19A568 (SENTRY) 
23D045 (SENTRY) 
TY727 (VUMC) 
TY728 (VUMC) 
TY729 (VUMC) 
TY732 (VUMC) 
Lausanne, Switzerland  
Lausanne, Switzerland  
Ankara, Turkey  
Amsterdam, the Netherlands 
Amsterdam, the Netherlands 
Amsterdam, the Netherlands 
Amsterdam, the Netherlands 
blood  
blood  
urinary tract  
oral cavity  
oral cavity  
oral cavity  
faeces (human) 
C. dubliniensis CBS 7987 
 
CBS 7988 
 
CBS 8500 
 
 
CBS 8501 
 
02A038 (SENTRY) 
05C118 (SENTRY) 
05C121 (SENTRY) 
18A221 (SENTRY)  
20C149 (SENTRY) 
23A137 (SENTRY) 
Dublin, Ireland 
 
Melbourne, Australia 
 
Nijmegen, the Netherlands 
 
 
Nijmegen, the Netherlands 
 
Brussels, Belgium 
Lyon, France 
Lyon, France 
Barcelona, Spain 
London, UK 
Ankara, Turkey 
oral cavity of HIV-infected  
   patient 
oral cavity of HIV-infected  
   patient 
blood of 38-year-old woman  
   with chronic myelogenous  
   leukaemia 
child with neutropeny induced  
   by chemotherapy 
blood 
pneumonia 
pneumonia 
blood 
pneumonia 
blood 
C. glabrata CBS 138 
ATCC 90030 
TY714 (VUMC) 
TY715 (VUMC) 
TY716 (VUMC) 
TY717 (VUMC)  
TY718 (VUMC) 
TY719 (VUMC) 
TY731 (VUMC) 
unknown 
Iowa, USA 
Amsterdam, the Netherlands 
Amsterdam, the Netherlands 
Amsterdam, the Netherlands 
Amsterdam, the Netherlands 
Amsterdam, the Netherlands 
Amsterdam, the Netherlands 
Amsterdam, the Netherlands 
faeces (human) 
blood 
oral cavity 
faeces (human) 
oral cavity 
oral cavity 
oral cavity 
oral cavity 
oral cavity 
C. guilliermondii CBS 566 
CBS 2024 
14A097 (SENTRY) 
unknown 
Berlin, Germany 
Cracow, Poland 
sputum (human) 
ulcer on horse 
blood 
C. krusei CBS 573 
TY722 (VUMC) 
TY723 (VUMC) 
TY726 (VUMC) 
Colombo, Sri Lanka 
Amsterdam, the Netherlands 
Amsterdam, the Netherlands  
Amsterdam, the Netherlands 
sputum of bronchitic convict 
oral cavity 
oral cavity 
faeces (human) 
C. lusitaniae CBS 4413 Portugal caecum of pig 
C. parapsilosis CBS 604 
CBS 2195 
ATCC 90018 
07A212 (SENTRY) 
10A120 (SENTRY) 
10A311 (SENTRY)  
14A161 (SENTRY)  
TY735 (VUMC) 
TY736 (VUMC) 
Puerto Rico 
Austria 
Virginia, USA 
Freiburg, Germany 
Genoa, Italy 
Genoa, Italy 
Cracow, Poland 
Amsterdam, the Netherlands 
Amsterdam, the Netherlands 
case of sprue (human) 
infected nail (11-year-old boy) 
blood 
blood 
blood 
blood 
blood 
oral cavity 
unknown 
C. pseudotropicalis CBS 607 Sri Lanka bronchitic patient 
C. tropicalis CBS 94 
CBS 2310 
11D028 (SENTRY) 
TY737 (VUMC) 
TY739 (VUMC) 
unknown 
unknown 
Roma, Italy 
Amsterdam, the Netherlands 
Amsterdam, the Netherlands 
bronchitic patient 
unknown 
urinary tract 
oral cavity 
oral cavity 
1 Identification of SENTRY isolates based on AFLP patterns 
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Extraction of DNA. DNA was extracted from approximately 107 cfu using the DNeasy 
Tissue kit (Qiagen, West Sussex, England) according to the manufacturer (protocol for 
isolation of genomic DNA from yeasts). DNA was eluted in 100 µl elution buffer (buffer AE 
of the kit) and stored at -20°C.  
 AFLP. The sequences of the adapters and primers used for AFLP are depicted in Table 2. 
DNA was extracted from approximately 107 cfu C. albicans as described above. Five µl of the 
DNA samples were added to 5 µl restriction-ligation reaction mixture (1x T4 DNA ligase 
buffer; 0.05 M NaCl; 0.5 µg BSA; 2 pmol EcoRI-adapter; 20 pmol MseI-adapter; 80 U T4 
DNA ligase; 1 U EcoRI; 1 U MseI, and incubated over night at 37°C. All enzymes were 
obtained from New England BioLabs (Beverly, USA). The mixture was diluted 1:5 with 0.1x 
TE (5 mM Tris-HCl (pH 7.5); 1 mM EDTA). Pre-selective PCR was performed using the core 
sequences, i.e. primers without extensions. The AFLP primers, core mix, and internal size 
standard were supplied by Applied Biosystems (Nieuwerkerk a/d IJssel, the Netherlands). Four 
µl of diluted restriction-ligation product was added to 15 µl of AFLP amplification core mix, 
0.5 µl EcoRI core sequence and 0.5 µl MseI core sequence. The mixture was amplified in a 
GeneAmp® PCR System 9700 machine under the following conditions: 2 min. at 72°C, 
followed by 20 cycles of 20 sec. at 94°C, 30 sec. at 56°C and 2 min. at 72°C each. The PCR 
product was diluted by adding 25 µl sterile double distilled water. In a second PCR reaction 
more selective primers were used: EcoRI-AC (FAM-labeled) and MseI-C. The conditions 
were: 2 min. at 94°C, followed by 10 cycles consisting of 20 sec. at 94°C, 30 sec. at 66°C 
decreasing 1°C every step of the cycle, and 2 min. at 72°C, followed by 25 cycles consisting of 
 20 sec. at 94°C, 30 sec. at 56°C and 2 min. at 72°C. After a final incubation of 30 min. at 
60°C the samples were prepared for capillary electrophoresis by adding 2 µl of the selective 
PCR product to 24 µl of deionized formamide and 1 µl of  GeneScan-500 (ROX-labeled) as an 
internal size standard. They were run on the ABI 310 Genetic Analyzer for 30 min. each. Data 
were analyzed with the BioNumerics software package, version 2.5 (Applied Maths, Sint-
Martens-Latem, Belgium) using the Pearson correlation as a similarity coefficient in 
combination with Unweighted Pair Group Method with Arithmatic Mean (UPGMA) cluster 
analysis.  
 
 
Table 2 
The adapter- and primer-sequences used for AFLP 
Adapter Sequence 
EcoRI 5'-CTCGTAGACTGCGTACC-3' 
   3'-CATCTGACGCATGGTTAA-5' 
MseI 5'-GACGATGAGTCCTGAG-3' 
   3'-CTACTCAGGACTCAT-5' 
Primer Sequence1 
EcoRI 5'-GACTGCGTACCAATTCAC-3' 
MseI 5'-GATGAGTCCTGAGTAAC-3' 
1 bold: selective nucleotides (used only in the second PCR reaction) 
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RESULTS AND DISCUSSION 
 
A dendogram representing all reference strains and clinical isolates is depicted in Figure 1. 
The AFLP-patterns of the reference strains clearly show that each species forms a distinct 
cluster, with the following cophenetic values: C. albicans: 78; C. dubliniensis: 92; C. glabrata: 
99; C. krusei: 84; C. pseudotropicalis: 98; C. tropicalis: 85; C. parapsilosis: 91; C. lusitaniae: 
98; C. guilliermondii: 94. These results were highly reproducible.  
The C. albicans isolates show two main clusters. One cluster contains clinical isolates from 
the VUMC and the SENTRY collection as well as reference strains from the CBS. The other 
cluster only contains isolates from the SENTRY collection. There is no clear relation between 
these clusters and the geographical origin or source of the isolates. North American C. 
albicans isolates show a three-part division by several typing methods, such as RAPD, 
multilocus enzyme electrophoresis (MLEE), and Southern blot hybridization with the 
moderately repetitive C. albicans specific Ca3 probe. In South-Africa, an additional cluster is 
found besides these same three clusters4,18,28. It will be interesting to investigate whether the 
two AFLP clusters of C. albicans correspond with the North American or South-African 
clusters.    
The C. dubliniensis isolates also show two clusters, with remarkable high similarities (91% 
and 98%) of the isolates within the clusters. One cluster contains all reference strains used and 
one SENTRY clinical isolate, the other cluster is composed of SENTRY isolates only. Using 
the C. dubliniensis-specific fingerprinting probe Cd25 on a panel of 98 isolates Gee et al. also 
recognized two different clusters, one of which contained mainly isolates from HIV-infected 
individuals while the other cluster contained mainly isolates derived from HIV-negative 
individuals9. Strains CBS 7987 and CBS 7988, both part of the same AFLP cluster, are 
isolated from an HIV-infected individual. However, data on the HIV-status of the patients of 
which the other isolates were obtained (CBS 8500, CBS 8501, and SENTRY isolates) is 
lacking. Further investigations are necessary to examine whether the AFLP clusters correspond 
with the Cd25 clusters.   
Another noteworthy finding is that all AFLP patterns for the C. glabrata isolates are very 
similar (90%), except for the CBS reference strain (58%). This reference strain (CBS 138) was 
isolated from human faeces in 1936. The fact that all other isolates studied were clinical 
isolates which were isolated fairly recently may account for this difference.  
The AFLP patterns of the 18 isolates from the VUMC all corresponded with the results of 
the phenotypic identification (Germ-tube test and Vitek). The clinical isolates from the 
European SENTRY collection were all originally identified on CHROMagar as being Candida 
albicans. However, based on the AFLP patterns shown in Figure 1, some of these strains 
presumably were misidentified and belong to different species. When the total collection of 
isolates previously identified as C. albicans (n = 213) was screened with AFLP, a 
misidentification rate of 6% was observed. Six strains are now identified as C. dubliniensis, 
four as C. parapsilosis, one as C. tropicalis, and one as C. guilliermondii (results partly shown 
in Figure 1).  
CHROMagar identification of Candida species is based on differences in colony color. It 
has been shown, that the reliability of this method depends on the incubation time and 
temperature used2,24,35. However, even  when optimum  conditions  are  used,  the method  is 
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Figure 1 
Dendogram representing all reference strains and clinical isolates (see also Table 1) 
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not ideal, and especially the differentiation between C. albicans and C. dubliniensis is 
problematic. Kurzai et al. reported that only 81% of their C. dubliniensis isolates showed the 
dark green color on CHROMagar, which is considered indicative for C. dubliniensis17. 
Furthermore, 15.9% of their C. albicans isolates also showed a dark green coloration, instead 
of the usual lighter green. Tintelnot et al. reported an even lower number of 57% of C. 
dubliniensis isolates that showed the dark green coloration on CHROMagar, and only 48% of 
the isolates of Kirkpatrick et al. showing the dark green coloration turned out to be C. 
dubliniensis15,31.  
 Other commercial tests that allow (presumptive) identification of C. albicans as well as 
non-albicans Candida species usually show high sensitivities and specificities for C. albicans, 
but are less reliable or need further testing for the identification of other, less common, 
species3,5,8,12. C. dubliniensis-specific PCR assays as well as generic PCR assays in 
combination with species-specific probes have been developed6,7,16,19,25. The advantage of 
AFLP, however, is that this method is based on ligation of known sequences (adapters) to 
restriction fragments, which function as targets for the PCR primers. Therefore, the technique 
is universally applicable. In the current assay we made use of two subsequent amplifications, 
but similar results were obtained when only the second amplification was used (unpublished 
observations). The use of an internal size standard with every sample for normalization 
purposes greatly enhances the reproducibility between tests. Storing all patterns, including 
those of the reference strains, in a general accessible database will provide a screening library 
for identification of species.  
Two other universally applicable methods for identification of Candida species have been 
described: PCR fingerprinting and reference strand-mediated conformational analysis 
(RSCA)20,21. However, whereas PCR fingerprinting uses mini- and microsatellite sequences as 
targets for the primers and RSCA is based on 18S rRNA sequences, AFLP patterns are a 
representation of the whole genome. Our results show very clear differences between 
medically important Candida species. Therefore, AFLP might prove to be a reliable method 
for the identification of medically important Candida species, including Candida dubliniensis.  
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ABSTRACT 
 
The differences in production of two putative virulence factors of Candida albicans, 
(phospho)lipase and proteinase, were determined for a large (n = 186) panel of clinical C. 
albicans isolates obtained from the European SENTRY program. Seventy-two percent of the 
isolates produced detectable amounts of (phospho)lipase, 95% of the isolates produced 
detectable amounts of proteinase. There was no clear correlation between the results of the 
(phospho)lipase- and proteinase assays and the geographical distribution of the isolates. 
However, isolates which originated from pneumonia produced significantly higher amounts of 
(phospho)lipase than isolates obtained from blood, the urinary tract or wound/skin/soft tissue, 
and also appeared to produce more proteinase. It is hypothesized that these virulent isolates 
involved in pneumonia originate from the oral cavity. Whether these results are caused by 
selection for these high virulent isolates remains to be solved. 
 
 
INTRODUCTION 
 
The opportunistic pathogen Candida albicans is considered to be the most virulent of the 
Candida species. Several putative virulence factors of C. albicans have been described, 
including phenotypic switching, host recognition biomolecules (adhesins), morphogenesis (the 
reversible transition between unicellular yeast cells and filamentous, growth forms), and 
secreted hydrolytic enzymes1. Two types of secreted enzymes have been described extensively: 
phospholipases and secreted aspartyl proteinases.  
 C. albicans strains show phospholipase B as well as lysophospholipase-transacylase 
activities. Both activities are performed by a single enzyme, C. albicans phospholipase B 
(caPLB). Besides this secreted phospholipase, C. albicans also shows a phospholipase D 
activity which appears to be membrane-associated12. The data on phospholipases in pathogenic 
fungi has been reviewed by Ghannoum6.  
 Several researchers have found indications that phospholipases are virulence factors of C. 
albicans. Ibrahim et al. compared the ability to produce phospholipases of clinical blood 
isolates with oral strains from healthy volunteers. Significantly more phospholipase activity 
was detected in the clinical isolates. Furthermore, in a mouse-model of haematogenously 
disseminated candidiasis, a C. albicans strain which produced high amounts of phospholipases 
was invasive whereas a low-producing strain was not, and phospholipase-activity was the only 
putative virulence factor tested that predicted mortality9. In another animal pathogenicity 
study, a significant correlation was found between phospholipase activity and the severity of 
kidney-infections10. The ultimate proof was delivered by Leidich et al., who cloned and 
disrupted a gene encoding for PLB and showed that the null mutant significantly attenuated 
virulence in mice and dramatically reduced the ability of the yeast to penetrate host cells11. 
Disruption of the gene did not affect adherence of the yeast cells to human endothelial or 
epithelial cells. Thus, phospholipases most likely contribute to the pathogenicity of C. albicans 
by damaging host cell membranes, aiding the fungus by invasion of host tissues. This role in 
invasion is also implied by the finding that phospholipases are mainly concentrated at the tips 
of the fungal hyphae15. Besides phospholipases, C. albicans strains also secrete lipases. It is 
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likely that these enzymes, like phospholipases, are involved in virulence of C. albicans5,8. 
 The role of C. albicans secreted aspartyl proteinases in pathogenicity has recently been 
reviewed by De Bernardis et al.4. These enzymes are encoded by a family of at least nine 
genes, and are capable of degrading epithelial and mucosal barrier proteins like collagen, 
keratin and mucin, as well as antibodies, complement and cytokines. Gene disruption 
experiments showed altered adherence of yeast cells and attenuation of virulence in different 
animal models2,7,17,18.  
 The expression of virulence factors may be associated with specific characteristics of 
Candida isolates such as geographic origin or the type of infection. Knowledge of such 
correlations may help to understand the epidemiology of these infections, which may result in 
improved therapeutic regimens. Price et al. developed a simple egg yolk agar plate assay for 
the detection of (phospho)lipase activity. Hydrolysis of lipid substrates present in the egg yolk 
results in the formation of a calcium complex with the fatty acids released by the action of the 
secreted enzymes. The diameter of this zone of precipitation around the colonies is very 
constant for any given isolate, and correlates well with a biochemical assay for hydrolysis of 
phosphatidylcholine14. Although this method does not detect (phospho)lipase activity in fungal 
isolates that produce very low levels of phospholipase6, it is an excellent screening method for 
large numbers of isolates. Therefore, we used this method to investigate the differences in 
(phospho)lipase activity of a large collection of clinical C. albicans isolates obtained from 12 
European countries, and the results were linked to data on the geographic origin of the isolates 
and the site of infection. For the detection of proteinase activity we incorporated bovine serum 
albumin (BSA) into YCB-agar plates and measured the clearing zone after staining with 
Coomassie blue.  
 
 
MATERIALS AND METHODS 
 
 Yeast strains. Candida albicans isolates were obtained from the European SENTRY 
program. Only one isolate per patient was included. A total of 186 isolates derived from 19 
medical centers in 12 European countries were studied (Table 1). One-hundred-and-thirty-one 
isolates (70%) originated from infections from blood, 7 (4%) from wounds/skin/soft tissue, 25 
(13%) from the urinary tract, and 23 (12%) from pneumonia. Most isolates were derived from 
the intensive care (36%), internal medicine (15%), surgery (14%), pediatrics (12%) or 
oncology ward (6%). The number of isolates derived from the most relevant hospital wards in 
relation to the site of infection is depicted in Table 2. Identification of the isolates was 
performed using CHROMagar plates (CHROMagar, Paris, France). The isolates were cultured 
on Blood Agar and subcultured on Sabouraud Dextrose Agar (SDA) at 37°C. 
(Phospho)lipase assay. SDA plates supplemented with 1 M NaCl, 5 mM CaCl2 and 8% 
sterile egg yolk (Oxoid, Basingstoke, England) were inoculated with 1 µl sterile saline 
containing approximately 105 cfu C. albicans, and incubated at 37°C for three days. Each 
isolate was tested in duplicate. The diameter of the colonies and the total diameter of the 
colonies plus precipitation zones were measured. (Phospho)lipase activity was determined by 
the ratio of the diameter of the colony plus precipitation zone to the diameter of the colony 
alone, and scored as follows: - = no precipitation zone; +/- = ratio between 1.01 and 1.25; + = 
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ratio between 1.26 and 1.50; ++ = ratio between 1.51 and 1.75; +++ = ratio between 1.76 and 
2.00; ++++ = ratio between 2.01 and 2.25.  
Proteinase assay. YCB-BSA plates (1.5% agar; 1.17% Yeast Carbon Base powder (Becton 
Dickinson, Le Pont de Claix, France); 0.2% Bovine Serum Albumin (Instruchemie, Hilversum, 
the Netherlands); 0.2% glucose; 100 µl/l Vitox solution (Oxoid)) were inoculated with 1 µl 
sterile saline containing approximately 105 cfu C. albicans, and incubated at 25°C for three 
weeks. Several isolates were tested twice or more. The plates were stained with Coomassie 
brilliant blue (0.5% Coomassie brilliant blue R250 (Pierce, Rockford, USA); 10% v/v acetic 
acid; 45% v/v ethanol) for 20 min. at room temperature, and destained three times with 
destaining solution (10% v/v acetic acid; 45% v/v ethanol) for 20 min. at 37°C and one time 
with water for 20 min. at 37°C. The diameter of the colonies was measured before Coomassie 
staining, the diameter of the clear zones was measured after staining. Proteinase activity was 
determined by the ratio of the diameter of the clear zone to the diameter of the colony, and 
scored as follows: - = no clear zone; +/-  = ratio < 0.9 (clear zone smaller than colony, limited 
proteinase activity); + = ratio between 0.9 and 1.1 (clear zone and colony of similar size); ++ = 
ratio > 1.1 (clear zone clearly larger than colony).  
 
 
Table 1 
The geographic origin of the isolates used in this study 
Country Center No. of isolates (%) 
Austria Linz 3 (2) 
France Paris 
Lille 
6 (3) 
7 (4) 
Germany Freiburg 
Dusseldorf 
9 (5) 
7 (4) 
Greece Athens 3 (2) 
Italy Genoa 
Roma 
24 (13) 
17 (9) 
the Netherlands Utrecht 6 (3) 
Poland Warsaw 
Cracow 
1 (1) 
2 (1) 
Portugal Coimbra 23 (12) 
Spain Sevilla 
Madrid 
Barcelona 
21 (11) 
4 (2) 
1 (1) 
Switzerland Lausanne 14 (8) 
Turkey Ankara 
Istanbul 
20 (11) 
6 (3) 
United Kingdom London 12 (6) 
 Total: 186 (100) 
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Table 2 
The number of isolates derived from the different hospital wards in relation to the site of infection 
 No. of isolates (%) 
Source IC Int. med. Surgery Pediatrics Oncology Other Total 
blood 39 (30) 22 (17) 22 (17) 18 (14) 11 (8) 19 (15) 131 (100) 
pneumonia 18 (78) 0 (0) 0 (0) 0 (0) (0) 5 (22) 23 (100) 
urinary tract 8 (32) 4 (16) 3 (12) 4 (16) 0 (0) 6 (24) 25 (100) 
wound/s/st 2 (29) 1 (14) 2 (29) 0 (0) 0 (0) 2 (29) 7 (100) 
IC: intensive care 
Int. med.: internal medicine 
wound/s/st: isolates originating from wounds, skin or soft tissue 
 
 
RESULTS 
 
(Phospho)lipase assay. One-hundred-and-eighty-six isolates were tested in the 
(phospho)lipase assay. The number of isolates and the different scores are depicted in Table 3. 
No (phospho)lipase activity was detected in 28% of the isolates. Duplicate testing of the 
isolates only showed minor differences (average difference between duplicate tests: 0.08). 
There was no clear correlation between the results of the (phospho)lipase assay and the 
geographical distribution of the isolates. 
The results of the (phospho)lipase assay in relation with the site of infection are shown in 
Table 4. Of all strains obtained from blood (n = 133), the urinary tract (n = 25), or 
wounds/skin/soft tissue (n = 7) that were tested in the (phospho)lipase assay, most isolates 
were either negative or produced only low amounts of (phospho)lipase (-, +/-, or +)(blood: 
64%, urinary tract: 72%, wound/sst: 85%). However, 61% of the isolates obtained from 
pneumonia (n = 23) produced high amounts of lipase (++, +++, or ++++). This difference was 
statistically significant (p = 0.042; Pearson chi-square test (exact)). 
 
 
Table 3 
Results of the (phospho)lipase assay 
Score - +/- + ++ +++ ++++ 
No. isolates (%) 53 (28) 13 (7) 51 (27) 33 (18) 28 (15) 8 (4) 
 
 
Table 4 
Results of the (phospho)lipase assay in relation with the site of infection  
 No. of isolates (%) 
Source - +/- + ++ +++ ++++ Total 
blood 38 (29) 10 (8) 36 (27) 22 (17) 19 (15) 6 (5) 131 (100) 
pneumonia 3 (13) 1 (4) 5 (22) 8 (35) 5 (22) 1 (4) 23 (100) 
urinary tract 7 (28) 2 (8) 9 (36) 3 (12) 3 (12) 1 (4) 25 (100) 
wound/s/st 5 (71) 0 (0) 1 (14) 0 (0) 1 (14) 0 (0) 7 (100) 
wound/s/st: isolates originating from wounds, skin or soft tissue 
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Proteinase assay. One-hundred-and-eighty-five isolates were tested in de proteinase assay. 
The number of isolates and the different scores are depicted in Table 5. In all but nine isolates 
proteinase activity was detected (95%). Several isolates were tested in duplicate or triplicate, 
and showed only minor differences (average difference between duplicate tests: 0.03). There 
was no clear correlation between the results of the proteinase assay and the geographical 
distribution of the isolates. 
Of all isolates obtained from pneumonia that were tested in the proteinase assay (n = 23), 
96% produced considerable amounts of proteinase (+ or ++), whereas for isolates obtained 
from the other sources (blood (n = 131), the urinary tract (n = 24), or wound/sst (n = 7)) this 
percentage was 80, 79, and 73% respectively (Table 6). However, this difference was not 
statistically significant.  
 
 
Table 5 
Results of the proteinase assay 
Score - +/- + ++ 
No. isolates (%) 9 (5) 25 (14) 118 (64) 33 (18) 
 
 
Table 6 
Results of the proteinase assay in relation with the site of infection  
 No. of isolates (%) 
Source - +/- + ++ Total 
blood 5 (4) 21 (16) 83 (63) 22 (17) 131 (100) 
pneumonia 0 (0) 1 (4) 14 (61) 8 (35) 23 (100) 
urinary tract 2 (8) 3 (13) 17 (71) 2 (8) 24 (100) 
wound/s/st 2 (29) 0 (0) 4 (57) 1 (14) 7 (100) 
wound/s/st: isolates originating from wounds, skin or soft tissue 
 
 
DISCUSSION 
 
Previous studies on the (phospho)lipase activity of C. albicans isolates reported a large 
variation in activity among different isolates, but a remarkably constant degree of activity of 
individual isolates which was fairly independent of inoculum size10,14,16. This is in agreement 
with our results: the ratio of the diameter of the colony plus precipitation zone and the colony 
alone ranged from 1.05 to 2.36 in the positive isolates, with an average difference between 
duplicate tests of 0.08.  
When looking at (phospho)lipase activity in relation to the site of infection, Price et al. 
found that 55% of the blood isolates studied were positive in the assay14. These isolates were 
also among the highest producers. Furthermore, 50% of the isolates cultured from wounds, and 
30% of the isolates from the urinary tract were also positive. Our results show different 
percentages: 71% of the blood isolates, 72% of the isolates from the urinary tract, and 29% of 
the isolates from wound/skin/soft tissue were positive in the assay. However, whereas Price et 
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al. examined substantially more wound isolates than we did (n = 28 versus n = 7), we tested 
larger numbers of isolates from blood and the urinary tract (blood: n = 131 versus n = 11; 
urinary tract: n = 25 versus n = 13). These differences may account for the different results.  
In addition to the sources described above, we also examined strains which originated from 
pneumonia. It appeared that this group showed the highest number of positive isolates in the 
(phospho)lipase assay (87%, n = 23). Furthermore, 61% of these isolates were among the 
higher producers (in comparison with the other sources: blood 37%; urinary tract 28%; 
wound/skin/soft tissue 14%)(Table 4). Although not statistically significant, a similar trend 
was observed for the proteinase assay: all isolates obtained from pneumonia were positive in 
the proteinase assay, and 96% of these isolates were high producers (other sources: blood 80%; 
urinary tract 79%; wound/skin/soft tissue 73%)(Table 6). According to fingerprinting data 
obtained with amplified fragment length polymorphism analysis (AFLP) only two isolates 
originating from pneumonia (from Genoa, Italy) were identical. The patterns of all other 
pneumonia isolates showed clear differences (results not shown). Therefore, there is no bias 
due to hospital outbreaks. 
 It is possible that our findings are related to earlier reports by Samaranayake et al. and 
Kothavade and Panthaki which mention relatively high numbers of (phospho)lipase producers 
among clinical oral C. albicans isolates (79% and 89% respectively)10,16. An exceptionally 
high number of 78% of our pneumonia isolates were derived from patients in the intensive 
care. For the three other sources this percentage was approximately 30% (Table 2). Albeit this 
data is lacking, it seems legitimate to assume that many of these patients were mechanically 
ventilated. In that case the C. albicans isolates causing the pneumonia may very well originate 
from the patient's own oral cavity. It is interesting to note that whereas oral C. albicans isolates 
from healthy volunteers show a relatively low phospholipase activity, clinical isolates from the 
oral cavities of patients suffering from oral candidosis produce relatively high amounts of this 
enzyme9,10,16. Furthermore, oral C. albicans isolates of HIV-positive individuals are known to 
cause unusual severe infections. These isolates also produce extremely high amounts of 
proteinases3,13. It is hypothesized that these infections are attributable to selection of 
commensal C. albicans isolates which are characterized by a higher virulence. It is a tempting 
idea that these more virulent isolates also have an increased potential of causing pneumonia in 
intensive care patients. The underlying mechanisms behind the selection of these high virulent 
strains are undetermined. 
 SAP production by C. albicans not only depends on strain type or type of infection, but also 
on phenotypic switch type, environmental conditions, and even the stage of infection4. 
Therefore, caution must be employed in the interpretation of proteinase assays. However, 
although especially the proteinase assay is a crude screening method, it is noteworthy that the 
results of both assays indicate a possible higher virulence for isolates involved in pneumonia. 
Whether this is caused by selection of more virulent isolates which are part of the commensal 
flora of the patients remains to be solved.  
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ABSTRACT 
 
Amplified Fragment Length Polymorphism (AFLP™) analysis was used to fingerprint a 
large panel of European clinical C. albicans isolates obtained from the SENTRY antimicrobial 
surveillance program, and the correlation between AFLP type and geographical origin of the 
isolates, the site of infection, and the production of (phospho)lipases and proteinases was 
studied. The isolates show a subdivision into two main clusters, cluster 1 and cluster 2. Isolates 
from most countries can be found in both clusters. However, isolates from Spain and Portugal 
(n = 49) are restricted to cluster 1, whereas isolates from the United Kingdom and Germany (n 
= 27) seem restricted to cluster 2. The differences between the two clusters in relation to the 
site of infection and the production of hydrolytic enzymes are probably due to sampling bias. 
In conclusion: our results suggest the presence of a clone specific for the Iberian peninsula, and 
possibly also a specific Northern European clone. 
 
 
INTRODUCTION 
 
Candida albicans is a commensal yeast which can cause severe infections in 
immunocompromised individuals. Relatively little is known about the epidemiology of 
Candida infections. Several typing methods have been used for Candida species, but none of 
them is considered the golden standard3,8,13-15,18. Amplified Fragment Length Polymorphism 
(AFLP™) analysis, first described by Vos et al. in 1995, has several advantages over other 
fingerprinting methods16,19. The technique is based on the restriction of chromosomal DNA 
and ligation of known sequences (adapters) to the restriction fragments, which serve as targets 
for PCR amplification. Therefore, AFLP is universally applicable without the need to design 
specific primers and probes. Depending on the organism under study, the primers are extended 
with one or more selective nucleotides to increase the specificity. Since the primer binding 
sites are known, stringent annealing temperatures can be used. This makes this technique more 
reproducible compared to Randomly Amplified Polymorphic DNA (RAPD) analysis10. 
Furthermore, only a limited amount of DNA is needed. This greatly reduces the risk of partial 
digestion, a major source of irreproducibility with Restriction Fragment Length Polymorphism 
(RFLP) analysis. Another difference with many other typing methods is that AFLP patterns are 
a representation of the whole genome. The patterns can easily be stored in general accessible 
databases, which may greatly facilitate the exchange of results between laboratories. 
 We have previously demonstrated the value of AFLP for the identification of different 
Candida species5. In the present study, AFLP was used to fingerprint a large panel of European 
clinical C. albicans isolates obtained from the SENTRY antimicrobial surveillance program. 
Furthermore, we studied whether specific AFLP types of C. albicans correlated with the 
geographical origin of the isolates, with the type of infection, and with the production of two 
putative virulence factors, (phospho)lipases and proteinases7,9. Knowledge of such correlations 
may help to understand the epidemiology of C. albicans infections, which may result in 
improved therapeutic regimens. 
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MATERIALS AND METHODS 
 
Yeast strains. Candida albicans isolates were obtained from the European SENTRY 
Program. Only one isolate per patient was included. A total number of 189 isolates derived 
from 19 medical centers in 12 European countries were studied. One-hundred-and-thirty-two 
isolates (70%) originated from infections from blood, 6 (3%) from wounds/skin/soft tissue, 26 
(14%) from the urinary tract, and 25 (13%) from pneumonia. Most isolates were derived from 
the intensive care (37%), internal medicine (15%), surgery (13%), pediatrics (11%) or 
oncology (6%). Identification of the isolates was performed using CHROMagar plates 
(CHROMagar, Paris, France). The isolates were cultured on Blood Agar and subcultured on 
Sabouraud Dextrose Agar (SDA) at 37°C. 
Extraction of DNA. DNA was extracted from approximately 107 cfu C. albicans using the 
DNeasy Tissue kit (Qiagen, West Sussex, England) according to the manufacturer (protocol 
for isolation of genomic DNA from yeasts). DNA was eluted in 100 µl elution buffer (buffer 
AE of the kit) and stored at -20°C.  
 AFLP. The sequences of the adapters and primers used for AFLP are depicted in Table 1. 
DNA was extracted from approximately 107 cfu C. albicans as described above. Five µl of the 
DNA samples were added to 5 µl restriction-ligation reaction mixture (1x T4 DNA ligase 
buffer; 0.05 M NaCl; 0.5 µg BSA; 2 pmol EcoRI-adapter; 20 pmol MseI-adapter; 80 U T4 
DNA ligase; 1 U EcoRI; 1 U MseI, and incubated over night at 37°C. All enzymes were 
obtained from New England BioLabs (Beverly, USA). The mixture was diluted 1:5 with 0.1x 
TE (5 mM Tris-HCl (pH 7.5); 1 mM EDTA). Pre-selective PCR was performed using the core 
sequences, i.e. primers without extensions. The AFLP primers, core mix, and internal size 
standard were supplied by Applied Biosystems (Nieuwerkerk a/d IJssel, the Netherlands). Four 
µl of diluted restriction-ligation product was added to 15 µl of AFLP amplification core mix, 
0.5 µl EcoRI core sequence and 0.5 µl MseI core sequence. The mixture was amplified in a 
GeneAmp® PCR System 9700 machine under the following conditions: 2 min. at 72°C, 
followed by 20 cycles of 20 sec. at 94°C, 30 sec. at 56°C and 2 min. at 72°C each. The PCR 
product was diluted by adding 25 µl sterile double distilled water. In a second PCR reaction 
more selective primers were used: EcoRI-AC (FAM-labeled) and MseI-C. The conditions 
were: 2 min. at 94°C, followed by 10 cycles consisting of 20 sec. at 94°C, 30 sec. at 66°C 
decreasing 1°C every step of the cycle, and 2 min. at 72°C, followed by 25 cycles consisting of 
 20 sec. at 94°C, 30 sec. at 56°C and 2 min. at 72°C. After a final incubation of 30 min. at 
60°C the samples were prepared for capillary electrophoresis by adding 2 µl of the selective 
PCR product to 24 µl of deionized formamide and 1 µl of  GeneScan-500 (ROX-labeled) as an 
internal size standard. They were run on the ABI 310 Genetic Analyzer for 30 min. each. Data 
were analyzed with the BioNumerics software package, version 2.5 (Applied Maths, Sint-
Martens-Latem, Belgium) using the Pearson correlation as a similarity coefficient in 
combination with Unweighted Pair Group Method with Arithmatic Mean (UPGMA) cluster 
analysis.  
 (Phospho)lipase assay. (Phospho)lipase activity of the isolates was determined by using 
the egg yolk agar plate assay developed by Price et al. as described before4,12. The activity was 
determined by the ratio of the diameter of the colony plus precipitation zone to the diameter of 
the colony alone. The isolates were classified as 'low producers' (ratio < 1.50) or 'high 
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producers' (ratio ≥ 1.50).  
Proteinase assay. Proteinase activity of the isolates was determined by using agar plates 
supplemented with bovine serum albumin (BSA) as described before4. The activity was 
determined by the ratio of the diameter of the clear zone to the diameter of the colony. The 
isolates were classified as 'low producers' (ratio < 0.9) or 'high producers' (ratio ≥ 0.9). 
 
 
Table 1 
The adapter- and primer-sequences used for AFLP 
Adapter Sequence 
EcoRI 5'-CTCGTAGACTGCGTACC-3'
3'-CATCTGACGCATGGTTAA-5'
MseI 5'-GACGATGAGTCCTGAG-3'
3'-CTACTCAGGACTCAT-5'
Primer Sequence1 
EcoRI 5'-GACTGCGTACCAATTCAC-3'
MseI 5'-GATGAGTCCTGAGTAAC-3'
1 bold: selective nucleotides (used only in the second PCR reaction) 
 
 
RESULTS 
 
A dendogram representing 50% of the results of the AFLP analysis, the (phospho)lipase 
assay, and the proteinase assay is shown in Figure 1. The complete dendogram can be obtained 
from the corresponding author. Identical isolates (similarity > 90%, based on duplicate testing) 
were found within one hospital as well as in different countries. The isolates show two main 
clusters, 1 and 2, and a few miscellaneous types (cophenetic values: cluster 1: 76; cluster 2: 
72). Cluster 1 contains isolates from France (n = 5), Germany (n = 1), Italy (n = 16), the 
Netherlands (n = 6), Poland (n = 1), Portugal (n = 23), Spain (n = 26), Switzerland (n = 7), and 
Turkey (n = 4). Cluster 2 contains isolates from Austria (n = 3), France (n = 10), Germany (n = 
15), Greece (n = 3), Italy (n = 25), Switzerland (n = 6), the United Kingdom (n = 11), and 
Turkey (n = 20). There is no correlation between AFLP type and hospital ward (results not 
shown). The relation between the clusters and the site of infection is depicted in Table 2. 
Cluster 1 contains significantly more isolates from infections of the urinary tract compared to 
cluster 2, whereas cluster 2 contains significantly more isolates from pneumonia compared to 
cluster 1 (p = 0.001, Pearson chi-square test (exact)).  
 
 
Table 2 
The relation between the AFLP clusters and the site of infection 
 No. of isolates (%)    
cluster blood pneumonia urinary tract wound/skin/soft tissue
1 64 (74) 4 (5) 17 (20) 1 (1) 
2 65 (69) 18 (19) 7 (7) 4 (4) 
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Figure 1 (previous page) 
Dendogram representing 50% of all C. albicans isolates studied  
1 Isolate codes starting with '01' are derived from Linz (Austria); 04: Paris (France); 06: Lille (France); 07: 
Freiburg (Germany); 08: Dusseldorf (Germany); 09: Athens (Greece); 10: Genoa (Italy); 11: Roma (Italy); 12: 
Utrecht (the Netherlands); 13: Warsaw (Poland); 15: Coimbra (Portugal); 16: Sevilla (Spain); 17: Madrid 
(Spain); 18: Barcelona (Spain); 19: Lausanne (Switzerland); 20: London (United Kingdom); 23: Ankara 
(Turkey); 24: Istanbul (Turkey).  
Isolates with an 'A' in the code are derived from blood; C: pneumonia; D: wound/skin/soft tissue; E: urinary 
tract 
2 P: proteinase; PL: (phospho)lipase; H: high producer; L: low producer; n.d.: no data 
 
 
The relation between the clusters and the production of hydrolytic enzymes is depicted in 
Table 3. Significantly more isolates in cluster 2 were among the high producers of 
(phospho)lipases and proteinases compared to the isolates in cluster 1 (p = 0.001 and p = 0.025 
respectively, Pearson chi-square test (exact)).  
 
 
Table 3 
The relation between the AFLP clusters and production of hydrolytic enzymes 
 (Phospho)lipase  Proteinase  
cluster low  high low high 
1 59 (76) 19 (24) 20 (26) 57 (74) 
2 44 (49) 45 (51) 10 (11) 78 (89) 
No. of isolates (%) 
 
 
DISCUSSION 
 
Strain typing is important in various situations, e.g. to find the source of a hospital outbreak 
or to elucidate the relationship between commensal and infecting strains. Furthermore, strain 
typing is essential to study the dynamics of a microorganism in a human population. Linking 
genotypic fingerprinting data to data on the geographic origin of certain isolates, the site of 
infection, or the expression of virulence factors will improve our understanding of the 
epidemiology of Candida infections. Furthermore, because Candida albicans reproduction is 
predominantly clonal, it may be the first step in identifying genetic markers for specific traits, a 
process which ultimately may lead to improved therapeutic regimens.  
 When we only take into account the countries of which ten or more isolates were studied, 
there seems to be a division between countries represented exclusively in cluster 1 (Portugal, 
Spain), countries represented exclusively (United Kingdom) or almost exclusively (Germany) 
in cluster 2, and countries of which the isolates are represented more or less equally in both 
clusters (France, Italy, Switzerland, Turkey). The possibility that our results demonstrate the 
presence of separate 'Iberian' and 'Northern-European' C. albicans clones which coexist in 
Central-European countries is appealing. Clemons et al. showed that 86 clinical isolates from 
three medical centers in the United Kingdom and six medical centers in the United States form 
two clusters, IA and IB, when typed by restriction endonuclease analysis using EcoRI6. We 
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examined 11 isolated from one medical center in the United Kingdom. Our results implying a 
clone specific for Northern Europe may be biased by the limited number of isolates and 
medical centers studied. Clusters IA and IB may correspond with the AFLP clusters 1 and 2. 
However, it is also possible that a third cluster exists, which is as yet undiscovered by AFLP. 
Forty-nine isolates from four medical centers throughout Spain and Portugal were included in 
our experiments, and none of them was found in cluster 2. Therefore, the existence of an 
Iberian clone is more convincing.   
The finding that cluster 1 contains significantly more isolates from infections of the urinary 
tract compared to cluster 2 (Table 2) can at least in part be explained by the relatively large 
number of urinary tract-derived isolates obtained from Portugal and Spain. The same holds 
true for the abundance of pneumonia-derived isolates in cluster 2: the isolates obtained from 
the Germany and the United Kingdom show relatively high numbers of isolates from this 
source. Whether there is an additional explanation for this relation between AFLP cluster and 
site of infection remains to be solved.  
Cluster 2 contains significantly more isolates which produce high amounts of 
(phospho)lipases and/or proteinases, both putative virulence factors of C. albicans (Table 3). 
We have shown previously that pneumonia-derived isolates show a relatively high production 
of hydrolytic enzymes4. Compared to cluster 1, cluster 2 contains a relatively high number of 
isolates which originate from pneumonia (Table 2). This may account for the difference in 
production of these hydrolytic enzymes between isolates in the two groups. 
The results of several typing methods for C. albicans, such as RAPD, multilocus enzyme 
electrophoresis (MLEE), and Southern blot hybridization with the moderately repetitive C. 
albicans specific Ca3 probe, show a good agreement13. To validate the results of AFLP typing, 
the technique should be compared with at least one of these other typing methods, using the 
same collection of isolates. However, AFLP typing has been used successfully for many 
organisms including Saccharomyces cerevisiae, a close relative of C. albicans1,16,19. 
Geographical specificities of certain C. albicans strains have been demonstrated before for 
isolates from South-Africa, Singapore, and the North-Eastern United States2,11,17. Our results 
suggest the presence of a clone specific for the Iberian peninsula, and possibly also a specific 
Northern European clone.  
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Despite the fact that the yeast Candida is the number 4 cause of bloodstream infections in 
the United States and ranks number 8 in Europe9,16, adequate detection methods are lacking. 
Furthermore, relatively little is known about the epidemiology of Candida, including the main 
Candida species, C. albicans. In both fields, knowledge has increased in the past decade due to 
the rapid development and improvements of molecular biological techniques. This is 
illustrated by the fact that a clinically relevant species, C. dubliniensis, was misidentified as C. 
albicans until the discovery of the genetic differences between the species led to its recognition 
in 199533. Our aim was to improve the detection of Candida infections and to study the 
epidemiology of these infections in Europe. Most research was performed by using two 
relatively new molecular biological tools: Nucleic Acid Sequence-Based Amplification 
(NASBA™)6 and Amplified Fragment Length Polymorphism analysis (AFLP™)35.  
 
 
DETECTION OF CANDIDA INFECTIONS 
 
The current routine detection method for Candida infections, automated blood culture, is 
inadequate. In many cases the blood cultures remain negative, even when the patient suffers 
from candidaemia20. It is hypothesized that at least in some cases this is a technical problem of 
the monitoring system. Shigei et al. and Tinghitella and Lamagdeleine have shown, that some 
automated blood culture instruments may fail to detect yeasts in spite of good growth of the 
organisms in the culture bottles, as was demonstrated by confluent growth after 
subculturing31,34. Other authors, however, claim that all important pathogens (including yeasts) 
are detected within the standard incubation time, without the need for terminal 
subculture18,26,37. In Chapter 1 we examined whether terminal subculture of negative blood 
culture bottles improves the detection rate for patients with candidaemia3. For three of the ten 
patients studied, subculturing resulted in extra information. For one patient, this information 
was clinically relevant: yeast was detected up to 7 days after the last positive blood culture. 
Since the patient was treated with antifungal agents, blood culturing alone would have 
suggested that the infection was adequately treated. Therefore, we believe that routine terminal 
subculturing of negative blood cultures from patients with suspected candidaemia and patients 
under treatment for candidaemia might be valuable. 
 Chapters 2, 3 and 4 describe the development of a NASBA assay for the detection of 
Candida species in blood and blood cultures. Preliminary experiments on clinical material 
showed that it is possible to detect the yeast in blood and serum samples, without the prior 
need for culture (Chapter 2)36. However, since only a very small number of Candida cells may 
be present in the blood during candidaemia25, we also investigated whether the NASBA assay 
can be used to improve the detection rate after blood culturing, by testing samples from blood 
culture bottles which remained negative in the blood culture system (Chapter 3). Furthermore, 
we examined whether a short pre-culture step of two days could improve the detection rate 
(Chapter 4). The results were encouraging in both cases. When the NASBA assay was used to 
detect Candida in blood cultures which were negative in the BacT/Alert monitoring system, 
the number of positive blood cultures increased with 62% (from 21% to 34%)4. Furthermore, 
we demonstrated that a substantial increase in detection rate can already be obtained with a 2 
day pre-culture step: 80% of all samples positive in the NASBA assay in Chapter 4 were pre-
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cultured for two days. In the same study, Candida RNA was detected in the blood of a patient, 
whereas no yeast was detected by the automated blood culturing system. In another patient the 
NASBA assay detected the infection two days earlier than the blood culture system5. Although 
the number of patients included in these studies was limited, the results indicate that improved 
detection of Candida infections (detection rate as well as speed) is possible. Improved 
detection will lead to a reduced morbidity and mortality.   
 One of the main advantages of the NASBA technology is also its disadvantage. The high 
sensitivity compared to other amplification methods makes it more prone to problems with 
contaminations. This was illustrated in Chapter 5, where an attempt to replace our in-house 
NASBA amplification protocol by a commercial kit failed due to contaminated kit 
components. Based on a literature review (Chapter 6) and our own experiences it was 
concluded that in many cases problems with contaminations occur because people are unaware 
of the impact which their undertakings have on the environment. Even non-molecular 
biologists may be working with large amounts of DNA and form an unexpected risk of 
contaminations, e.g. protein chemists who study recombinant proteins by using plasmids as 
expression systems. Therefore, all researchers using the same laboratory space and equipment 
should conduct themselves to stringent precautions, without any exceptions. The problem 
described in Chapter 5 originated from the manufacturer. Although it is difficult to take 
stringent measures for contamination control in a large-scale production process, the 
increasing request for standardized nucleic acid amplification assays obligates diagnostic 
companies to reevaluate their procedures.  
 The NASBA assay is able to detect most medically important Candida species. However, 
it is unfeasible to implement probes for all the different species in the assay. It is highly likely 
that uncommon species are encountered, which cannot be identified with the NASBA assay. 
Therefore, the availability of an identification tool which is universally applicable is desired. 
This is especially important considering the fact that less common Candida species are 
emerging and a new species (C. dubliniensis) was recognized only recently17,32. In Chapter 7 
of this thesis we show that AFLP is an excellent method for the identification of Candida 
species. The different species show very distinct clusters, and by using this technique we 
discovered that 6% of our (phenotypically identified) collection of clinical Candida isolates 
was misidentified. The potential of storing AFLP patterns in general accessible databases will 
greatly enhance the chances of a correct identification.  
 
 
EPIDEMIOLOGY OF CANDIDA INFECTIONS 
 
The second objective of this thesis was to study the epidemiology of Candida albicans 
infections in Europe. Some strains of the same species may be associated with a specific type 
of disease or may be restricted to a certain geographic region. It is important to recognize such 
correlations, and to identify the underlying mechanisms. Although Candida albicans is capable 
of sexual reproduction and recombination occurs to some extent, the yeast reproduces mainly 
clonally11,12,14,19. Therefore, all genes are associated and research on the epidemiology of 
clinically important traits such as the expression of virulence factors may lead to the 
identification of genetic markers for these traits. This may result in improved therapeutic 
regimens. 
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In Chapter 8 we investigated whether the expression of two putative virulence factors of C. 
albicans, (phospho)lipases and proteinases8,10, are associated with a certain type of infection or 
with the geographic origin of the isolates. It appeared that compared to infections of blood, the 
urinary tract or wound/skin/soft tissue, a relatively high number of isolates which were 
involved in pneumonia produced (phospho)lipases. Also, a significantly higher number of 
these isolates were among the higher producers of this enzyme. A similar trend was observed 
for the production of proteinases: all isolates obtained from pneumonia were positive in the 
proteinase assay, and 96% of these isolates were high producers. These results suggest that 
isolates involved in pneumonia are more virulent than isolates obtained from the other types of 
infection that were studied. It is hypothesized that selection for more virulent isolates in 
debilitated individuals occurs in HIV-positive patients7,7,23. Also, oral C. albicans isolates from 
healthy volunteers show a relatively low phospholipase activity, whereas clinical isolates from 
the oral cavities of patients suffering from oral candidosis produce relatively high amounts of 
this enzyme15,27. It will be interesting to study whether the enhanced (phospho)lipase and 
proteinase production in pneumonia-derived isolates is caused by a positive selection of more 
virulent isolates, and to elucidate the mechanisms behind such a selection.  
 Another interesting epidemiological finding is described in Chapter 9. By using AFLP as a 
fingerprinting method, we typed a large collection of European C. albicans isolates. It was 
discovered, that isolates from Portugal and Spain all belonged to the same AFLP cluster 
(cluster 1), whereas isolates from the United Kingdom and all but one isolate from Germany 
belonged to another cluster (cluster 2). Isolates from France, Italy, Switzerland, and Turkey 
were represented in both clusters. These results indicate the presence of an Iberian and a 
Northern European clone. Geographical specificities of certain C. albicans strains have been 
demonstrated before for isolates from South-Africa, Singapore, and the North-Eastern United 
States2,24,29. To our knowledge, this is the first time that such specificities have been 
demonstrated for Europe. 
Although AFLP has been established as a typing method for several microorganisms 
including the yeast Saccharomyces cerevisiae1,28, we will need to compare AFLP with another 
fingerprinting method on the same group of isolates to validate the feasibility of this technique 
as a typing method for C. albicans. The difficulty, however, is that no other typing method has 
been accepted as the golden standard for typing of Candida.  
 
 It can be concluded that our first objective, improved detection of Candida infections, was 
feasible. Although the implementation of the NASBA assay in a routine laboratory needs 
further efforts, we have demonstrated that this assay can lead to a more rapid detection as well 
as increased detection rates. The second objective, to study the epidemiology of C. albicans 
infections in Europe, resulted in two interesting discoveries: C. albicans isolates involved in 
pneumonia seem to be more virulent than isolates involved in other types of infection, and 
European C. albicans isolates can be distinguished in an Iberian and a Northern European 
AFLP-type, which are mingled in Central European countries. These last two findings can be 
the onset of extensive epidemiological studies.  
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Candida is een opportunistische gistsoort die ernstige infecties kan veroorzaken in patiënten 
met een verminderde afweer. Candida albicans komt het meest voor, maar andere Candida 
soorten zoals C. glabrata en C. krusei worden steeds vaker geïsoleerd. Risicogroepen voor 
Candida infecties zijn neutropene kankerpatiënten, beenmerg- en orgaantransplantatie-
patiënten, AIDS-patiënten, diabetici, patiënten die worden behandeld met breedspectrum 
antibiotica en patiënten die parenterale voeding krijgen. Van alle micro-organismen die 
bloedbaan infecties veroorzaken komt Candida op de 4e plaats in Noord-Amerika, en op de 8e 
plaats in Europa. Toch is de standaard detectiemethode voor deze infecties, geautomatiseerde 
bloedkweek, niet toereikend. Veel infecties blijven ongedetecteerd of worden pas na meerdere 
dagen aangetoond. Daarna duurt het nog één of soms meerdere dagen voordat duidelijk is om 
welke soort Candida het gaat. Sommige onderzoekers zijn van mening dat de detectie 
verbeterd kan worden door de negatieve bloedkweken af te enten. Uit het onderzoek 
beschreven in hoofdstuk 1, waarin negatieve bloedkweken van patiënten met candidaemie 
werden afgeënt, blijkt dat dit afenten kan leiden tot extra (klinisch relevante) informatie: na 
afenten werden positieve bloedkweken gevonden op een moment dat de patiënt werd 
behandeld met antimycotica. Bloedkweken zonder afenten zou hebben gesuggereerd dat de 
behandeling aansloeg. Het is daarom aan te bevelen om negatieve bloedkweken van patiënten 
die verdacht worden van candidaemie of patiënten die behandeld worden voor deze infectie af 
te enten voor verder onderzoek. 
Het is belangrijk om te weten welke Candida soort de veroorzaker is van een infectie. C. 
krusei is bijvoorbeeld resistent tegen één van de meest gebruikte antimycotica, fluconazol, en 
het is bekend dat C. glabrata deze resistentie snel kan ontwikkelen. Om zo snel mogelijk met 
de juiste behandeling te kunnen starten is het dus belangrijk om een detectiemethode te hebben 
die niet alleen snel is, maar ook tot op soortniveau kan aangeven welke gist de infectie 
veroorzaakt. 
Door hun snelheid en gevoeligheid zijn nucleïnezuur-amplificatiemethoden belangrijke 
kandidaten voor het verbeteren van de diagnostiek van infecties. De meest gebruikte techniek 
is de Polymerase Chain Reaction (PCR), waarin specifieke stukjes DNA worden vermeerderd 
tot een aantoonbaar niveau. In 1991 werd echter een nieuwe techniek beschreven die een aantal 
voordelen heeft boven PCR. Deze techniek, Nucleic Acid Sequence-Based Amplification 
(NASBA), is gebaseerd op het vermeerderen van specifieke stukjes RNA in plaats van DNA. 
In tegenstelling tot PCR vindt dit proces plaats bij een constante temperatuur waardoor er geen 
dure warmtewisselaar hoeft worden aangeschaft. Daarnaast wordt er per reactie veel meer 
product gevormd dan bij PCR, waardoor de techniek gevoeliger is.  
De hoodfstukken 2, 3 en 4 beschrijven de ontwikkeling van een NASBA assay voor het 
aantonen van Candida RNA in bloed en bloedkweken. Uit hoofdstuk 2 blijkt dat het mogelijk 
is om de gist direct in bloed aan te tonen. Omdat er bij candidaemie echter vaak sprake is van 
zeer kleine aantallen gistcellen in het bloed, is er tevens gekeken naar de mogelijkheid om de 
detectie van bloedkweken te verbeteren door met NASBA gist RNA aan te tonen in negatieve 
bloedkweken (hoofdstuk 3). Daarnaast is in hoofdstuk 4 onderzocht of een korte voorkweek 
stap van twee dagen de detectie verbeterde. In beide gevallen waren de resultaten 
bemoedigend. Door de NASBA assay te gebruiken voor het aantonen van gist RNA in 
bloedkweken die negatief bleven in de geautomatiseerde monitor werden 62% meer positieve 
kweken gevonden (een stijging van 21% naar 34%). Daarnaast verbeterde de detectie 
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substantieel na een korte voorkweek stap: 80% van de monsters die positief waren in de 
NASBA assay in hoofdstuk 4 waren dat na twee dagen voorkweken. In dezelfde studie werd 
Candida RNA aangetoond in het bloed van een patiënt waarvan alle bloedkweken negatief 
waren gebleven. Bij een andere patiënt werd de infectie twee dagen eerder gedetecteerd in 
vergelijking met de bloedkweken. Hoewel maar een klein aantal patiënten geïncludeerd was in 
deze studies, blijkt uit de resultaten dat een verbetering van de detectie (zowel in aantal als in 
snelheid) mogelijk is. Dit kan uiteindelijk leiden tot minder morbiditeit en mortaliteit bij de 
patiënten.  
 Het belangrijkste voordeel van de NASBA is tevens ook een nadeel. Door de hoge 
gevoeligheid vergeleken met andere technologiën is er ook een grotere kans op contaminaties. 
Een duidelijk voorbeeld hiervan wordt beschreven in hoofdstuk 5, waar een poging om de 
NASBA assay te standaardiseren met behulp van een commerciële kit mislukte doordat 
bepaalde bestanddelen van de kit gecontamineerd waren met gist- of schimmel RNA. Naar 
aanleiding van dit onderzoek en een literatuuronderzoek (beschreven in hoofdstuk 6) werd 
geconcludeerd dat de meeste problemen met contaminaties zich voordoen omdat mensen zich 
niet bewust zijn van het effect van hun handelen op hun omgeving. Ook niet-moleculair 
biologen kunnen met grote hoeveelheden DNA werkzaam zijn en zo een onverwacht risico 
vormen, bijvoorbeeld tijdens onderzoek naar recombinant-eiwitten die door middel van 
plasmiden tot expressie gebracht worden. Het is daarom aan te raden dat alle onderzoekers die 
dezelfde laboratoria en benodigdheden gebruiken zich aan dezelfde strenge 
voorzorgsmaatregelen houden. Het in hoofdstuk 5 beschreven probleem stamde af van de 
fabrikant. Hoewel het moeilijk is om strenge voorzorgsmaatregelen te nemen in een 
grootschalig productieproces, zouden fabrikanten zich het belang van zulke maatregelen beter 
moeten realiseren.  
 Met de in dit proefschrift ontwikkelde NASBA assay kunnen de belangrijkste Candida 
soorten snel herkend worden. Het is echter hoogst aannemelijk dat er ook gistsoorten 
gevonden zullen worden die met deze methode niet gespecificeerd kunnen worden. Het is 
ondoenlijk om voor elke soort een extra probe aan de assay toe te voegen. Men zou daarom 
naast de NASBA assay ook de beschikking moeten hebben over een universeel toepasbare 
techniek, hoewel die doorgaans meer tijd in beslag nemen. In hoofdstuk 7 werd onderzocht of 
zo'n universele techniek, Amplified Fragment Length Polymorphism analysis (AFLP) geschikt 
is voor de identificatie van verschillende Candida soorten. De onderzochte soorten blijken 
allemaal een uniek bandenpatroon te hebben, en met behulp van deze methode werd 
aangetoond dat 6% van een grote collectie C. albicans isolaten in het verleden verkeerd 
geïdentificeerd was. AFLP patronen zijn gemakkelijk op te slaan in algemeen toegankelijke 
databestanden, hetgeen de kans op een correcte identificatie vergroot.  
 Naast het verbeteren van de detectie van Candida infecties wilden we in dit onderzoek ook 
kijken naar de epidemiologie van C. albicans in Europa. Binnen een soort kunnen er bepaalde 
stammen zijn de geassocieerd zijn met een bepaald type infectie of met een bepaalde 
geografische locatie. Het aantonen van zulke relaties leidt tot een beter begrip van de 
epidemiologie van een soort, en kan tevens een aanzet zijn tot bijvoorbeeld het vinden van 
moleculaire markers voor belangrijke eigenschappen als virulentie. Uiteindelijk kan dit leiden 
tot verbeterde therapeutische voorschriften. In hoofdstuk 8 werd onderzocht of er een relatie 
bestaat tussen de productie van twee virulentiefactoren van C. albicans, (fosfo)lipasen en 
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proteïnasen, en het type infectie of de geografische herkomst van de isolaten. In vergelijking 
met isolaten afkomstig uit bloed, de urinewegen of wond/huid-infecties bleken significant 
meer isolaten die betrokken waren bij pneumonieën (fosfo)lipasen te produceren. Tevens 
produceerde een significant hoger aantal van deze isolaten grote hoeveelheden van dit enzym. 
Vergelijkbare bevindingen werden gedaan voor proteïnasen: alle pneumonie-isolaten 
produceerden dit enzym, en 96% van deze isolaten produceerden grote hoeveelheden. Deze 
resultaten tonen aan dat isolaten betrokken bij pneumonie waarschijnlijk virulenter zijn dan 
isolaten van andere typen infecties. Mogelijk heeft dit te maken met selectie van virulente 
isolaten in patiënten met een verminderde afweer.  
 Een andere interessante bevinding werd gedaan on hoofdstuk 9. Een groot aantal Europese 
C. albicans isolaten werd getypeerd. Hiervoor werd opnieuw gebruikt gemaakt van AFLP, een 
techniek die naast identificatie van soorten ook geschikt is voor het aantonen van verschillen 
binnen een soort. De Europese isolaten bleken onderverdeeld te kunnen worden in twee 
clusters. Opvallend was, dat isolaten afkomstig uit Portugal en Spanje allen tot cluster 1 
behoorden, terwijl isolaten uit het Verenigd Koninkrijk en Duitsland vrijwel allemaal tot 
cluster 2 behoorden. Isolaten uit Frankrijk, Italië, Zwitserland en Turkije waren verdeeld over 
de twee clusters. Deze resultaten impliceren het bestaan van een Iberische en een Noord-
Europese kloon.  
 In conclusie: in dit proefschrift is aangetoond dat een verbetering van de detectie van 
Candida infecties mogelijk is, zowel in aantal als in snelheid. Daarnaast is ontdekt dat C. 
albicans isolaten betrokken bij pneumonie virulenter zijn dan isolaten uit andere typen 
infecties. Tevens lijkt het er op dat er binnen Europa sprake is van een Iberische- en een 
Noord-Europese C. albicans-kloon. Deze laatste twee bevindingen kunnen het begin zijn van 
een grootschalig epidemiologisch onderzoek.  
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Na een onmogelijk lijkende eindsprint is het dan nu toch echt af. Het zal vreemd zijn om 
het EWI te verlaten. Ik heb de afgelopen 4½ jaar vrijwel altijd met veel plezier hier 
rondgelopen, en hoewel ik de enige was die met NASBA en Candida werkte zijn er heel wat 
mensen die hun steentje hebben bijgedragen aan dit boekje. Gelukkig is daarvoor het 
dankwoord uitgevonden. 
Mijn grote dank gaat uit naar mijn co-promotor. Ad, het was soms bijna eng hoe goed wij 
op één lijn zaten. Bedankt voor de tijd die je nooit had maar altijd wist te vinden, voor de 
gezellige tijd op congressen, en vooral voor je vertrouwen in mijn kunnen de laatste twee 
maanden. Het wordt tijd voor een ASM meeting in Atlanta, dan kun je margherita's komen 
drinken en beren spotten in de Smokey's! Mijn promotor, professor Verhoef, wil ik bedanken 
voor de mogelijkheid om binnen het EWI mijn promotieonderzoek uit te voeren.  
 Adrienne, jij leerde mij de fijne kneepjes van het NASBA-gebeuren, en daarmee het belang 
van schoon. Daarnaast wist ik jouw hoekje altijd te vinden als het tijd was voor een klaagsessie 
over mislukte proeven of collega's die er geen bal van snapten. Dank voor je schouder.  
 Jeena, jij was mijn eerste logeeradres in Utrecht, waardoor ik niet meer met de laatste trein 
terug hoefde. Bedankt dus voor de oranje bank, maar ook voor de vele theepauzes, bij 
voorkeur onder het genot van een kinderei ("die is te zwaar, dat is zo'n stomme"). 
 Ingrid, mijn oudste vriendinnetje, en dan bedoel ik natuurlijk dat ik je al héél lang ken, 
bedankt voor het buddende zeebeest. Ik vind hem prachtig! 
 De mensen van Organon zorgden voor meer dan alleen de financiën voor dit onderzoek. In 
den beginne waren er Bob, Rianne en Piet die mij naar Boxtel haalden en leerden dat PCR een 
vies woord is. Later volgden de beide Peters en Margot en de wondere wereld van de Basic 
Kit. Jullie allemaal bedankt voor de steun en ook voor de vrijheid om dit onderzoek naar eigen 
inzicht uit te voeren.  
 Het NASBA-onderzoek zou nooit hebben kunnen plaatsvinden zonder de bereidwillige 
medewerking van de patiënten en hun families. Bedankt dat u ook in moeilijke tijden open 
stond voor wetenschappelijk onderzoek. Nog veel meer mensen waren betrokken bij dit 
onderzoek. Maurine Leverstein-Van Hall, Edwin Boel, Henk van Leeuwen, Dr. Dekker, Dr. 
Vos, Dr. Bindels, de verpleegkundigen van de betrokken afdelingen en natuurlijk de analisten 
van de klinische bacteriologie, zowel in Utrecht als in Veldhoven. Jullie allemaal bedankt voor 
de medewerking.   
 Het AFLP-werk liep ook al uit op één groot samenwerkingsverband. In Amsterdam: Paul, 
Erik en Madelon, jullie bedankt voor het helpen opstarten, de brainstorms als alles weer eens 
mislukte, en de AFLP-stage in jullie eigen lab. De buren van het CBS: Teun, bedankt voor je 
kritische oog bij het lezen van mijn schrijfsels. Bart, bedankt voor de prachtige bomen en voor 
de uren dat we samen vloekend achter de computer zaten in een poging om Candy te koppelen 
aan Lolita. Misschien zien we elkaar komende winter aan de andere kant van de grote 
haringvijver. 
 Mijn 'kindjes': Wendy van de mega-PCRs, Marcel die het aandurfde om een jaar te blijven 
(interessant hè, die Candida!), Cindy die de ene na de andere carrière bedacht en nog steeds 
gezellig bij het EWI werkt, Mariette, één van de weinige geneeskunde-studenten met een 
pipetteer-duim, en Bregje die maar heel kort van mij was maar gelukkig heel flexibel bleek. 
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 Ook in het lab waren velen onmisbaar. Mirjam, Stefan, Karlijn en Alice, altijd bereid om 
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(bedankt voor de liften naar Amsterdam), Camiel (shoppen in Chicago), Desiree (die borrel 
lukt vast een keer), Dirk (kort maar gezellig), Gunnar (alias 'Gladiator'), Hessel (sorry voor 
mijn eeuwige zooi), James (tot ziens in de trein), Leonie (groeten van de toverdoos), Leontine 
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Mireille (de afwezige buuv), Monique (da's lang geleden), Pieter-Jan (wanneer bloeit je plant 
nou eindelijk?), Ruzena (het koekiemonster), Steven (IJS!), Wilco (mijn eerste buurman), 
Wouter (de kamerfilosoof), oftewel DE kamergenoten, onmisbaar in het leven als AIO. De 
vele koppen thee, koffie of chocolademelk op het onverwoestbare dienblaadje, het meedenken 
over woorden, zinnen, de kleur van een poster, de verkleedpartijen voor promoties en 
bruiloften, de steun in moeilijke tijden, ik zal jullie heel erg missen. Ik laat jullie mijn 
pennencollectie na. Laat ze niet gejat worden! 
 Roel, bedankt voor je steun en advies toen het allemaal even minder leuk was. 
 Chris, thanks for your enthusiasm which made writing the proposal almost fun. Your sight-
seeing tour in Atlanta was truly a memorable event. I look forward to working with you this 
fall! 
 De dames van de betere lichamen, oftewel de Zeister sportclub, Adrienne, Ellen en Carla. 
Bedankt dat ik als semi(demi?)Zeistenaar ook lid mocht worden. Marcheer op rechts! 
 De zwemzwerm en alle vrienden in Amsterdam en daarbuiten, die het afgelopen half jaar 
niets meer van mij hoorden: bedankt voor jullie begrip. 
 Pim, die er voor zorgde dat ik ook in Utrecht fietsend door het leven ging. 
 Mijn ouders, die mij altijd alle vrijheid en mogelijkheden hebben gegeven om te worden 
wat ik wilde.  
 Mijn broer Dr. Ir. Pim, altijd een paar jaar eerder met alles en daarom toch een beetje een 
voorbeeld. Stuur je veel foto's van mijn prachtige nicht als ik weg ben? 
 En dan Martijn… Wat had ik zonder jou gemoeten? Je bent de enige die weet wat een 
enorme stresskip ik ben, en degene die altijd de volle laag kreeg. Bedankt voor je eindeloze 
geduld, brede schouders en knuffels. De dikste knuffel is nu voor jou: {{{Martijn}}
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CURRICULUM VITAE 
 
 Annemarie Borst werd geboren op 20 mei 1972 te Castricum. Na het behalen van het 
eindexamen VWO aan het Bonhoeffer College te Castricum werd in 1990 gestart met de studie 
Medische Biologie aan de Vrije Universiteit te Amsterdam. Tijdens de studie verrichtte zij 
wetenschappelijk onderzoek bij de vakgroep Celbiologie van de Vrije Universiteit en het 
laboratorium voor Parasitologie en Mycologie van het Rijksinstituut voor Volksgezondheid en 
Milieu (RIVM). Als extra stageperiode werd een half jaar onderzoek uitgevoerd aan de 
Washington State University te Pullman, WA, Verenigde Staten. In 1996 werd het 
doctoraaldiploma behaald, waarna zij gedurende anderhalf jaar werkzaam was bij het 
Onderwijsbureau van de faculteit Biologie van de Vrije Universiteit.  
 Het in dit proefschrift beschreven onderzoek werd aangevangen in 1998 bij het Eijkman-
Winkler Instituut, UMC Utrecht (Prof. J. Verhoef), onder begeleiding van Dr. A.C. Fluit. Haar 
werk werd in 2000 beloond met een Student Travel Grant Award van de American Society for 
Microbiology (ASM).  
 Een in samenwerking met Dr. C.J. Morrison geschreven onderzoeksvoorstel voor een post-
doctoral fellowship werd gehonoreerd door de ASM en het National Center for Infectious 
Diseases (NCID), waardoor zij vanaf oktober 2002 gedurende twee jaar werkzaam zal zijn bij 
de Mycotic Disease Branch van de Centers for Disease Control and Prevention (CDC) in 
Atlanta, GA, Verenigde Staten.  
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